CN1348815A - Medicine for preventing and treating coronary heart disease and angina pectoris and its prepn and other use - Google Patents

Abstract

The present invention relates to traditional Chinese medicine for treating coronary heart disease and stenocardia is made from (by wt.%) salvia root 50-97%, notoginseng 2-48% and borneol 0.2-3%, in which the salvia root and notoginseng and hot extracted with water, then filtering, concentrating, alcohol precipitating, standing still, recovering ethyl alcohol, concentrating, into extractum, further blended with borneol and adjuvant polyglycol-6000 to form into product.

Description

A kind of prevention and treatment treating coronary heart disease and angina pectoris and preparation method thereof and other purposes

Technical field

The present invention relates to a kind of prevention and treatment treating coronary heart disease and angina pectoris and preparation method thereof, referring to a kind of especially is the drop pill that the special extracting method of prepared using is made through special process with the Chinese herbal medicine, and commodity are called FUFANG DANSHEN DIWAN.

Background technology

FUFANG DANSHEN DIWAN is improvement and the raising on FUFANG DANSHEN PIAN (being recorded in 77 years versions of Pharmacopoeia of People's Republic of China, 85 years versions, 95 years versions and version in 2000) basis, but it has significant difference with FUFANG DANSHEN PIAN on prescription proportioning, manufacturing process and clinical effectiveness, since obtaining Ministry of Health of the People's Republic of China's approval in 1993, existing millions of people uses, and has obtained good society and economic benefit.Up to now, the prescription proportioning of FUFANG DANSHEN DIWAN and manufacturing process etc. are not published.

Along with the rejuvenation of growth in the living standard, world population aging and morbidity colony, cardiovascular and cerebrovascular vessel patient increases year by year, has become the second largest disease of harm humans health.Angina pectoris is a kind of caused by the temporary transient ischemia of cardiac muscle, anoxia, serves as the clinical syndrome of main performance with ictal chest pain or chest discomfort.Angina pectoris is meant because coronary atherosclerosis or spasm cause myocardial ischemia, the caused angina pectoris of anoxia, accounts for 90% of patient with angina pectoris.

The anginal method of treatment is based on blood vessel dilating, reduction blood viscosity, antiplatelet aggregation, anticoagulation at present.Traditional Western medicine of using is nitrate, nitrous acid ester, beta-receptor resistance preparation, calcium antagonist etc., but all has bigger toxic and side effects, should not take for a long time, mostly is symptomatic treatment and course of disease progress is not had bigger effect.For example take and occur jumping pain, palpitating speed in feeling of fullness in the head, the head behind the nitroglycerin sometimes, even faint and [, find again in recent years to cause severe hypotension [referring to contemporary Chinese medical journal 1997 referring to new pharmacology [the 14th edition) 264 page]; 7 (4): 42; Shaanxi medical journal 1996; 25 (5): 315], easily produce toleration [referring to southern nursing magazine 1996; 3 (5): 7-9] etc. problem has hindered its application clinically.

Though the anginal Chinese patent medicine of many treatments is also arranged, wherein ball, loose, cream, pellet, decoction becomes old historical already, the modern seldom uses.There are preparations such as common compound Salviae Miltiorrhizae tablet and capsule to sell in the market, but conventional tablet, capsule manufacture technology are more backward, active constituent content is low, no quality control standard, need be oral through gastrointestinal absorption, go into blood at liver generation first pass effect post-absorption, bioavailability is low, absorb slowly, can not be fit to the need of angina pectoris patient's first aid.

Summary of the invention

At the deficiencies in the prior art recited above, the object of the present invention is to provide a kind of can efficient, quick-acting, steady effect, treat and prevent the compound red sage root preparation of angina pectoris longer.

Another object of the present invention provides this compound red sage root preparation other purposes except that the control angina pectoris.

Another purpose of the present invention provides each proportioning components of this compound red sage root preparation.

A further object of the present invention provides the method for preparing medicine of the present invention by said ratio.

Summary of the invention

Compound basis of the present invention is based on Traditional Chinese medical theory and modern pharmacological research.Theory of Chinese medical science thinks that blood stasis stagnates in heart arteries and veins, and the blood vessels operation is smooth and cause the heart and become homeless fosterly, and the thoracic obstruction, pained takes place.We are on the basis of long-term pharmacological testing and clinical investigation, through the prescription screening, with the Radix Salviae Miltiorrhizae is that monarch drug, Radix Notoginseng are that ministerial drug, Borneolum Syntheticum are the effect that adjuvant drug is made blood circulation promoting and blood stasis dispelling, diffusing impediment and relieving pain, causing resuscitation with aromatic drugs, be used to prevent and treat the medicine of diseases such as angina pectoris, the present invention makes dropping pill formulation with above-mentioned three kinds of components and proper supplementary material by method of the present invention, has improved curative effect greatly.

The effect of medical treatment angina pectoris of the present invention realizes by following mechanism: 1. the blood flow that increases ischemic region: obvious diastole coronary artery, coronary blood flow increasing also promotes side Zhi Xunhuan, improves the ischemic region blood supply, dwindles infarction size.2. remove the free radical effect: remove hypoxic-ischemic and the hydroxy radical that produces, alleviate the damage of hydroxy radical, and improve ATP content in the myocardial mitochondria, the effect of performance protection cardiac muscle to myocardial mitochondria.3. antiplatelet aggregative activity: suppress the release of platelet factor significantly, prevent platelet aggregation, and improve PGI ₂/ TXA ₂Ratio produces anticoagulant and anti-thrombosis function.4. effect for reducing blood fat: give birth to cholesterol in suppressing, and reduce the generation of TG, LDL.

Good fortune will waits by force [referring to Chinese combination of Chinese and Western medicine magazine 1996; 16 (5): 287-288] using Radix Salviae Miltiorrhizae treats 24 routine patients with coronary heart disease, the variation of lipid peroxide (LPO) and superoxide dismutase (SOD) content among the observation treatment front and back patients serum, and compare with 20 routine healthy people, the result shows: LPO is apparently higher than healthy people (P＜0.01) in the patients with coronary heart disease serum, and SOD is starkly lower than healthy people (P＜0.01) in the patients with coronary heart disease serum; After adopting Treated with Radix Salviae Miltiorrhizae, LPO obviously reduces (P＜0.01) among the patients serum, and activity of SOD in serum more significantly raise (P＜0.05).Radix Salviae Miltiorrhizae reduces LPO, and the mechanism that improves activity of SOD in serum may be with antiplatelet aggregation, reduce blood viscosity, improve myocardial ischemia, the protecting myocardial cell film is relevant.

Chang Yingzi is [referring to Chinese Journal of Pathophysiology 1991; 7 (5): 449-452] etc. adopt FeSO ₄/ ascorbic acid system is observed oxygen-derived free radicals to Mus myocardial mitochondria H ⁺The damaging action of-ATP enzyme and the protective effect of danshensu.The result shows: FeSO ₄/ ascorbic acid can make Mitochondrial H ⁺-ATP enzyme hydrolysis is active obviously to descend, and danshensu has significant protective effect, and it can prevent Mitochondrial H ⁺The active decline of-ATP enzyme hydrolysis, and be certain concentration dependence and " saturation effect ".

Zheng Ruoxuan etc. are [referring to Chinese combination of Chinese and Western medicine magazine 1992; 12 (7): 424-425] 1 give rat lumbar injection Radix Salviae Miltiorrhizae water extract (5g crude drug/kg), the acute myocardial ischemia that causes for the ligation coronary artery has tangible preventive effect, the electrocardiogram that the administration treated animal improves owing to myocardial ischemia " S-T " section is significantly less than matched group, chamber, left side myocardial ischemia area dwindles gradually, and the survival rate of animal also increases.

Han Chang etc. are [referring to Chinese Journal of Pathophysiology 1991; 7 (4): 337-341] adopt in the rabbit general anesthesia, open under the condition of breast, autonomous respiration and autonomous cardiac rhythm, chamber, ligation arteria coronaria left side Zhi Zaocheng acute myocardial ischemia model, and then unclamp ligation form reperfusion injury organize lipid peroxidation content and regional blood flow to change to measure, be aided with electrocardiographic monitoring simultaneously; With the Radix Salviae Miltiorrhizae Injection is that protective agent is observed its action effect.The result shows that along with the continuity of Ischemia Time, Myocardial Lipid Peroxidation content increases gradually; When ischemia poured into after 60 minutes 30 minutes again, lipid peroxide contents still continues to rise, and apparently higher than 60 minutes groups of ischemia, but does not more then have significant difference with 90 minutes groups of ischemia; After pouring into again, its ischemic region local organization blood flow only recovers 53.2%.Give the decline of the perfusion group again 56.0% (P＜0.005=of Radix Salviae Miltiorrhizae protection; The local organization blood flow recovers then to improve 32.0% (P＜0.001=.

Jiang Wende etc. [referring to Shanghai first medical college journal 1982:9 (1): the 13-19] compare research with four kinds of tests to medicines such as danshensu, Radix Salviae Miltiorrhizae diterpenoid acid mixture (DS-781), protocatechualdehyde (PCAD) and persantins; confirm: danshensu energy significant prolongation mice hypoxia endurance time; the rat ischemia electrocardio that pituitrin is caused changes; remarkable protective effect is arranged, for persantin, DS-781, PCAD can't be obtained.Behind the acute ligation Canis familiaris L. arteria coronaria left anterior descending branch, danshensu can significantly resist left ventricle and shrink the decline of peak pressure (LVPSP) and the rising that (LVEDP) pressed at the easypro end of left ventricle.On the contrary, PCAD then reduces LVPSP and rising LVEDP more significantly.Quiet notes persantin group follows significant blood pressure lowering that LVPSP is descended and LVEDP does not raise.The heart infarction scope is dwindled after 24 hours, and is the most obvious with danshensu.

Wu Huaizhu etc. are [referring to Chinese Journal of Hematology 1994; 15 (9): 458-460] think that through experimental study effective component in red sage 764-3 can significantly suppress ADP or collagen-induced human blood platelets ATP release and the gathering of release dependency external, inhibitory action is obvious amount-result relation; 0.01-0.08mmol/L764-3 can prolong the activatory lag phase of arachidonic acid (AA) induced platelet, concentration increases to 0.08mmol/L, and then anticoagulant and ATP discharge fully when above.Discover the platelet endochylema Ca that 764-3 can obviously prevent collagen to cause with the platelet suspension of load aequorin ²⁺Concentration ([Ca ²⁺] i) raise, and 764-3 is to Ca ²⁺Interior stream and internal memory Ca ²⁺Mobilize and all show inhibitory action.764-3 still significantly suppresses the inductive platelet T XB2 of AA and generates.Comprehensive research result shows that the mechanism of action of 764-3 may be to suppress platelet AA metabolism.

Sun Ximing etc. are [referring to Chinese herbal medicine 1991; 22 (1): 20-23] with cell model the pharmacological action of danshensu is studied, find that it has that to reduce the cell inner cholesterol synthetic and the lipotropism electrophoretic mobility of protein is obviously slack-off, the toxic action of obvious minimizing of MDA content and oxidation lipoprotein pair cell obviously weakens in the oxidation lipoprotein, and the prompting danshensu can be used for atherosclerotic control.

Shi Lin etc. are [referring to Acta Pharmacologica Sinica 1990; 11 (1): 29-32] analyze Radix Notoginseng total arasaponins (PNS) to rat artery wall PGI with radioimmunology ₂The synthetic platelet T XA that reaches ₂The influence of content.The result is ig PNS 25,50 respectively, continuous 10 days of 100mg/kg, arterial wall PGI ₂Content all descends.Prompting PNS anti-AS effect may with rising arterial wall PGI ₂, correct PGI ₂-TXA ₂Unbalance relevant.

Li Hongtai etc. are [referring to herbal pharmacology journal 1990; 11 (3): 213-217] adopt stripped papillary muscle AP of Cavia porcellus right ventricle of synchronous recording and F _cAnd measure and cultivate neonatal rat myocardial cell ⁴⁵Ca absorbs two kinds of methods, and research Radix Notoginseng total arasaponins (PNS) is to myocardial cell Ca ²⁺The influence of interior stream.PNS shortens the APD of fast response AP, weakens F _cAnd the V of inhibition long response time AP _MaxAnd APA.PNS suppresses the cultivation neonatal rat myocardial cell ⁴⁵The Ca picked-up.The result shows that PNS suppresses the Ca of myocardial cell ²⁺Interior stream.

Hu Yuejuan etc. are [referring to CHINA JOURNAL OF CHINESE MATERIA MEDICA 1992; 17 (6): 361-363] the mice hypoxia-bearing capability be can strengthen with Radix Notoginseng cultured cell (SCC) crude extract lumbar injection, coronary flow and decreased heart rate strengthened.The effect that the antagonism norepinephrine shrinks aortic article has spasmolysis to the intestinal tube smooth muscle.Mouse stomach SCC powder suspension can shorten hemorrhage and clotting time.The above-mentioned pharmacologically active of SCC is identical with the Radix Notoginseng crude drug.

Xu Qing etc. are [referring to CHINA JOURNAL OF CHINESE MATERIA MEDICA 1993; 18 (6): 367-368] gavage 7 days for rat and two kinds of hyperlipidemia model animals of Carnis Coturnicis japonicae with Radix Notoginseng total saponin from leaves 200mg/kg, 100mg/kg, all can significantly reduce the content (P＜0.05=of its serum total cholesterol and serum triglycerides.

Sun Jianjuns etc. are [referring to Journal of Traditional Chinese Medicine 1994; 35 (1): 5-6] by clinical observation, find using blood-activating and stasis-removing is main treatment, or the patient that nitrate, propranolol, nifedipine etc. can not the Satisfactory Control angina pectoris attackses, adds Radix Notoginseng or single with big its outbreak of multipotency Satisfactory Control behind the Radix Notoginseng.Once observed 11 examples with the treatment of other Chinese medicines and above-mentioned routine of western medicine more than one month, angina pectoris patient that can not its outbreak of Satisfactory Control uses the Radix Notoginseng treatment of taking after mixing it with water instead, 10 examples wherein, equal Satisfactory Control after the week.

Jiang Wende etc. are [referring to Acta Pharmaceutica Sinica 1979; 14 (11): 655] only irritate stomach with using Borneolum Syntheticum 0.5g/, the anesthesia Canis familiaris L. to ligation left coronary artery anterior descending branch formation acute myocardial infarction can make its decreased heart rate, and arteriovenous oxygen difference reduces.To the mice hypoxia endurance test, also show to make anoxia mice prolonged survival period.

The present invention is implemented by following scheme.

Pharmaceutical preparation of the present invention, its formulation ratio is (in a weight percentage):

Radix Salviae Miltiorrhizae 48%～97%

Radix Notoginseng 2%～50%

Borneolum Syntheticum 0.2%～3%

Pharmaceutical preparation optimizing prescriptions proportioning of the present invention is (in a weight percentage):

Radix Salviae Miltiorrhizae 63.0%～94%

Radix Notoginseng 4.0%～35.0%

Borneolum Syntheticum 0.5%～2.0%

Pharmaceutical preparation optimizing prescriptions proportioning of the present invention is (in a weight percentage):

Radix Salviae Miltiorrhizae 75.2%～90%

Radix Notoginseng 9%～23.5%

Borneolum Syntheticum 0.5%～1.3%

Pharmaceutical preparation best prescription proportioning of the present invention is (in a weight percentage):

Radix Salviae Miltiorrhizae 82.87%

Radix Notoginseng 16.21%

Borneolum Syntheticum 0.92%

Medicine production method of the present invention mainly is: Radix Salviae Miltiorrhizae, the pseudo-ginseng of learning from else's experience and pulverizing, and boiling water boils to be carried, filter, merging filtrate, and filtrate is suitably concentrated; Add ethanol and carry out precipitate with ethanol in concentrated solution, leave standstill, supernatant reclaims ethanol, is condensed into extractum; With gained extractum and Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.

The concrete steps of medicine production method of the present invention are as follows: take by weighing Radix Salviae Miltiorrhizae, pseudo-ginseng through pulverizing according to the above ratio 1., add water, heating extraction 2～4 times, extracting temperature is 60～100 ℃, each amount of water is 4～8 times of medical material amount, leach cooking liquid filters, merging filtrate, and filtrate is concentrated into medicine liquid volume and the medical material weight ratio is 1 liter: 0.7～1.3 kilogram; 2. add 95% ethanol in concentrated solution, making determining alcohol is 50～85%, leaves standstill 4～24 hours, and supernatant filters, filtrate recycling ethanol, and the simmer down to relative density is 1.15～1.45 extractum; With gained extractum and aforementioned proportion Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.

Pharmaceutical preparation of the present invention can be said dosage form on any pharmaceutics, and wherein preferred dosage form is a drop pill, and it is shaped as reddish brown-brownish black round bead shape, and size evenly.

The drop pill preparation method of medicine of the present invention be mainly with above-mentioned gained extractum and Borneolum Syntheticum and adjuvant mixed evenly after, add the transconversion into heat material, move into dripping jar of drop pill machine, medicine liquid droplet is removed liquid paraffin to cryogenic liquid paraffin, select ball.

Wherein: adjuvant is a Polyethylene Glycol-6000, and 53～58 ℃ of its condensation points, addition are extractum and Borneolum Syntheticum weight 2～6 times; Changing the material temperature is 60～100 ℃; The temperature of liquid paraffin is 0～10 ℃ (the best is 5～10 ℃); Ball heavily is 5～50mg/ grain, diameter 1.95～4.29mm.

The present invention utilizes modern special extraction process and high-tech Quality Control means, improves content of effective and quality control standard, really guarantees the safety and the effectiveness of medicine.Preferred dosage form drop pill of the present invention can be given full play to the dosage form advantage.Drop pill can be referred to as solid solution, and medicine is dispersed in the substrate with molecularity, forms uniform solid dispersion, and is can the bonding dosed administration accurate; Drug microparticles is embedded in the substrate, tight, and secluding air has increased stability of drug; After medicine and the substrate congruent melting medicine is dispersed in the substrate, condensation forms superfine crystallization, helps dissolving and absorbs, and brings into play curative effect rapidly, improves bioavailability, reduces side effect; Medicine is avoided first pass effect through sublingual administration, the bioavailability height; The effective ingredient oral transmucosal absorbs directly into blood, and the performance curative effect can reach quick-acting purposes.

Below by elaboration, the beneficial effect that the present invention uses is described in pharmacy to FUFANG DANSHEN DIWAN animal experiment study and clinical research.

FUFANG DANSHEN DIWAN animal experiment study one. to the influence of anesthetized dog myocardial ischemia, myocardial infarction and relevant coronary flow, myocardial oxygen consumption and blood parameters

Observe the influence of FUFANG DANSHEN DIWAN,, inquire into the pharmacological action of its treatment ischemic heart desease by the variation of myocardial oxygen consumption and biochemical indexes to experimental dog myocardial ischemia and myocardial infarction.

1. method

1.1 experiment grouping: (1) blank group, normal saline 3ml/kg; (2) Composite Salvia Dropping Pill group, 2g crude drug/kg; (3) positive controls, diltiazem tablet (diltiazem), 5mg/kg.All be mixed with equal-volume (3ml/Kg) through duodenal administration before the above-mentioned medicine experiment with normal saline.

1.2 experimental technique: the laboratory animal dog is anaesthetized through pentobarbital sodium, opens breast, separates LCA and anterior descending branch stage casing, and the threading ligation causes the acute myocardial ischemia model.The record epicardial electrogram, (S-T section rising mv counts ∑-ST) and myocardial ischemia scope (raise total points N-ST) of S-T section to the calculating myocardium degree of ischemia.Record Coronary vein oxygen content; Measure serum creatine creatine phosphokinase (CK) lactic acid dehydrogenase (LDH), ET, TXB2 and 6-Keto-PGF _{1 α}Measure arterial oxygen content, with arteria coronaria venous oxygen content, the common calculating myocardium oxygen consumption of coronary flow, come the calculating myocardium oxygen consumption: myocardial oxygen consumption=(arterial oxygen content-Coronary vein oxygen content) * coronary flow/100 with the arteria coronaria venous oxygen content.

After the medication 180 minutes, take off heart, weigh, section, dye in nitro tetrazole orchid (N-BT) dye liquor, the infarct (the non-dyeing of N-BT district) of measuring every myocardium bilateral and non-infarct (N-BT dye district) calculate infarct and account for ventricle and reach the percentage ratio of dirty weight whole-heartedly.

Experimental result is judged its significance with the t check.

2. result

(1) to the influence of dog myocardial ischemia (epicardial electrogram mapping), FUFANG DANSHEN DIWAN has the reduction degree of myocardial ischemia, and there were significant differences with the matched group ratio, sees Table 1.1.

(2) to the influence of dog myocardial ischemia scope (N-ST), FUFANG DANSHEN DIWAN has the effect of obvious minimizing myocardial ischemia scope, sees Table 1.2.

(3) to the influence of dog myocardial infarct size (N-BT staining mensuration), compare with matched group, FUFANG DANSHEN DIWAN can obviously reduce infarct, sees Table 1.3.

(4) to the influence of myocardial ischemia dog venous oxygen content, with the matched group ratio, FUFANG DANSHEN DIWAN can obviously increase the coronary sinus vein oxygen content, sees Table 1.4.

(5) to the influence of myocardial ischemia dog blood biochemical index, with the matched group ratio, CK, the LDH that FUFANG DANSHEN DIWAN causes in the time of obviously suppressing myocardial ischemia, myocardial infarction is active to raise; Can significantly suppress ET and TXB ₂Discharge, improve 6-Keto-PGF _{1 α}Content improves 6-Keto-PGF _{1 α}/ TXB ₂Ratio see Table 1.5,1.6,1.7.

Conclusion: experimental results show that, FUFANG DANSHEN DIWAN has the obvious effect that improves dog acute myocardial ischemia and infraction, improves the venous sinus oxygen content, suppresses myocardium the overflowing of serum CK, LDH when impaired, reduce the activity of serum CK, LDH, suppress vaso-excitor material ET and TXB ₂Activity, improve vasodilator material 6-Keto-PGF _{1 α}Content, improve 6-Keto-PGF _{1 α}/ TXXB ₂Ratio.Each administration group of table 1.1 is to (the influence of ∑-ST) of dog acute myocardial ischemia degree

Value rate of change before dosage/kg medicine

Other suitable esters include, but are not limited to the following compounds: methyl acetate theophylline mannuronic acid silanol Esters, acetaminophen Salou acetylation hydroxyproline hexadecyl ester, acetylated glycol stearate, acetylated sucrose Glucose distearate, acetyl methionyl easily Las Stand methyl ester silanol (elastinate), acetyl tributyl citrate Butyl, acetyl triethyl citrate, acetyl tributyl citrate, hexyl acrylate Ishiguri, allethrin, Allyl hexanoate, amyl acetate, amyl benzoate, amyl salicylate, behenic acid, peanut yl (arachidy) Esters, glycol isostearate group peanut, peanut propionate ester, di palmitic acid ester of ascorbic acid, palmitic acid, anti- Ascorbic acid esters, stearic acid ester of ascorbic acid, aspartame, shark liver alcohol esters of isostearic acid, stearic acid esters of shark liver alcohol, Soybean palmitate esters, behenyl beeswax, behenic acid, dodecyl ester of behenic acid, Behenic ester of erucic acid, isostearic acid, dodecyl, behenyl / isostearyl wax, benzene -1,2,4 - Acetate, benzoin gum, benzoyloxy-quinoline (benzoxiquine), benzyl acetate, benzyl benzoate, cinnamate Acid benzyl ester, benzyl ester of hyaluronic acid, lauric acid benzyl ester, nicotinic acid benzyl ester, p-hydroxybenzoic acid benzyl ester, benzyl salicylate Esters, acetic acid esters of β-sitosterol, borage (Borago Officinalis) acrylate, butoxyethyl acetate, butyl acid Ethyl group, butoxyethyl stearate, butyl acetate, butyl acetyl ricinoleate, butyl benzoate, Butyl benzyl phthalate, acetic acid 2 - tert-butyl-cyclohexyl acrylate, butylene glycol dicaprylate / dicaprate, butylene Montanic acid ester, ethylene / MA copolymer, butyl, PVM / MA copolymer, butyl, butyl, decyl glucoside esters, Iso-butyl stearate, butyl lactate, butyl methacrylate, butyl myristate, butyl octyl beeswax, benzene Butyloctanedioate acid esters, candelilla butyloctanedioate oleate, butyloctyl salicylate, butyloctyl oleate, butyl, PABA butyl, butyl paraben, butyl phthalyl butyl glycolate, butyl stearate, Thioglycolic acid butyl, hexyl citrate butanoyl, C18-36 glycol esters, PEG-8 C12-20 acid Benzoate, caffeine, panthenol cysteamine acid, calcium stearoyl lactate, C18-28 alkyl esters of acetic acid, C18-38 alkyl beeswax, C30-50 alkyl beeswax, behenic acid, C20-40 alkyl esters, C24-54 acid, C18- 38 alkyl esters, C-8 alkyl phosphate ester, hydroxy stearoyl stearate, C18-38 esters, C12-13 alkyl lactate Ester, lactic acid alkyl esters of C12-15, C12-13 alkyl acid ester, acid C12-15 alkyl salicylate, C12-15 Alkyl esters, C18-36 alkyl esters of stearic acid, stearic acid, C20-40 alkyl stearate, C30-50 alkyl acrylate, C40-60 alkyl esters of stearic acid, ethyl glucoside hexanoyl, octanoyl salicylic acid, butyric acid, octyl benzene castor oil Ester, cholesterol / lanosterol C10-30 esters, cellulose acetate, cellulose acetate butyrate, cellulose acetate propionate Cellulose, cellulose acetate propionate carboxylate, Ceteareth-7 stearate, Setchell Ali behenic acid ester, Candelilla acid (candelillate) Setchell Ali (Setchell Ali) ester, isobutyl ester of azelaic acid Setchell Ali, Ali, bitterness Setchell Palmitate, Setchell Ali stearate Setchell Ali acetate, hexadecyl ester, acetyl ricinoleate ten Six alkyl ester, cetyl octanoate, C12-15-Pareth-9 carboxylic acid hexadecyl ester, hexadecyl, isostearyl glycol Esters, iso-nonanoic acid hexadecyl ester, cetyl lactate, cetyl laurate, cetyl myristate, octyl Acid hexadecyl ester, oleic acid hexadecyl ester, palmitic acid, cetyl alcohol esters, PCA hexadecyl ester, PPG-2 Isodeceth-7 Carboxylic acid hexadecyl ester, cetyl ricinoleate, cetyl ricinoleate benzoate stearate, sixteen Alkyl esters, C16-20 glycol isostearate, C20-30 glycol isostearate, C14-16 glycol Brown Palm ester, shark liver alcohol esters of isostearic acid, stearic acid esters of shark liver alcohol, chlorogenic acid, cholesteryl acetate, lauroyl- Yl acid cholesteryl / behenyl / octyldodecyl butyrate, cholesteryl esters, cholesteryl dichlorobenzoic acid Alcohol esters, cholesteryl hydroxy stearic acid esters, isostearic acid cholesteryl esters, cholesteryl isostearyl carbonate, cholesteryl Wool alcohol ester (lanolate), Australia Kennedy acid (Macadamiate) cholesteryl esters, cholesteryl nonanoate, Lauroylglutamate cholesteryl / octyldodecyl oleate, cholesteryl stearate, cholesteryl esters, cinnamic Acetate, laurel ether ester, citronellol acetate, coco caprylate / caprate, coconut alcohol esters of rapeseed (Rapeseedate), ethyl coco glucoside, PCA methyl silanol copper, European hazel, ethyl, C12-15 Pareth-9 Hydrogenated tallow acid ester (tallowate), C11-15 Pareth-3 oleate, C12-15 Pareth-12 oleate, C11-15 Pareth-3 stearate, C11-15 Pareth-12 stearate, isobutyl stearate, decyl myristate, decyl acrylate, Decyl oleate, decyl succinate, DEDM Hydantoin dilaurate, dextrin behenate, dextrin Laurate, dextrin myristate, dextrin palmitate, dextrin stearate, glycerol diacetate, hexyl Dibutyl oxalate, dibutyl phthalate, dibutyl sebacate, dibutyl adipate C12-15 Alkyl esters, fumaric acid esters of C12-15 alkyl, C12-13 alkyl malate ester, tartaric acid C12-13 Alkyl esters, tartaric acid esters of C14-15 alkyl, dioctyl adipate, dioctyl maleate, di linoleic acid se Tea Li ester dimer, adipic acid, cetyl acid diethyl sulfide, cetyl stearyl citrate two coconut Acid pentaerythritol ester, succinic ethoxyethyl, acetyl aspartic acid diethyl ester, coconut acid ethylamino Ethyl ester, PEG-5 coconut diethyl amino ethyl, PEG-5 laurate diethylaminoethyl stearate diethylamino Yl ester, aspartic acid, diethyl ester of diethylene glycol dibenzoate, diisononyl acid glycol dicaprylate Diethylene glycol, diethylene acid / ethylene glycol di-iso-nonyl acid, glutamic acid, diethyl oxalate, diethyl palmitoyl Aspartic acid diethyl ester group, diethyl phthalate, diethyl sebacate, diethyl succinate, bis gallic acid Base trioleate, diglyceryl stearate malate, dihexyl adipate, hexyl lauroyl glutamate Decyl acrylate, dihydroabietic behenic acid ester, methacrylic acid ester dihydroabietylamine, dihydro cholesteryl butyrate esters, Isostearic dihydro cholesteryl esters, cholesteryl macadamia nut dihydro ester (macadamiate), nonanoic acid, dihydrogen Cholesteryl esters, octyl caprate dihydro cholesteryl oleate, cholesteryl esters dihydro-, hydroxyethyl palmitoyl dihydride monium sulfate, dimethyl dihydrogenated tallow phthalate, octyl caprate dihydro phytosterol esters, Oleic acid hydroxyethylamino hydroxypropyl acrylate, dihydroxyethyl amine soybean (Soyamine) dioleate, adipic Diisobutyl oxalate, diisobutyl adipate, diisopropyl hexadecyl ester, diisodecyl adipate, diisobutyl adipate Propyl, two diisopropyl dimer of linoleic acid, cinnamic acid isopropyl ester, oxalate, diisopropyl sebacate Di-iso-propyl chloride, stearyl amidopropyl diisopropyl epoxypropyl monium, trimethylol diisopropyl stearyl Trimethylolpropane siloxy silicate, iso-stearyl adipate, di isostearyl acrylate linoleic acid dimer, Di-iso-stearyl fumarate, diethyl glutarate, isostearyl acrylate, isostearyl malate ester, Dilaureth- 7 citrate, sulfur dilauryl thiodipropionate, dimethicone copolyol acetate, polydimethylsiloxane Siloxanes copolyol adipate, dimethicone copolyol ester almond (almondate), polydimethylsiloxane Siloxanes copolyol beeswax, dimethicone copolyol behenate, dimethicone copolyol Benzoate, dimethicone copolyol ester borage (borageate), dimethicone copolyol Cream alcohol ester (butterate), dimethicone copolyol Dhupa cream, poly (dimethylsiloxane) Copolyol hydroxy stearate, dimethicone copolyol isostearate, dimethicone copolyol Alcohol esters Kokum butter, dimethicone copolyol lactate, dimethicone copolyol laurate Esters, dimethicone copolyol ester Mango butter, dimethicone copolyol Meadowfoamate, dimethicone copolyol ester Mohwa butter, dimethicone copolyol Citrate octyldodecyl alcohol, dimethicone copolyol ester olive (olivate), polydimethylsiloxane Siloxanes copolyol phthalate, dimethicone copolyol Sal cream, poly dimethylsiloxane Shea butter alkyl esters copolyol, dimethicone copolyol stearate, dimethicone copolyol Alcohol, undecylenic acid esters, wax alcohols polydimethylsiloxane, polydimethylsiloxane alcohol behenate, poly Dimethiconols borage esters, polydimethylsiloxane alcohol Dhupa cream, poly dimethyl siloxane Linoleic alcohol glycol dimethyl fluorine, hydroxyl polydimethylsiloxane stearate, dimethicone alcohol Illipe Cream, poly (dimethylsiloxane) isostearate, polyethylene Kokum butter dimethiconol esters, Polydimethylsiloxane alcohol lactate, polydimethylsiloxane alcohol Mohwa cream, poly dimethylsiloxane Sal cream alkanol esters, polydimethylsiloxane alcohol stearate, dimethyl adipate, methyl acrylate, Methyl group, ethyl dimethyl Brazil, cystine dimethyl ester, dimethyl glutarate, dimethyl maleate, Dimethyl oxalate, dimethyl phthalate, dimethyl succinate, tartrate myristate, sulfur dipropionate Dimyristyl ester, dinonoxynol-9 citrate esters, dioctyl adipate, di Xin Jiding amido triazone, Dioctyl ester of linoleic dimer two lauroyl glutamate dodeceth-2 dioctyl adipate, dioctyl ten Dioxane, di octyldodecyl linoleic acid dimer, dodecanedioic octyldodecyl, lemon Octyldodecyl fluorine acid heptyl, octyl lauroyl glutamate dodecyl acrylate, stearyl two linoleic Dioctyl dodecyl dimers, octyldodecyl stearoyl glutamic acid alkyl ester, dioctyl fumarate, Apple Acid dioctyl maleate octyl phthalate, dioctyl phthalate, dioctyl sebacate, dioctyl succinate, Dioleoyloxy Edetolmonium dimethyl sulfate, dipalmitoyl hydroxyproline, dipentaerythritol six bitterness Ester / Six caprate, heptanoate dipentaerythritol hexa / Six caprylate / caprate six, dipentaerythritol hexa hydroxy stearic Esters, dipentaerythritol hexa hydroxystearate / stearate / resin esters, dipentaerythritol hexa dicaprylate / diethyl Dodecanoate, dipentaerythritol five hydroxy stearate / isostearate, acid diphenylmethyl ester and naphthalene Pyran, dipropyl adipate, caprylic acid, dipropylene glycol, dipropylene glycol dibenzoate, dipropylene glycol salicylate Oxalate, dipropyl, Laureth-7 disodium citrate, PEG-5 lauryl sulfosuccinate, disodium citrate, PEG-8 ricinoleic acid (ricinosuccinate) disodium glycyrrhetinic acid, succinic acid disodium 2 - sulfonic group dilaurate Sodium, Disteareth-2 lauroyl glutamate, Disteareth-5 lauroyl glutamate, sulfur acid bis Stearyl acrylate, ditallow-ethyl hydroxyethyl monium sulfate, dimethyl adipate, di (tridecyl), Two linoleic acid di (tridecyl) dimer, sulfur acid bis (tridecyl), gallic acid, dodecyl acrylate, arachidonic Vegetable acid esters scoop child, children scoop dish erucic alcohol esters of oleic acid ester dish scoop children, ethiodized oil, diethyl ethoxy Glycol acetate, ethoxyethanol acetate, ethyl acetate, ethyl almond (Ethyl Almondate), almond Ethyl (ethyl Apricot Kernalate), arachidonic acid ester, aspartic acid ethyl ester, oil, sorbic acid (avocadate) Ethyl benzoate, biotin acid (biotinate) ethyl, butyl acetyl amino propionate, cinnamic acid Ethyl cyano acrylate, cyclohexyl propionate, ethyl dihydroxypropyl PABA, diisopropylethylamine Meat Gui ethyl, Brazil acid glycol ester, ethylene carbonate, ethyl hydrolyzed animal protein, hydrolyzed Ethyl keratin, hydrolyzed silk ethyl, PVM / MA copolymer, ethyl ferulate, ethyl glutamate Ethyl, isostearic acid, ethyl lactate, ethyl cinnamate, ethyl linoleate, ethyl linolenate, methyl Ethyl acrylate, methoxy ethyl cinnamate, ethyl methyl phenyl glycidyl, mink ethyl (Ethyl Minkate), Min liver did not, ethyl myristate, ethyl nicotinate, ethyl oleate, ethyl olives, PABA Ethyl, ethyl palmitate, ethyl parahydroxybenzoate, PCA, ethyl, nonyl, ethyl peach acid (persate) Acrylate, ethyl benzene, ethyl ricinoleate, ethyl ester, ethyl stearate, ethyl thioglycolate, Urocanic acid ethyl ester, wheat germ acid (germate) acrylate, ethyl acetylene Simon Wood, ETAN Kelilieni (Etocrylene), farnesyl acetate ester, galactose acid lactone, the ancient incense Punta fat, γ-lactone azelaic acid, acetic acid Mang cattle Children esters, gluconic acid lactone, gluconic acid esters, glucose pentaacetate, glucuronolactone, Glycereth- 7 benzoate, Glycereth-7 diisononyl esters, Glycereth-8 hydroxy stearate, Glycereth-5 milk Esters, Glycereth-25 PCA isostearate, Glycereth-7 triacetate, hydroxy stearic triacetyl Glycerides, glyceryl triacetyl ricinoleate, 2 - hydroxyethyl amide stearate, ethylene / butylene lignite Acetate, ethylene glycol catearate, ethylene glycol behenate, ethylene glycol dilaurate, ethylene glycol dicaprylate , Ethylene glycol dioleate, ethylene glycol distearate, ethylene glycol butter, ethylene glycol hydroxy stearic Esters, montanic acid esters of ethylene glycol, ethylene glycol dicaprylate, ethylene glycol monooleate, ethylene glycol palmitate, ethylene Alcohols ricinoleate, glycol salicylate, glycol stearate, glycol stearate SE, glycyrrhetinic Stearic acid ester, iso-hexadecyl ethylene glycol distearate, hexanediol beeswax, hexanediol distearate, Hexanetriol beeswax, hexyl decyl benzoate, hydrolyzed collagen hexyl decyl acrylate, hexyl decyl isostearate, Hexyl laurate, decyl acrylate, hexyl decyl octanoate, hexyl decyl oleate, hexyl decyl palmitate, stearate, hexyl Decyl acrylate, dodecyl acrylate hexyl salicylate, hexyl isostearate, hexyl laurate, hexyl nicotinate, Hou Mosapride Pull ester (homosalate), hydrogenated castor oil, hydroxy stearate, isobutyl stearate, hydrogenated castor oil, hydrogenated castor Oil laurate, stearate, hydrogenated castor oil, hydrogenated castor oil triisostearate, hydrogenated rosin ester, Hydrogenated rosin, PCA hydroquinone, cetyl isostearate hydroxy esters, hydroxy stearic acid, stearyl dihydroxydiphenyl, Six PCA inositol, iodopropynyl butyl carbamate acetate, isoamyl laurate, isoamyl p-methoxy Cinnamic acid isoamyl acetate, isobutyl acetate, butyl lanolin oil, isobutyl benzoate, isopropyl myristate, Butyl, isobutyl palmitate, isobutyl paraben, isobutyl azelaic acid, stearic acid, isobutyl acetate, butter Isobutyl, Isoceteareth-8 stearate, Isoceteth-10 stearate, isohexadecane behenic acid ester, Isohexadecane isodecanoic acid ester, isostearic Isohexadecane laurate Isohexadecane esters, linoleoyl stearate Iso-hexadecyl ester, isopropyl myristate, cetyl octanoate, isohexadecane palmitate, iso-hexadecyl ester, salicylic Isohexadecane acid ester, isobutyl stearate, hexadecyl acrylate, stearyl isostearate, hexadecyl ester, Isodeceth-2 Coconut Oleate, isodecyl citrate, coconut acid, isodecyl acrylate, isodecyl hydroxy stearate, isononyl, isodecyl, month Cinnamate isodecyl myristate, isodecyl pivalate, isodecyl octanoate, isodecyl oleate, isodecyl, palmitic Isodecyl acrylate, isodecyl paraben, isodecyl salicylate, stearate, isodecyl laurate, isohexyl esters, Pivalate, isohexyl palmitate, isohexyl esters, behenic acid esters of isododecane, isomerized jojoba oil, ferulic acid Isononyl isooctyl thioglycolate, isopropyl acetate, isopropyl peanuts, avocado isopropyl, behenic acid Iso-propyl benzoate, isopropyl salicylate, benzyl acetate, isopropyl citrate, C12-15-Pareth-9 carboxylic Isopropyl, hydroxy isopropyl stearate, isopropyl isostearate, jojoba acid, isopropyl acid isopropyl wool Ester, isopropyl laurate, isopropyl linoleate, isopropyl myristate, isopropyl oleate, methyl p-hydroxybenzoate Isopropyl, PPG-2-Isodeceth-7 carboxylic acid isopropyl ester, isopropyl ricinoleate, sorbic acid, isopropyl, hard Isopropyl stearate, isopropyl tallowate, isopropyl mercapto acid, isosorbide laurate, Isosteareth-10 Stearate, isostearyl avocado acid esters, behenic acid, isostearyl benzoate, isostearyl acrylate, iso-erucic acid Stearyl Isononyl stearyl, isostearyl isostearyl acrylate, isostearyl isostearate ten Eight alkyl ester, alkyl esters isostearyl lactate, isostearyl acrylate lauric, myristic acid, isostearyl pivalate, isobutyl Stearyl octanoate, isostearyl palmitate, isostearyl acrylate, stearyl isostearate, stearyl acrylate, Isononyl tridecyl esters isotridecanoic lauric, myristic acid isotridecanoic ester, Jojoba (Buxus chinensis) oil, jojoba esters, kojic dipalmitate (kojic) acrylate, Laneth-9 Acetate, Laneth-10 acetate Esters, Laneth-4 phosphate, lanolin linoleate, lanolin ricinoleate, Laureth-2 acetate, Laureth-2 benzoate, Laureth-6 citrate, Laureth-7 citrate, Laureth-2 acid ester, Laureth-7 tartrate, ethyl lauroyl glucoside, lauryl acid, behenic acid, lauryl acrylate, coconut Oleic acid, lauryl isostearate, lauryl lactate, lauryl methacrylate, lauryl acrylate, myristic Kou acid, lauryl octanoate, lauryl oleate, lauryl palmitate, lauryl stearate, sodium lauryl Acetate, linalyl acetate, linalyl acetate lactate, Madecassicoside, lauric acid dehydration mannitol oleate Mannitol dehydration acetate  acetate,  anthranilic acid esters, lactic acid esters , PCA  salicylate,  acetate, methoxy isopropyl, succinic acid methoxy-PEG-7 rutin Stand acid (rutinyl) acetate, methyl acetate, Methyl acetyl ricinoleate, methyl anthranilate, methyl behenate, methyl benzoate, hexyl acetate, Octanoate, caprylic / capric acid methyl ester, coconut oil methyl ester, 6 - methyl coumarin, dehydrogenated rosin, methyl dihydro Rosin, methyl dihydro jasmonate, methyl benzoate Gluceth-20, methyl glucose dioleate Esters, methyl glucose isostearate, methyl glucose laurate, methyl glucose sesquioleate caprylic / capric acid esters, Cocoate methyl glucose sesquioleate, methyl glucose sesquiisostearate stearate, laurate, methyl glucose sesquioleate Esters, methyl glucose sesquioleate, methyl glucose sesquistearate, methyl licorice, hydrogenated rosin Methyl, hydroxy stearic acid, methyl isobutyl methyl stearate, methyl laurate, methyl linoleate 3 - methyl room Methyl paraben, methyl myristate, methyl nicotinate, methyl oleate, methyl palmitate, palmitic acid methyl Esters, methylparaben, nonyl acetate, methyl ricinoleate, methyl resin, methyl salicylate, Acetyl-disulfonic acid methyl ester silane, methyl carboxymethyl theophylline silanol, methyl carboxymethyl theophylline silanol Alginates, hydroxyproline methyl silanol, silanol-hydroxyproline methyl aspartate, methyl silanol Gan Lu uronic acid ester, methyl silanol PCA, soybean oil fatty acid methyl ester, methyl stearate, methyl thioglycolate, Condensates monosaccharide lactates, Myreth-3 caprate, Myreth-2 laurate, Myreth-2 myristate, Myreth-3 myristate, Myreth-3 caprylate, Myreth-3 palmitate, myristyl-ethyl Portuguese Glucoside, myristoyl lactate, myristyl isostearate, myristyl lactate, myristyl tetracosanoic Esters, myristyl myristate, myristyl octanoate, myristyl propionate, salicylate, myristyl acrylate, stearyl Myristate, neopentyl glycol dicaprate alcohol, neopentyl alcohol, glycol dicaprylate / dicaprate, neopentyl alcohol Glycol dicaprylate / dipelargonate / dicaprate, neopentyl glycol diheptanoate alcohol, neopentyl alcohol, ethylene glycol di Isostearate, neopentyl alcohol, ethylene glycol dilaurate, neopentyl alcohol, ethylene glycol dicaprylate, nonyl acetate, ethyl Nuobu Ji acid esters, diethylene glycol stearyl isostearate, octyl acrylate, phenyl bis cyano, acetoxy stearate Octyl acrylate, octyl benzoate, caprylic / capric octyl, coconut oil, octyl oleate, octyl decyl acrylate, octyl behenate Dodecyl benzoate, octyl, dodecyl octyl dodecyl erucic acid, octyldodecyl hydroxystearate, Octyldodecyl isostearate, octyldodecyl lactate, octyldodecyl lanolin acid, Meadowfoamate octyldodecyl myristate, octyldodecyl neodecanoate, octyldodecyl, Pivalate, octyldodecyl octanoate, octyl dodecyl, octyl dodecanoate octyldodecyl oleate, octyl Yl dodecyl acrylate, octyl dodecyl olive acid, ricinoleic acid octyldodecyl stearate, octyldodecyl Esters, stearyl stearate, octyl, dodecyl gallate, octyl acrylate, octyl hydroxy stearate, hydroxystearic acid Octyl palmitate, octyl, isononyl acrylate, iso octyl palmitate, octyl isostearate, laurate, octyl linoleoyl Octyl stearate, octyl methoxycinnamate, octyl myristate, pivalic acid, octyl octanoate, octyl oleate Octyl acrylate, octyl palmitate, PCA octyl, nonyl, octyl acrylate, octyl salicylate, octyl stearate, oleyl acetate Glucoside, Oleth-2 benzoate acetate, oleyl acetate, oleyl arachidonic acid, erucic acid oleyl phosphate, Oleyl ester ethyl lactate, oleyl esters, lanolin acid oleyl ester, linoleic acid, oleyl myristate, oleyl ester, Oleic acid oleyl phosphate, oleyl stearate, oleyl ester, oryzanol (oryzanol), ozonation jojoba oil, Palmitoyl Kika Ni Lin (carniline), palmitoyl inulin, palmitoyl serine (serinate) myristate, Two panthenol cysteamine, pan ethyl alcohol, panthenol triacetate, acetate, PCA oleate, glyceryl palmitate peas Esters, PEG-18 castor oil dioleate, PEG-5 DMDM ​​hydantoin oleate, PEG-15 DMDM Hydantoin stearate, PEG-30 hydroxystearate dimer, PEG-20 hydrogenated castor oil isostearate, PEG-50 hydrogenated castor oil isostearate, PEG-20 hydrogenated castor oil triisostearate, PEG-20 dehydration Mannitol laurate, PEG-20 methyl glucose distearate, PEG-80 methyl glucose laurate Esters, PEG-20 methyl glucose sesqui caprylate / caprate half times, PEG-20 methyl glucose lauric half times Esters, PEG-5 oleamide dioleate, PEG-150 pentaerythritol tetrastearate, PEG-3/PEG-2 hydroxy Stearate / glyceryl isostearate / sorbitan esters, PEG-4 proline linoleate, PEG-4 Proline Flax Esters, PEG-8 propylene glycol cocoate, PEG-55 propylene glycol oleate, PEG-25 stearate, propylene glycol, PEG-75 stearate, propylene glycol, PEG-120 stearate, propylene glycol, PEG-40 sorbitan oleate six esters, Six PEG-50 sorbitan oleate ester, PEG-30 sorbitan tetraoleate sorbitan laurate esters, PEG- 60 tetrastearate, PEG-5, trioctyl citrate, PEG-5 cetyl citrate esters, PEG-5 trisodium Lauryl acrylate, PEG-5 trimethylol propane tri myristate, PEG-5 citrate myristate, PEG-5 Tristearyl citrate, PEG-6 ester of undecylenic acid, pentadecalacione, pentaerythritol dioleate, Pentaerythritol distearate, hydrogenated rosin pentaerythritol ester, isostearic acid / capric acid / caprylic acid / neopentyl adipate Tetraol esters, pentaerythritol esters of rosin, pentaerythritol esters of stearic acid, stearic acid / capric acid / caprylic acid / neopentyl adipate Tetraol stearate / isostearic acid / adipic acid / glycolic acid pentaerythritol ester, pentaerythritol ester of rosin acid four, Pentaerythritol tetraacetate, Pentaerythritol tetrabehenate, pentaerythritol tetrabenzoate, four caprylic / capric acid four Pentaerythritol esters, four cocoate, pentaerythritol tetra-iso-nonanoic acid, pentaerythritol, four pentaerythritol monolaurate, Myristic acid, pentaerythritol four, four acid pentaerythritol ester, pentaerythritol tetraoleate, pentaerythritol tetrapelargonate acid Alcohol esters, pentaerythritol tetrastearate, pentaerythritol trioleate acetate, ethyl benzene, phenolphthalein, p-hydroxybenzoate Phenoxy carboxylic acid ethyl ester, phenyl benzoate, p-hydroxybenzoic acid phenyl ester, phenyl salicylate, Macadamiate phylosteryl ester, Poloxamer105 benzoate, Poloxamer182 dibenzoate, polycaprolactone, Poly dimethylaminoethyl methacrylate esters, polyacrylic acid, ethyl acrylate, polyglutamic acid ethyl ester, polymethyl methacrylate Acid ethyl ester, polyacrylic acid methyl esters, polyglutamic acid methyl ester, polysorbate 80 acetate, poly ethyl acetate Alkenyl ester, potassium butylparaben, Deceth-4 phosphate, potassium phosphate, potassium p-hydroxybenzoate, ethyl p-hydroxybenzoate Potassium methyl, potassium propylparaben, PPG-2 Isoceleth-20 acetate, PPG-14 Laureth-60 Two alkyl carbamate, PPG-20 methyl glucose ether acetate, PPG-20 methyl glucose ether distearate Esters, PPG-2 myristyl ether propionate, PPG-14 Palmeth-60 alkyl bis carbamate, PPG-15 steryl ether benzoate, nandrolone desogestrel acetate, propyl acetate, propyl benzoate, propylene carbonate, sea Propylene glycol esters of alginic acid, behenic acid, propylene glycol, propylene glycol octanoate, propylene glycol Ceteth-3 acetate, propylene Ceteth-3 alcohol, propionate, citrate, propylene glycol, propylene glycol cocoate, diethylene glycol ester of capric acid, dihexyl Propylene glycol, diethylene glycol octanoate ester, two coco propylene glycol, propylene glycol di-iso-nonanoic acid, di-iso-hard Propylene glycol fatty acid esters, propylene glycol dilaurate, propylene glycol dicaprylate, propylene glycol dioleate, di-nonanoic acid Propylene glycol distearate, propylene glycol, di (undecanoic acid) propylene glycol, propylene glycol hydroxystearate, Isoceteth-3 acetate, propylene glycol, propylene glycol isostearate, propylene glycol laurate, propylene glycol linoleate Esters, linolenic acid, propylene glycol myristate, propylene glycol, propylene glycol myristyl ether acetate, oleic acid, malonic Alcohol esters, propylene glycol oleate SE, propylene glycol ricinoleate, propylene glycol esters of soybean, propylene glycol monostearate, Propylene glycol stearate SE, propyl gallate, propyl paraben, pyricarbate, pyridoxine two Octanoate, pyridoxine dilaurate, dioctyl pyridoxine acrylate, pyridoxine dipalmitate, pyridoxine Gan Caoting esters, pyridoxine tripalmitate, raffinose myristate, raffinose oleate, ethyl resorcinol Ester, acetate retinyl acetate, retinyl linoleate palmitate, retinyl propionate, retinyl acetate, riboflavin acid Esters, ribonolaclone, rosin acrylate, silicone triol inositol hexaphosphate, Silylbum Marianum Ethyl ester, behenic acid lactate, sodium butylparaben, hexanoyl lactate, cocoyl lactylate, Dilaureth-7, sodium citrate, sodium p-hydroxybenzoate, ethyl 2 - sulfo-ethyl laurate, sodium isostearyl Sodium lactate, Laureth-7 tartrate, sodium lauroyl lactate, sodium methylparaben 2 - sulfo Month Sodium methyl Gui, oleyl lactate, panthenol cysteamine, sodium phytate, sodium methyl p-hydroxybenzoate Propyl gallate, sodium stearoyl lactylate, Sorbeth-2 cocoate, Sorbeth-6 six stearate, Sorbeth-3 Isostearic acetate, sorbitol esters, palmitic acid esters of soybean, soy sterol acetate ester, stearamide DEA- Distearate, stearamide DIBA-stearate, stearamide MEA-stearate, Steareth-5 Hard Fat acid esters, stearoyl lactic acid, acetic acid stearyl ester, acetyl acid octadecyl ester, stearyl beeswax, Stearyl behenate, stearyl benzoate, stearyl octanoate, stearyl citrate, erucic eighteen Alkyl esters, glycol stearyl isostearate, stearyl glycyrrhetinate esters, stearyl heptanoate, lactate ten Eight alkyl ester of linoleic acid octadecyl ester, stearyl octanoate, stearyl stearate, stearyl stearate, ten Eight alkyl esters, sucrose acetate isobutyrate, sucrose benzoate, sucrose cocoate, sucrose dilaurate, Sucrose distearate, sucrose laurate, sucrose myristate, sucrose octaacetate, sucrose oleate, Sucrose palmitate, sucrose esters mountainous Yu, cottonseed sucrose esters, sucrose laurate, sucrose poly- Oleate, sucrose palmitate, sucrose soy ester, sucrose stearate, sucrose ricinoleate, Sucrose stearate, sucrose tetrastearate triacetate, sucrose tribehenate, sucrose tristearate, Tallow-ethyl glucoside, tannic acid, TEA-lauroyl lactate, telmesteine, terpineol acetate Esters of hydroxybenzoic acid tetrabutyl phenyl acrylate, myristyl stearate, eicosyl acrylate, decyl acrylate ascorbyl tetrahexylammonium, Titanium tetrahydrofurfuryl acrylate, tetrahydrofurfuryl acrylate ricinoleate, tocophersolan, tocopheryl acetate, linoleate birth Phenolic esters, linoleic acid / oleic acid, tocopherol acetate, tocopherol nicotinate, tocopheryl succinate, tributyl citrate, Citrate-C12-13 alkyl esters, citrate ester-C14-15 alkyl citrate, octyl, behenic acid ten Trialkyl esters, tridecyl cocoate, tridecyl esters of erucic acid, nonanoic acid, iso-tridecyl laurate, tridecyl acrylate, Tridecyl acid, myristic acid, pivalic acid tridecyl octanoate, tridecyl stearate, tridecyl acrylate, stearyl Yl tridecyl stearate, tridecyl trimellitate esters, triethyl citrate, hydrogenated rosin triethylene glycol ester, Citrate (hexyl decyl) citrate, tri-iso cetyl esters, isopropyl citrate, three three isopropyl linoleate, Isostearyl citrate esters, three linoleic three isostearyl acrylate, three lactim, trilauryl citrate, three Trimethylolpropane caprylate / tridecyl esters, trimethylol propane tri cocoate, trimethylolpropane TRIDODECYLAMINE Ester, trimethylol propane trioctanoate, trimethylol propane tristearate, di trimethylpentyl isobutyrate ester, Trioctyl citrate, borate octyldodecyl, trictyl trimellitic acid esters, citrate ester oils, Panthenol three PABA esters, propylene glycol citrate, stearyl citrate, stearyl phosphate, acetate Vinyl acetate and yeast palmitate esters. ...^*74.87 ± 14.10 ^*70.59 ± 13.85 ^{* *}61.61 ± 14.00 ^{* *}57.95 ± 13.94 ^{* *}55.60 ± 16.05 ^{* *}40.63 ± 11.43 ^{* *}FUFANG DANSHEN DIWAN 2g 291.40 ± 17.85 256.00 ± 50.45 245.80 ± 60.34 268.20 ± 58.15 246.80 ± 69.83 243.00 ± 57.51 201.60 ± 50.05##, 177.80 ± 54.22## (n=5) (100%) 87.95 ± 16.89 ^*84.06 ± 18.59 ^*91.57 ± 17.03 83.97 ± 20.83 ^*82.78 ± 16.16 ^*68.90 ± 14.48 ^{* *}60.56 ± 15.91 ^*

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}Self compare with medication is preceding P＜0.001: #P＜0.05 ##P＜0.01 ###P＜0.001.Table 1.2 is equipped with the influence of administration group to dog acute myocardial ischemia degree (N-ST)

Value rate of change before dosage/kg medicine

(min) group behind the medicine

(100%) 1,530,456,090,120,180 saline 3ml 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 29.60 ± 0.55 (n = 5) (100%) 100.00 ± 0.00 100.00 ± 0.00 100.00 ± .000 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 100.00 ± 0.00 thiocyanuric Troponoid 5mg 30.00 ± 0.00 29.80 ± 0.45 29.60 ± 0.55 29.20 ± 1.10 28.40 ± 1.52 27.00 ± 2.00 # 26.80 ± 1.64 # 25.20 ± 1.79 # # (n = 5) (100%) 99.33 ± 1.49 98.67 ± 1.83 97.33 ± 3.65 94.67 ± 5.06^*90.00 ± 6.67 ^*89.33 ± 5.48 ^*84.00 ± 5.96 ^*FUFANG DANSHEN DIWAN 2g 30.00 ± 0.00 29.20 ± 1.10 30.00 ± 0.00 29.80 ± 0.45 29.20 ± 1.10 29.00 ± 1.22 28.40 ± 1.1#, 27.80 ± 0.45## (n=5) (100%) 97.33 ± 3.65 100.00 ± 0.00 99.33 ± 3.65 97.33 ± 3.65 96.67 ± 4.08 94.67 ± 3.80 92.67 ± 1.49

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}Self compare with medication is preceding P＜0.001: #P＜0.05 ##P＜0.01 ###P＜0.001.Each administration group of table 1.3 is to the influence of dog acute myocardial ischemia degree (N-ST)

Group dosage/kg heart area mm2 ventricle area mm2 infarct size mm2 infarct/cardiac infarction district/ventricle normal saline 3ml 13494.2 ± 1091.4 5228.6 ± 646.0 1110.05 ± 218.01 8.48 ± 0.48 20.66 ± 1.99 diltiazem 5mg 14096.5 ± 3056.4 5377.8 ± 411.2 378.98 ± 138.41 ^{* *}2.52 ± 1.35 ^{* *}7.22 ± 2.87 ^{* *}FUFANG DANSHEN DIWAN 2g 16186.1 ± 261.3 5641.0 ± 365.3 407.70 ± 131.42 ^{* *}2.56 ± 0.84 ^{* *}7.82 ± 1.94 ^{* *}

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}P＜0.001

Each administration group of table 1.4 is to dog venous oxygen content (VO ₂Ml%) influence

Before dosage/kg ischemia behind the ischemia behind (value before the medicine) medicine (min)

Group

(normal value) rate of change (100%) 30 60 90 120 180 normal saline 3ml 18.52 ± 2.55 17.58 ± 1.61 1836 ± 2.79 16.78 ± 2.80 16.84 ± 3.23 17.2 ± 2.24 17.02 ± 2.36

(n=5) 95.89 ± 11.18 104.41 ± 12.95 95.28 ± 11.64 95.50 ± 13.59 98.47 ± 11.66 96.78 ± 9.70 diltiazem 5mg 15.44 ± 2.42 16.56 ± 1.61 16.08 ± 1.13 15.84 ± 1.43 15.92 ± 1.29 15.20 ± 1.50 14.82 ± 2.28

(n=5) 111.45 ± 33.86 97.70 ± 10.36 95.95 ± 8.27 96.37 ± 5.54 92.15 ± 9.42 89.62 ± 11.94 FUFANG DANSHEN DIWAN 2g 16.46 ± 3.38 17.46 ± 2.69 17.50 ± 2.58 16.98 ± 1.94 15.80 ± 2.01#, 15.60 ± 2.60# 15.28 ± 2.87

(n＝5)??????????????????????????107.17±8.78???100.36±3.92???97.79±5.54????90.83±3.67????89.37±6.70????87.32±7.01

Annotate: with self is relatively before the medication: #P＜0.05 ##P＜0.01 ###P＜0.001.Each administration group of table 1.5 is to the comparison of dog serum CK (U/L), LDH (U/L)

(min) group behind (value before the medicine) medicine behind the preceding ischemia of dosage/kg ischemia

(Normal) rate of change (100%) 306090120180 saline 3ml 310.60 ± 56.08 442.40 ± 90.32 # 533.80 ± 86.96 # 644.20 ± 130.96 # 857.60 ± 262.32 # 960.80 ± 247.68 # 1157.60 ± 180.72 # # (n = 5 ) 144.27 ± 24.29 123.19 ± 20.86 147.64 ± 25.98 191.80 ± 26.52 219.41 ± 45.62 268.67 ± 35.47CK diltiazem 5mg 316.20 ± 63.04 699.60 ± 211.52 660.40 ± 184.88 737.80 ± 159.04 820.80 ± 289.76 972.40 ± 347.28 1238 .60 ± 309.12 # # (n = 5) 219.80 ± 38.93^*97.20 ± 12.50 ^*108.84 ± 20.71 ^*115.31 ± 19.97 ^{* *}314.91 ± 23.35 ^*179.51 ± 10.60 ^{* *}FUFANG DANSHEN DIWAN 2g 399.00 ± 25.60 546.40 ± 92.88# 746.60 ± 286.32 994.00 ± 357.60 944.20 ± 250.16#, 1097.80 ± 268.48#, 1097.40 ± 235.84# (n=5) 136.52 ± 21.54 133.85 ± 42.37 177.26 ± 44.50 172.86 ± 40.89 197.71 ± 34.95 200.03 ± 29.77 ^*physiological saline 3ml 120.00 ± 46.00 214.60 ± 54.08#, 214.60 ± 54.08#, 216.60 ± 46.08#, 221.00 ± 64.00#, 221.80 ± 39.36##, 252.80 ± 72.96#, (n=5) 137.36 ± 16.71 137.36 ± 16.71 140.08 ± 21.23 140.51 ± 13.77 145.73 ± 15.56 162.51 ± 16.19LDH CRD401 5mg 106.40 ± 19.12 143.40 ± 28.64 143.40 ± 28.64 134.40 ± 46.48 153.00 ± 70.80 194.60 ± 76.72 164.80 ± 49.36, (n=5) 101.14 ± 17.90^*101.14 ± 17.90 ^*92.58 ± 15.17 ^*99.31 ± 19.02 ^*121.32 ± 22.12 117.24 ± 26.69 ^*FUFANG DANSHEN DIWAN 2g 131.80 ± 17.04 185.20 ± 38.24 185.20 ± 38.24 193.80 ± 43.76 175.00 ± 31.20 195.20 ± 41.04 191.80 ± 28.69 ^*(n=5) 90.81 ± 11.17 ^{* *}90.81 ± 11.17 ^{* *}95.19 ± 10.21 ^*87.87 ± 15.53 ^{* *}98.96 ± 18.62 ^*191.80 ± 28.96

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}Self compare with medication is preceding P＜0.001: #P＜0.05 ##P＜0.01 ###P＜0.001.Each administration group of table 1.6 is to dog plasma ET (pg/ml), TXB ₂(pg/ml) comparison

Dose / kg before ischemia ischemia (drug previous value) after the drug (min) groups (normal) rate of change (100%) 306090120180 saline 3ml 39.47 ± 12.59 47.59 ± 5.79 61.38 ± 10.66 # 60.70 ± 12.19 55.40 ± 10.73 60.83 ± 6.64 # 67.38 ± 6.37 # # (n = 5) 131.40 ± 33.06 128.97 ± 13.55 127.94 ± 20.07 122.34 ± 38.90 130.39 ± 21.06 143.28 ± 12.27ET diltiazem 5mg 34.41 ± 9.41 55.51 ± 3.59 47.51 ± 7.39 46.38 ± 9.02 39.97 ± 7.95 # 41.42 ± 15.69 45.74 ± 9.40 (n = 5) 178.30 ± 57.33 85.14 ± 13.98^*84.06 ± 18.24 ^*71.69 ± 12.10 ^*74.30 ± 17.04 ^*82.16 ± 14.09 ^{* *}FUFANG DANSHEN DIWAN 2g 50.98 ± 2.53 74.98 ± 10.42 65.03 ± 14.86 76.38 ± 12.16 55.96 ± 5.19# 69.90 ± 17.26 69.39 ± 26.20 (n=5) 146.82 ± 18.13 87.34 ± 16.19 ^*102.16 ± 10.76 ^*75.64 ± 6.72 ^*93.30 ± 20.94 90.15 ± 34.40 ^*Normal saline 3ml 120.00 ± 46.00 214.60 ± 54.08#, 214.60 ± 54.08#, 216.60 ± 46.08#, 1511.9 ± 252.2 1164.9 ± 223.0 1268.1 ± 154.8 (n=5) 137.36 ± 16.71 137.36 ± 16.71 140.08 ± 21.23 114.06 ± 8.07 116.22 ± 8.09 134.90 ± 31.09TXB ₂Diltiazem 5mg 106.40 ± 19.12 143.40 ± 28.64 143.40 ± 28.64 134.40 ± 46.48 1093.4 ± 320.9 1284.1 ± 695.0 1032.7 ± 343.1 (n=5) 101.14 ± 17.90 ^*101.14 ± 17.90 ^*92.58 ± 15.17 ^*69.72 ± 8.76 ^{* *}63.03 ± 14.20 ^{* *}62.77 ± 14.51 ^*FUFANG DANSHEN DIWAN 2g 131.80 ± 17.04 185.20 ± 38.24 185.20 ± 38.24 193.80 ± 43.76 938.7 ± 46.4 883.6 ± 107.7##, 902.6 ± 118.3# (n=5) 90.81 ± 11.17 ^{* *}90.81 ± 11.17 ^{* *}95.19 ± 10.21 ^*90.11 ± 14.32 83.00 ± 3.65 ^{* *}84.67 ± 5.80 ^*

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}Self compare with medication is preceding P＜0.001: #P＜0.05 ##P＜0.01 ###P＜0.001.

Each administration group of table 1.7 is to dog plasma 6-Keto-PGF _{1 α}, 6-Keto-PGF _{1 α}/ TXB ₂Comparison of dose / kg before ischemia ischemia (drug previous value) after the drug (min) groups (normal) rate of change (100%) 306090120180 saline 3ml 1673.2 ± 221.0 1469.0 ± 283.6 # 1200.6 ± 335.3 # 1099.2 ± 301.0 # # # 1056.2 ± 210.2 # # 1095.0 ± 215.2 # 1052.8 ± 187.7 # # (n = 5) NS 3ml 120.00 ± 46.00 214.60 ± 54.08 # 1.174 ± 0.383 # 1.037 ± 0.381 # 1.037 ± 0.381 # 1.040 ± 0.368 # 0.852 ± 0.218 (n = 5) 137.36 ± 16.71 73.30 ± 4.14 65.57 ± 8.52 65.67 ± 11.87 65.67 ± 11.87 57.95 ± 11.776-Keto-PGF_{1 α}Diltiazem 5mg 106.40 ± 19.12 143.40 ± 28.64 1.507 ± 0.505##, 1.501 ± 0.358# 1.980 ± 0.924 1.980 ± 0.924 1.801 ± 0.596/TXB ₂(n=5) 101.14 ± 17.90 ^*148.42 ± 17.35 ^{* *}155.44 ± 28.97 ^{* *}203.82 ± 83.25 ^*203.82 ± 83.25 ^*198.48 ± 87.02 ^*FUFANG DANSHEN DIWAN 2g 131.80 ± 17.04 185.20 ± 38.24 1.523 ± 0.441 1.764 ± 0.270 1.320 ± 0.254 1.320 ± 0.254 1.388 ± 0.388 (n=5) 90.81 ± 11.17 ^{* *}108.02 ± 21.11 ^*158.76 ± 77.62 ^*105.35 ± 25.55 ^*105.35 ± 25.55 ^*105.05 ± 19.85 ^*

Annotate: compare with matched group: ^*P＜0.05 ^*P＜0.01 ^{* *}Self compare with medication is preceding P＜0.001: #P＜0.05 ##P＜0.01 ###P＜0.001.Two. to the protective effect of Ischemia and Reperfusion in vivo in Rats myocardial damage

This research and inquirement FUFANG DANSHEN DIWAN is to the Ischemia and Reperfusion in vivo in Rats myocardial damage, the especially influence of apoptosis of cardiac muscle.

1. animal model: Wistar strain male rat, open chest anesthetized is kept breathing, around left coronary artery, and carries out ligation between left auricle and pulmonary conus.

2. method: rat is divided into 5 groups at random: 1. sham operated rats (sham-operated control), normal saline is irritated stomach, 1ml/ days, totally 4 days; 2. myocardial ischemia-reperfusion group (M-IR), it is the same to irritate the stomach method; 3. FUFANG DANSHEN DIWAN I group (DSP I) was dissolved in the 1ml normal saline with 150ml/Kg/ days, irritated stomach (method is the same); 4. FUFANG DANSHEN DIWAN II organizes (DSPII), and with 300ml/kg/ days, all the other methods were with DSP I; 5. FUFANG DANSHEN DIWAN III organizes (DSPIII), and with 450ml/kg/ days, all the other methods were with DSP I.

Testing index:

2.1 myocardial infarct size is measured: ligation left coronary artery once more before the sacrifice of animal, take out after injecting 1% her Wen orchid in the ventricle, with the PBS rinsing, freezing 1h.After removing unnecessary tissue, the 30min that in 1%TTC, dyes (37 ℃).With weight method calculating myocardium ischemia hazardous area (she does not dye the district by the Wen orchid), infarcted region (TTC does not dye the district).

2.2 cardiomyocyte apoptosis cell in-situ marker detection and analysis: each heart get 3 different parts section each 1, press duPT breach end-labelling (TdT-mediateflourescein-duTP nick end labeling, TUNEL) DNA3 ' in the labelling cardiomyocyte apoptosis nucleus-OH end of the band fluorescence of end deoxyribonucleic acid transferase (TdT enzyme) mediation.Select 5 visuals field, in 300 myocardial cell of each visual field counting positive cell number with the shared percentage ratio of average computation positive cell number as the apoptosis of cardiac muscle positivity index (apoptotic index, AI)

3. result

3.1 the variation of myocardial infarct size: sham-operation 7h does not see the myocardial infarction phenomenon; Myocardial infarction was obvious after myocardial ischemia 1h poured into 6h again; FUFANG DANSHEN DIWAN (DSP) can be dwindled the ischemia-reperfusion myocardial infarct size, and increases with dosage, and myocardial infarct size dwindles and significantly sees Table 2.1.

Variation group infarcted region weight/left ventricular mass (%) infarcted region weight/hazardous area weight (%) Sham-control that table 2.1 is respectively organized myocardial infarct size organizes 00 M-IR group, 41.8 ± 7.9 63.2 ± 8.6 DSP I group 34.6 ± 7.2 ^{* △}55.7 ± 8.4 ^*DSPII group 27.1 ± 6.5 ^{* △}47.3 ± 7.7 ^{* △}DSPIII group 19.4 ± 6.1 ^{* △ △ ◇}38.9 ± 7.5 ^{* △ △ ◇}Annotate: compare with the M-IR group, ^*P＜0.05, ^*P＜0.01; Compare with DSP I group, ^△P＜0.05, ^{△ △}P＜0.01;

Compare with DSP II group, ^◇P＜0.05.3.2 the change of cardiomyocyte apoptosis cell: relatively large DSP can obviously reduce ischemia-reperfusion cardiac cellular apoptosis quantity, and AI descends along with the increase of DSP dosage, sees Table 2.2.

Variation group example number myocardial cell AI (%) Sham-control that table 2.2 is respectively organized the apoptosis of cardiac muscle cell quantity organizes 10 0.82 ± 0.47 M-IR and organizes 10 22.76 ± 13.17DSP I and organize 10 20.93 ± 13.25 ^*DSPII organizes 10 16.28 ± 11.96 ^{* △ ◇}DSPIII organizes 10 10.75 ± 9.44 ^{△ △ ◇ ▲}Annotate: compare with the Sham-cotrol group, ^*P＜0.01; Compare with the M-IR group, ^△P＜0.05, ^{△ △}P＜0.01;

Compare with the DSPI group, P＜0.05, ^{◇ ◇}P＜0.01; Compare with the DSPII group, ^▲P＜0.05

Conclusion: studies show that originally FUFANG DANSHEN DIWAN can obviously dwindle the myocardial infarct size of myocardial reperfusion rat, show that further DSP pours into the myocardium cell necrosis variation again to ischemic myocardial cells good protective action is arranged.Three. the proteic influence of Fas/FasL during to the neonatal rat myocardial cell anoxia of cultivating and anoxia _ reoxygenation

The Fas gene is the apoptotic stimulus gene, and its protein expressioning product Fas antigen is epicyte protein, finds in the experiment of cardiac muscle cells anoxia that recently the mRNA expression of Fas gene has substantial connection with apoptosis of cardiac muscle.FasL is the part of Fas, is the FasL of TNF homology type membrane-spanning protein surface of cell membrane, can conduct dead signal to the Fas receptors bind of cell surface in cell.

1. method: cultivate newborn 5-7 days neonatal rat myocardial cell routinely, carry out the test of anoxia and anoxia _ reoxygenation after cultivating 24 hours, the second immunohistochemical method detects the variation of myocardial cell Fas/FasL protein expression.

2. the result shows

2.1 anoxia 4.5h group and anoxia 30min be the variation of oxygen supply 4h group Fas/FasL protein expression again.Anoxia group and reoxygenation group significantly increase than matched group Fas/FasL protein expression, and more not protection group of FUFANG DANSHEN DIWAN protection group Fas/FasL protein expression significantly descends, and sees Table 3.1.

2.2 anoxia 10.5h group and anoxia 30min be the variation of oxygen supply 10h group Fas/FasL protein expression again.Anoxia group and reoxygenation group significantly increase than matched group Fas/FasL protein expression, and more not protection group of FUFANG DANSHEN DIWAN protection group Fas/FasL protein expression significantly descends, and sees Table 3.2.

2.3 anoxia 10.5h group has increase trend than anoxia 4.5h group Fas/FasL protein expression, but no significant difference.

2.4 reoxygenation 10.5h group and reoxygenation 4h group no significant difference.

2.5 the Fas/FasL protein expression becomes dependency.

Above result shows the generation of the expression decreased apoptosis that FUFANG DANSHEN DIWAN can be by intervening Fas/FasL, and the protection cell is avoided the damage of anoxia and anoxia _ reoxygenation.

Table 3.1 anoxia 4.5h group and anoxia 30min be the variation of oxygen supply 4h group Fas/FasL protein expression again

Fas albumen PEI (%) FasL albumen PEI (%)

No compound Salviae Miltiorrhizae has compound Salviae Miltiorrhizae not have compound Salviae Miltiorrhizae compound Salviae Miltiorrhizae is arranged

Drop pill protection drop pill protection drop pill protection drop pill protection matched group 2.59 2.61 2.27 2.26 anoxia 4.5h group 18.01 ^*9.62 ^*19.67 ^*10.74 ^*Reoxygenation 4h group 19.02 ^*10.00 ^*20.71 ^*10.69 ^*Annotate: compare with matched group, ^*The comparison of P＜0.05 and no FUFANG DANSHEN DIWAN protection group, ^*P＜0.05 table 3.2 anoxia 10.5h group and anoxia 30min be the variation of oxygen supply 10h group Fas/FasL protein expression again

Fas albumen PEI (%) FasL albumen PEI (%)

No compound Salviae Miltiorrhizae has compound Salviae Miltiorrhizae not have compound Salviae Miltiorrhizae compound Salviae Miltiorrhizae is arranged

Drop pill protection drop pill protection drop pill protection drop pill protection matched group 2.89 2.22 2.22 2.11 anoxia 10.5h group 21.75 ^*11.64 ^*22.83 ^*14.20 ^*Reoxygenation 10h group 19.70 ^*12.95 ^*22.12 ^*13.08 ^*Annotate: compare with matched group ^*P＜0.05 is with the comparison of no FUFANG DANSHEN DIWAN protection group ^*P＜0.05 four. to rabbit hyperlipemia and atherosclerotic influence

1. method

1.1 experiment grouping: (1) normal control group (8): feed with normal diet;

(2) high fat moulding group: feed with high lipid food.Nursing to 4 weekend, weigh, survey blood fat, with high fat moulding component is 4 groups (12 every group): 1. high fat matched group, 2. 3. 4. simvastatin group (1mg/kg/ days) of FUFANG DANSHEN DIWAN small dose group (2g crude drug/kg/ days) of the heavy dose of group of FUFANG DANSHEN DIWAN (4g crude drug/kg/ days); Except that above-mentioned dosed administration, all the other all give distilled water, to off-test at 12 weekends.

1.2 experimental technique and index

(1) aortic disease pathology procuratorial work: be administered to and put to death animal 8 weekends, take out aorta, peel off adventitia and fatty on every side, cut off along center line, vertical get 1/5 aorta and be used for lipid assay, remainder is used to calculate the plaque area and the whole tremulous pulse gross area with soudan III dyeing, obtains pathological changes percentage ratio and classification.The location cuts aorta system paraffin section, and HE dyeing is observed with micrometer and measured inner membrance speckle average thickness.

(2) coronary artery pathological changes pathology procuratorial work: 0.4cm place and centroid point 0.8cm place's crosscut makes into three fritters below the arteria coronaria ditch, carry out soudan III dyeing, observe and calculate coronary artery the blood vessel number of speckle and pathological changes incidence rate (pathological changes incidence rate=have blood vessel sum * 100% of blood vessel number/each tangent plane of pathological changes) are arranged, carry out classification by speckle occluding vascular degree in addition, calculate average with integration method.

2. result:

(1) to the influence of rabbit anteserum lipid content: test shows takes 2,4,8 weeks after the FUFANG DANSHEN DIWAN, and index all is starkly lower than high fat to group, sees Table 4.1.

(2) aorta AS area: it is smooth to observe visible normal rabbits aortic tunica intima, and no AS speckle, clause occur, and Composite Salvia Dropping Pill group rabbit aortic disease area percentage all is significantly less than high fat matched group (P＜0.05).The aorta lipid content: be administered to for 8 weekends, high fat matched group man rabbit aorta TC, TG content are all apparently higher than matched group (P＜0.001), and Composite Salvia Dropping Pill group TC is starkly lower than high fat matched group (P＜0.05) and sees Table 4.2.

(3) to the influence of liver coefficient and liver lipid content: test shows that Composite Salvia Dropping Pill group and high fat matched group specific energy obviously reduce TG content (P＜0.05), see Table 4.3.

Conclusion: test shows that FUFANG DANSHEN DIWAN obviously reduces rabbit anteserum TC, TG, LDL-C, VLDL-C concentration and TC/HDL-C ratio, reduces the aorta plaque thickness, the aorta plaque area is had the trend that reduces.The prompting FUFANG DANSHEN DIWAN has the effect of blood lipid regulation, and the effect of the atherosclerosis of preventing (AS) is arranged simultaneously to a certain extent.

The influence of table 4.1 pair rabbit anteserum lipid content (mmol/L, n=8, the test period group dosage TC LDC-C VLDC-C TC/HDL-C TG of x ± s)

Normal control group 2.23 ± 0.19 0.79 ± 0.20 0.41 ± 0.20 2.25 ± 0.59 0.74 ± 0.17

FUFANG DANSHEN DIWAN 4g 2.26 ± 0.14 0.91 ± 0.14 0.50 ± 0.19 2.75 ± 0.59 0.81 ± 0.18 before high fat matched group 2.31 ± 0.22 0.94 ± 0.16 0.42 ± 0.24 2.58 ± 0.80 0.74 ± 0.21 test

FUFANG DANSHEN DIWAN 2g 2.21 ± 0.19 0.84 ± 0.17 0.40 ± 0.12 2.30 ± 0.29 0.78 ± 0.30

Simvastatin 1mg 2.27 ± 0.18 0.87 ± 0.21 0.51 ± 0.27 2.72 ± 0.85 0.72 ± 0.15

Normal control group 2.19 ± 0.20 ^{* *}0.87 ± 0.20 0.45 ± 0.12 ^{* *}2.51 ± 0.30 ^{* *}0.83 ± 0.21 ^*

FUFANG DANSHEN DIWAN 4g 27.48 before high fat matched group 26.69 ± 3.86 19.40 ± 4.19 6.42 ± 2.31 31.17 ± 9.49 2.25 ± 1.03 administrations ± 6.83 20.25 ± 6.80 6.34 ± 2.57 32.07 ± 9.70 2.10 ± 0.74

FUFANG DANSHEN DIWAN 2g 28.43 ± 5.46 20.77 ± 6.55 6.84 ± 2.28 36.51 ± 12.31 2.25 ± 0.86

Simvastatin 1mg 26.92 ± 7.72 19.69 ± 8.33 6.35 ± 1.42 31.68 ± 10.14 2.04 ± 1.00

Normal control group 2.15 ± 0.34 ^{* *}0.88 ± 0.22 ^{* *}0.37 ± 0.14 ^{* *}2.43 ± 0.42 ^{* *}0.74 ± 0.10 ^{* *}

High fat matched group 34.15 ± 6.97 26.66 ± 6.21 6.65 ± 1.40 43.02 ± 11.38 3.01 ± 0.84 administrations, 2 all FUFANG DANSHEN DIWAN 4g 24.81 ± 6.94 ^*16.54 ± 699 ^*7.39 ± 1.93 29.62 ± 11.16 ^*1.60 ± 0.56 ^*

FUFANG DANSHEN DIWAN 2g 31.74 ± 7.91 25.27 ± 7.45 5.66 ± 1.70 39.31 ± 7.23 2.12 ± 0.91

Simvastatin 1mg 27.06 ± 4.46 ^*19.54 ± 5.71 ^*6.66 ± 1.65 32.29 ± 7.39 ^*1.85 ± 0.55 ^*

Normal control group 2.30 ± 0.20 ^{* *}0.97 ± 0.30 ^{* *}0.38 ± 0.19 ^{* *}2.48 ± 0.41 ^{* *}0.78 ± 0.17 ^{* *}

High fat matched group 37.87 ± 6.92 27.73 ± 7.19 9.06 ± 2.30 35.95 ± 9.19 2.84 ± 0.71 administrations, 4 all FUFANG DANSHEN DIWAN 4g 25.96 ± 5.64 ^*18.06 ± 6.02 ^*6.72 ± 1.46 ^*22.19 ± 5.07 ^*1.74 ± 0.39 ^*

FUFANG DANSHEN DIWAN 2g 35.46 ± 8.86 27.41 ± 8.17 6.94 ± 1.17 ^*32.56 ± 8.52 2.34 ± 0.33

Simvastatin 1mg 26.1 ± 3.03 ^{* *}18.22 ± 3.37 ^*6.54 ± 0.74 ^*19.6 ± 4.38 ^{* *}1.80 ± 0.31 ^*

Normal control group 2.06 ± 0.26 ^{* *}0.64 ± 0.44 ^{* *}.044 ± 0.28 ^{* *}2.14 ± 0.41 ^{* *}0.80 ± 0.27 ^{* *}

High fat matched group 46.19 ± 8.26 32.04 ± 9.69 13.37 ± 3.51 64.27 ± 21.3 4.34 ± 1.45 administrations, 8 all FUFANG DANSHEN DIWAN 4g 27.8 ± 7.99 ^{* *}19.35 ± 8.05 ^*7.44 ± 2.17 ^*26.9 ± 10.76 ^*2.73 ± 0.75 ^*

FUFANG DANSHEN DIWAN 2g 32.47 ± 4.73 ^*22.59 ± 4.94 ^*8.91 ± 2.17 ^*35.8 ± 11.72 ^*3.67 ± 0.88

Simvastatin 1mg 26.3 ± 4.40 ^{* *}17.78 ± 5.69 ^{* *}7.30 ± 2.05 ^{* *}22.3 ± 6.54 ^{* *}2.70 ± 0.77 ^*Annotate: compare with high fat matched group ^*P＜0.05, ^*P＜0.01, ^{* *}P＜0.001

Table 4.2 pair aorta lipid content influence group dosage (/kg/ days) number of animals (n) TC normal control group 8 0.51 ± 0.08 ^{* *}High fat matched group 8 7.80 ± 2.07 FUFANG DANSHEN DIWAN 4g 8 5.30 ± 1.62 ^*FUFANG DANSHEN DIWAN 2g 8 5.51 ± 1.86 ^*Simvastatin 1mg 8 4.93 ± 2.62 ^*Annotate: compare with high fat matched group ^*P＜0.05, ^{* *}P＜0.001

Table 4.3 couple hepatic tissue TG and liver coefficient influence group dosage (/kg) TG (mg/g histoorgan) liver coefficient (g/100g body weight) normal control 5.50 ± 1.05 ^*2.83 ± 0.36 ^{* *}High fat contrast 9.70 ± 1.69 5.57 ± 0.78 FUFANG DANSHEN DIWAN 4g 7.38 ± 1.67 ^*5.08 ± 0.77

2g 8.76 ± 0.86 5.80 ± 1.16 simvastatin 1mg 7.44 ± 1.49 ^*5.16 ± 0.60 annotates: compare with high fat matched group ^*P＜0.05, ^{* *}P＜0.001 five. the effect () of antioxidation and removing free radical is to the influence of myocardial ischemia reperfusion injury serum MDA, SOD etc.

By with diltiazem relatively, observe the influence of FUFANG DANSHEN DIWAN to the serum MDA of ischemia-reperfusion cardiac muscle and related biochemical indicator, SOD etc.

1. method:

(1) experiment grouping: matched group (getting serum), model group (normal saline), diltiazem group (30mg/kg) as normal control, FUFANG DANSHEN DIWAN 4.8,2.4g/kg group, each group all is diluted to desired concn with normal saline, and dosage is 3ml/kg, and route of administration is a duodenum.

(2) experimental technique: the anesthesia of Wistar animal via pentobarbital sodium, face upward the position and fix, open breast, open pericardium, expose heart, in left anterior descending coronary artery root threading, be equipped with ligation and use.Separate 12 rectum, feed and be subjected to the reagent thing.After 2 hours, blood is got in the abdominal cavity, measures serum MDA, SOD content.

2. result: Composite Salvia Dropping Pill group SOD increases, and with matched group notable difference (P＜0.01) is arranged relatively, and the influence of not observing the MDA value sees Table 5.1.

Table 5.1 FUFANG DANSHEN DIWAN is to the influence of activity of SOD in serum and MDA content

Group dosage SOD (U/ml) MDA (μ mol/L) * 10 ^-3Normal control group 830.8 ± 31.9 2.60 ± 0.35

Model group 627.7 ± 70.9## 5.42 ± 0.97## diltiazem group 30mg 817.6 ± 115.6 ^*5.29 ± 1.07 FUFANG DANSHEN DIWAN 3.0g/kg 801.7 ± 74.6 ^*5.83 ± 1.24

6.0g/kg?????794.2±122.6 ^**?????????5.43±1.06

Annotate: ## and normal group comparative control P＜0.01; ^*Compare P＜0.01 with model group.

Conclusion: FUFANG DANSHEN DIWAN has protective effect to ischemical reperfusion injury, can obviously increase the activity of SOD.

(2) to the influence of rabbit anteserum, liver SOD activity and MDA content

1. method: experiment is divided into: (1) normal control group: feed with normal diet; (2) high fat moulding group: feed with high lipid food.Nursing to 4 weekend, weighing, survey blood fat, is 4 groups with high fat moulding component: 1. high fat matched group, the 2. heavy dose of group of FUFANG DANSHEN DIWAN (4g crude drug/kg/ days), 3. FUFANG DANSHEN DIWAN small dose group (2g crude drug/kg/ days), 4. simvastatin group (1mg/kg/ days); Give the rabbit gastric infusion by above-mentioned dosage, normal control group and high fat matched group are given the equal-volume distilled water, to off-test at 12 weekends.

2. result

(1) serum MDA and SOD measure and show; In 8 weeks of administration, high fat matched group MDA content is apparently higher than normal control group (P＜0.01), and SOD is active to compare no significant difference with the normal control group; Each administration group SOD activity and MDA content and high fat matched group be no significant difference relatively all.

(2) liver MDA and SOD measure and show: 8 weeks of administration, high fat matched group MDA content is apparently higher than normal control group (P＜0.001), the SOD activity is starkly lower than normal control group (P＜0.001), heavy dose of group of FUFANG DANSHEN DIWAN and simvastatin group liver MDA content all are starkly lower than high fat matched group (P＜0.001), and each administration group SOD activity is all apparently higher than high fat matched group (P＜0.01).See Table 5.2.

Table 5.2 FUFANG DANSHEN DIWAN is to rabbit anteserum, liver SOD activity and MDA content influence (x ± s)

Group dosage n serum liver

(/kg/d)?????????SOD???????????MDA?????????????SOD???????????????MDA

(u/ml) (nmol/ml) (10 ³The u/g tissue wet) (10 ³The u/g tissue wet) normal control group 8 776.9 ± 72.8 2.73 ± 0.42 ^*12.85 ± 0.50 ^{* *}189.1 ± 30.0 ^*High fat matched group 8 754.7 ± 44.2 6.82 ± 3.54 9.87 ± 0.98 387.3 ± 38.3 FUFANG DANSHEN DIWAN 4g crude drugs 8 781.7 ± 152.3 6.24 ± 3.22 11.67 ^*± 0.82 256.3 ± 20.0 ^{* *}

2g crude drug 8 772.4 ± 84.8 6.24 ± 2.16 11.37 ± 0.59 ^*325.7 ± 119.9 simvastatin group 1mg 8 816.7 ± 77.2 5.63 ± 1.30 11.62 ± 0.38 ^{* *}249.3 ± 42.6 ^{* *}Annotate: compare with the hyperlipidemia matched group ^*P＜0.01 ^{* *}P＜0.001

MDA is the main degradation products of lipid peroxidation, but the major injury membrane structure causes cells of organs infringements such as conscience.SOD is the scavenger of ultra-oxygen anion free radical, can suppress the lipid peroxidation that free radical starts.FUFANG DANSHEN DIWAN can make the SOD vigor significantly rise, and MDA significantly descends, and has reduced level of lipid, plays the effect that alleviates visceral organ injury.Six. to the arrhythogenic influence of external source free love base

Adopt the method for Lngendorff perfusion device, duplicate the arrhythogenic model of free radical, observe the influence of FUFANG DANSHEN DIWAN it to Wastar isolated rat heart perfusion ferrous sulfate (0.25mmol/L)/anti-bosom hematic acid (1.0mmol/L).

1. experiment grouping

(1) blank group (normally): continue perfusion 45 minutes with perfusate, observe electrocardiogram and change.

(2) Composite Salvia Dropping Pill group: add FUFANG DANSHEN DIWAN with 50mg/L concentration in the perfusate and continue perfusion 45 minutes,, observe electrocardiogram and change.

(3) radical damage group (free radical): after isolated heart was irritated 15 minutes in advance, perfusate added ferrous sulfate (0.25mmol/L)/anti-bosom hematic acid (1.0mmol/L) and continues perfusion 30 minutes, observes electrocardiogram and changes.

(4) FUFANG DANSHEN DIWAN protection group (FUFANG DANSHEN DIWAN+free radical): add the pre-filling of FUFANG DANSHEN DIWAN after 15 minutes with 50mg/L concentration in the perfusate; add ferrous sulfate (0.25mmol/L)/anti-bosom hematic acid (1.0mmol/L) in the perfusate and continue perfusion 30 minutes, observe electrocardiogram and change.

(5) isoptin protection group (isoptin+free radical): add the pre-filling of isoptin after 15 minutes with 1ml/L concentration in the perfusate; add ferrous sulfate (0.25mmol/L)/anti-bosom hematic acid (1.0mmol/L) in the perfusate and continue perfusion 30 minutes, observe electrocardiogram and change.

2. result: the basis set incidence of arrhythmia that makes the isolated perfusion rat of exogenous freedom is up to 100%, and the ventricular fibrillation incidence rate is 43%, and 1mg/L isoptin and 50mg/L FUFANG DANSHEN DIWAN can make the arrhythmia rate reduce by 71.4% and 87.5%, see Table 6.1.Show that FUFANG DANSHEN DIWAN has the arrhythmia effect due to the free radical resisting.

Table 6.1 FUFANG DANSHEN DIWAN is to the arrhythmia effect due to the external source free love base generation system

The routine number atrioventricular dissociation ventricular premature contraction chamber speed of dividing into groups chamber total arrhythmia of quivering

The normal 70000000000 compound danshen dripping pills 70000000000 free radical 75 71.4 5 71.4 3 42.7 3 42.7 7 100 isoptins+free radicals 6001 16.6 1 16.6 002 of number of cases % number of cases % number of cases % number of cases % number of cases %^*33.3 FUFANG DANSHEN DIWAN+free radical 81 12.5 0000001 ^*12.5 annotate: compare with freedom is basis set, ^*P＜0.05 ^*P＜0.001 seven. to the therapeutical effect of severe acute pancreatitis in rats

This experiment merges the variation of research endothelin level on the multiple organ dysfunction model and the therapeutical effect of FUFANG DANSHEN DIWAN in severe acute pancreatitis in rats.

1. experiment grouping

Make the Severe Acute Pancreatitis SAP animal model according to classical through the retrograde injection of gallbladder ductus pancreaticus Na-Tc.Animal is the Wistar rat.

(1) normal control group (matched group): not ligation gallbladder ductus pancreaticus, only open abdomen, only turn over pancreas and promptly close abdomen.Preceding 30 minutes of art and postoperative 2 hours be subcutaneous injection normal saline (5ml/kg) at twice, and postoperative blood sampling in 12 hours is put to death.

(2) brine treatment group (saline group): model was made preceding 30 minutes and model is made back 2 hours subcutaneous injection normal saline (5ml/kg) at twice, and model is made blood sampling in back 12 hours and put to death.

(3) composite salvia dropping pill for curing group (Radix Salviae Miltiorrhizae group): model was made preceding 30 minutes and model is made back 2 hours at twice with FUFANG DANSHEN DIWAN (400mg/kg) filling stomach, and model is made blood sampling in back 12 hours and put to death.

2. result

Glutamate pyruvate transaminase (GPT), blood urea nitrogen (BUN), amylase (Amg) content all obviously raise and (compare with matched group in the saline treated animal serum, P＜0.01), though Composite Salvia Dropping Pill group GPT, BUN, Amg content raise to some extent and (compare with matched group, P＜0.01) but all be lower than the saline group and (compare with the saline group, P＜0.01), sees Table 7.1.Endothelin (ET) content obviously raises (comparing P＜0.001 with matched group) in the saline treated animal blood plasma, and ET content is starkly lower than saline group (P＜0.05) and compares P＞0.05 with matched group in the Composite Salvia Dropping Pill group blood plasma, sees Table 7.2.Mirror is observed the metamorphosis of pancreas, liver, lung tissue down, and visible Composite Salvia Dropping Pill group is greatly improved than the saline group.

GPT (u/l), BUN (mmol/L), Amg (u) changes of contents in each treated animal of table 7.1

Matched group saline group Composite Salvia Dropping Pill group GPT 48.89 ± 10.84 1162.48 ± 258.90 ^*612.13 ± 155.50 ^*##BUN 9.04 ± 1.47 27.43 ± 2.61 ^*19.74 ± 3.23 ^*#Amg 4880 ± 1850.07 11970.7 ± 1530.65 ^*9458.4 ± 782.32 ^*# annotates: compares with matched group, ^*P＜0.01 ^*P＜0.001

Compare #P＜0.01 ##P＜0.001 with the saline group

The variation of ET (pg/mg) content in each treated animal blood plasma of table 7.2

Matched group saline group Composite Salvia Dropping Pill group ET 149.091 ± 19.537 247.096 ± 116 ^*149.291 ± 41.865 ^*#

Annotate: compare with matched group, ^*P＞0.05 ^*P＜0.001

Compare #P＜0.05 with the saline group

More than experiment prompting Severe Acute Pancreatitis SAP merging multiple organ dysfunction endothelin level content obviously raises, and composite salvia dropping pill for curing bleeding from anus slurry content of ET obviously descends and significantly improves the organ functions such as liver, kidney and pancreas of animal.Eight. antiplatelet aggregation and thrombosis

1. to the influence of rat platelet aggregation: male rat, about body weight 300g, 3% pentobarbital sodium ip anesthesia, from carotid artery blood sampling 1ml, centrifugal, get platelet rich plasma (PRP) and platelet poor plasma (PPP), in PRP, add ADP, survey platelet aggregation rate in the 5min.See Table 8.1.

(X ± SD) assembles inhibiting rate % control group buffer solution 31 66.74 ± 2.04 compound danshen dripping pillses 0.4 14 35.09 ± 2.55 48.12 " Tongmailing "-medicine for promoting blood-circulations 0.2 10 53.10 ± 2.75 21.74 " Xuesaitong Injection " 0.4 11 48.29 ± 5.5 24.543. to the thrombotic impact of rat experiment to table 8.1: with reference to the Umetsu method, test on the average PAR of group dosage (g/kg) model number that affects of the outer platelet aggregation of ADP inductor. Found that FUFANG DANSHEN DIWAN heavy dose (100mg/kg) can significantly suppress rat suppository and form, and do not have obvious influence during little metering (50mg/kg), see Table 8.2.

Table 8.2 pair rat experiment is thrombotic to influence the average aggregation rate of group dosage (g/kg) model number (suppression ratio % matched group normal saline 10 21.8 ± 2.4 aspirin 30 10 10.6 ± 2.1 of X ± SD) ^*49.2 FUFANG DANSHEN DIWAN 50 10 21.2 ± 2.9 6.5

100 10 11.7 ± 2.6 ^*44.8 annotate: compare with matched group ^*P＜0.014. is to the influence of rabbit platelet cAMP content: adopt radio immunoassay to measure cAMP content, precipitation is measured protein content with the Hartree method.Found that, with matched group relatively, FUFANG DANSHEN DIWAN heavy dose (100mg/kg) can significantly improve platelet cAMP content, and does not have obvious influence when low dose of (50mg/kg), sees Table 8.3.

(group dosage (mg/kg) sample number (cAMP) of X ± SD) is albumen matched group normal saline 15 6.2 ± 2.1 aminophyllines 0.6 20 15.4 ± 3.9 (Pmol/mg) in the influence of table 8.3 pair rabbit platelet cAMP content ^*FUFANG DANSHEN DIWAN 1.0 20 8.7 ± 3.2

2.0 10 13.6 ± 2.5 ^*Annotate: compare with matched group ^*P＜0.015. is to the influence of rat plasma cAMP content: blood sample cAMP content adopts radio immunoassay to measure.Found that compare with matched group, 30min and 60min all can significantly improve plasma cAMP content after FUFANG DANSHEN DIWAN heavy dose (100mg/kg) administration, and low dose of (50mg/kg) group there be not obvious the influence, sees Table 8.4.

The influence of table 8.4 pair plasma cAMP content (group dosage (mg/kg) the number of animals CAMP content (Pmol/ml blood plasma) of X ± SD)

60min matched group normal saline 10 11.8 ± 3.6 11.4 ± 3.2 aminophyllines 30 10 20.7 ± 3.2 21.1 ± 3.8 FUFANG DANSHEN DIWAN 50 10 13.4 ± 4.1 13.3 ± 3.3 after the 30min administration after the administration

100 10 18.4 ± 2.9 17.6 ± 3.1 annotate: compare with the time with matched group ^*P＜0.01

Conclusion: the raising of cAMP level, can suppress phosphate and Cycloxygenase, reduce the generation of prostaglandin peroxide; Also but activated protein kinase makes memebrane protein composition phosphorylation, has changed the adaptability of memebrane protein composition to the induced platelet aggregation substance, thereby anticoagulant reaches antithrombotic effect.FUFANG DANSHEN DIWAN can improve platelet and plasma cAMP content and have antithrombotic effect.Nine. to the influence of diabetes rat blood vessel and neuropathy

Method: 38 SD rats are divided into normal control group, model group and Composite Salvia Dropping Pill group at random.Diabetes rat carries out modeling with lumbar injection STZ60mg/kg.The drop pill group is with FUFANG DANSHEN DIWAN (0.25/kg.d ^-1) sneak into the normal diet administration; Model group and normal control group are fed normal diet.Experiment periods is 6 months.T-CHOL (TC), high density lipoprotein-c (HDL-c), low density lipoprotein, LDL-c (LDL-c) adopt U.S. Berer company test kit, and triglyceride (TG) is used the acetylacetone,2,4-pentanedione development process; Blood plasma nitric oxide (NO) fluorescence spectrophotometry detects; Propylene glycol (MDA) reacts colorimetry with TBA; Whole blood glutathione peroxidase (GSH-PX) adopts the DTNB direct method; Tissue plasminogen activator (t-PA), plasminogen activator inhibitor (PAI), DD, FDP euzymelinked immunosorbent assay (ELISA) detect; The insulin radioimmunology detects; Glycolated hemoglobin (HbA ₁C) adopt high-efficient liquid phase technique; Hemorheology Contraves low share 30 type hemorheology instrument (Switzerland's product) are measured.

The result: 24 hours albumen of drop pill group significantly is lower than model group (P＜0.001) and is 45% of model group in the time of 6 months, and uric acid (UA) also obviously reduces (P＜0.001) simultaneously; But serum creatinine (Scr), serum urea nitrogen (BUM) and urine are measured between two groups still no significant difference (P＞0.05), see Table 9.1.Model group, drop pill group PAI, DD and FDP are apparently higher than normal group (P＜0.001), and t-PA significantly is lower than normal group (P＜0.001); Compare with model group, drop pill group t-PA significantly raises (P＜0.001), and PAI, DD and FDP obviously reduce (P＜0.001), see Table 9.2.Active and the model group no significant difference (P＞0.05) of drop pill group TG, TC, HDL-c, NO, MDA content and GSH-PX.Retina digestion shop sheet inspection, the endotheli ocytosis of drop pill group and pericyte's minimizing are obvious not as model group, and endotheliocyte and pericyte's ratio (E/P) relatively have the significance difference with model group, see Table 9.3.Through rat retina digestion shop sheet morphology, kidney light microscopic pathomorphology, thoracic aorta and the morphology of femoral nerve pathology, retina light microscopic pathomorphology, kidney transmission electron microscope, retina transmissioning electric mirror checking, the change of pathomorphology such as drop pill group kidney and retina obviously is lighter than model group.

Conclusion: though developing of diabetes rat nervus vasculairs pathological changes can not be protected or stop to FUFANG DANSHEN DIWAN fully; but can delay or alleviate developing of appearance, the especially albuminuria of 6 months diabetes rat nervus vasculairs pathological changes and kidney, retinal microvascular pathological changes.This may can improve the hemorheology disorder with FUFANG DANSHEN DIWAN, and enhancing fibrinolytic etc. are relevant.

Table 9.1 is respectively organized renal function variation in 6 months and is compared

N Scr (mg/dl) BUN (mg/dl) UA (mg/dl) urine amount (ml) 24h albumen (mg) normal group 10 0.76 ± 0.219 17.3 ± 3.24 1.79 ± 0.326 13.6 ± 5.03 11.41 ± 4.04 model group 7 0.72 ± 0.075 35.6 ± 15.5# 3.47 ± 0.903 ^*155.8 ± 29.8 111.7 ± 23.845 Drop pill group 7 0.73 ± 0.087 31.98 ± 11.45 ^*2.66 ± 1.04# ^△145.3 ± 25.41 50.5 ± 28.24 ^{△ *}Annotate: compare with normal group, P＜0.001, ^*P＜0.01, #P＜0.05; Compare with model group, ^△P＜0.001

Table 9.2 is respectively organized t-PA, PA, DD and FDP variation and is compared

N t-PA (IU/ml) PAI (IU/ml) DD (mg/l) FDP (ug/ml) normal group 10 0.579 ± 0.033 0.748 ± 0.026 0.42 ± 0.048 4.645 ± 0.33 model group 7 0.186 ± 0.011 ^*0.898 ± 0.02 ^*0.714 ± 0.018 ^*6.667 ± 0.087 ^*Drop pill group 7 0.255 ± 0.011 ^*# 0.855 ± 0.014 ^*# 0.532 ± 0.077 ^*# 5.643 ± 0.037 ^*# annotates: compares with normal group, ^*P＜0.001; Compare #P＜0.001 with model group

Table 9.3 retina digestion shop sheet E/P relatively

The n endotheliocyte E/P of pericyte normal group 10 667 ± 40.855 333 ± 40.741 2.042 ± 0.394 model group 7 861 ± 43.760 ^▲138 ± 43.760 ^▲6.829 ± 2.246 ^▲Drop pill group 7 737 ± 32.408 ^△# 262 ± 32.408 ^△# 2.864 ± 0.533 ^{■ *}Annotate: compare with normal group, ^▲P＜0.001, #P＜0.01, ^■P＜0.001; Compare with model group, ^△P＜0.001 ^*P＜0.001 in a word; FUFANG DANSHEN DIWAN energy coronary blood flow increasing; the vasodilator smooth muscle; promote the opening of collateral circulation, improve the venous sinus oxygen content, obviously improve acute myocardial ischemia and infraction; the generation of the expression decreased apoptosis by intervening Fas/FasL; the protection cell is avoided the damage of anoxia and anoxia _ reoxygenation, microcirculation improvement, and ischemic myocardial cells is poured into the myocardium cell necrosis variation again good protective action; arrhythmia; antiplatelet aggregation promotes fibrinolytic, reduces blood viscosity; blood lipid regulation; prevent atherosclerosis, improve anoxia endurance, anti peroxidation of lipid; remove harmful free radicals; reduce the content of endothelin level, significantly improve the liver of animal; organ function such as kidney and pancreas stops developing of blood vessel and neuropathy.

FUFANG DANSHEN DIWAN clinical experimental study one. the general curative effect situation of composite salvia dropping pill for curing angina pectoris () composite salvia dropping pill for curing angina pectoris

After the FUFANG DANSHEN DIWAN listing, carried out fairly large clinical research in China.Each clinical trial matched group medication is different, is undertaken by " FUFANG DANSHEN DIWAN clinical research scheme " but the diagnostic criteria of case is unified, and clinical and laboratory observation index is also accomplished unified as far as possible.Short summary is as follows as a result: see Table 1-1

Table 1-1 protects the clinical efficacy of the red treatment of heart angina pectoris and sums up

The case clinical effective rate % ECG-of hospital effective percentage % contrasts medicine ⁽¹⁾North China university of TCM 80 87.5--162 86.6 70.7-Zhejiang institute of traditional Chinese medicine of-Shandong Wei Fang hospital 100 96 ^*-FUFANG DANSHEN PIAN (50; 92%;--) 98 93.9 58.3-Guangzhou institute of traditional Chinese medicine of attached institute of Hunan College of Traditional Chinese Medicine 100 96 ^*63 ^*FUFANG DANSHEN PIAN (30; 63.3%; 30%)

95.1 60.4 sorbitrates (48; 79.2%; 37.5%) Tangshan institute of traditional Chinese medicine 101 [84.2] ^*[46.5] ^*[87.5%; 43.8%] the attached institute 46 95.7 of Anhui Chinese Medicine College ^*76.1 ^*Nifedipine (32; 75%; 43.8%) the bimodal hospital 32 in Hunan-- ⁽²⁾82.4 ^*Sorbitrate (31;--; 74.5% Shaanxi Province hospital 97 78.4 ^*41.5 FUFANG DANSHEN PIAN (41; 65.9%; 32.3%) 120 92.5 60-Shenyang the 7th hospital of four 39 92.4 79.5-Guangzhou province institutes of traditional Chinese medicine of Xijing hospital of medical university, 62 93.5 74.2 sorbitrates (30; 72.5%; 60%) the attached institute 30 66.7 of Guangdong Chinese medicine--sorbitrate (23; 69.6%) the Gate of Pervasive Peace academy of traditional Chinese medicine 40 92.5 60 sorbitrates (20; 90%; 55%) Tianjin first hospital 128 82.8--the attached institute of Anhui Chinese Medicine College 102 [88.3] [37.3] nitroglycerin (30; [93.3%; 40%] the Hebei Medical College first attached institute 34)-- ^{(3) * *}--sorbitrate (30) Tianjin Huan Hu hospital 58 96.5 ^*53.5 FUFANG DANSHEN PIAN (152; 75.1%; 46.2%) 100 96 89.1-changzhou hospital of Fujian Province hospital 43 95.3 ^*62.8 ^*FUFANG DANSHEN PIAN (43; 74.4%; 37.5%) 206 92 63.6-Xingtai hospital of the Shaanxi academy of traditional Chinese medicine 60 96.7 ^*63.3 FUFANG DANSHEN PIAN (30; 76.6%; 43%) first 90 91.1 60-Jinan provincial hospital of 30 83.3 56.6-Henan Electric Power hospital of attached institute 60 76.7 of Shanghai medical university ^*61.7 ^*Sorbitrate (30; 53.3%; 36.7) Xi'an military project hospital 87 96 ⁽⁴⁾64.6 nitroglycerin (87 ⁽⁴⁾)

Amount to 2,105 90.06 61.8 explanations: the effect of [] interior numeral quick-acting antalgesic effect or quickly improving ECG

Compare with matched group, ^*P＜0.05; ^*P＜0.01

(1) bracket inner digital is followed successively by: routine number, curative effect to treat angina pectoris and ECG curative effect percent;

(2) observation index has cardiac output (CO), stroke volume (SV), ejection fraction (EF), left LVSF (FS), β platelet microglobulin, blood

The plain β of bolt ₂, Holter measures ST-T and changes number of times etc.;

(3) observation index has heart rate (HR), systolic pressure (SBP), and the product of the two (Product), diastolic pressure (DBP), stroke volume (SV), cardiac output (CO),

Cardiac index (CI), ejection fraction (EF), indexs such as angina pectoris attacks number of times and nitroglycerin consumption;

(4) this test is the pairing cross matching, and the curative effect to treat angina pectoris of two medicines and ECG curative effect do not have the statistics difference;

By table 1-1 as seen, FUFANG DANSHEN DIWAN significantly is better than FUFANG DANSHEN PIAN to the therapeutic effect of angina pectoris, and there were significant differences on the statistics; And basic identical with the curative effect of sorbitrate etc., there is not significant difference on the statistics.FUFANG DANSHEN DIWAN is as pure Chinese medicinal preparation, have that curative effect height, consumption are little, taking convenience, easily absorb, safe and reliable, advantage such as side effect is little.(2) FUFANG DANSHEN DIWAN is to the curative effect of angina pectoris quickly alleviating pain

By contrasting, inquire into the curative effect of composite salvia dropping pill for curing angina pectoris quickly alleviating pain with nitroglycerin.

1. case: select patients with coronary heart disease 132 examples, be divided into two groups at random, 102 examples are organized in treatment, matched group 30 examples.By tcm syndrome differentiation and typing be: treatment group qi stagnation and blood stasis type 42 examples, phlegm-damp impatency type 24 examples, yang deficiency cold-condensing type 7 examples, deficiency of both QI and YIN blood stasis type 29 examples of holding concurrently; Matched group is respectively 11 examples, 7 examples, 2 examples, 10 examples.

2. method: look into electrocardiogram before the angina pectoris attacks 1 time, treatment group buccal FUFANG DANSHEN DIWAN is 10 during angina pectoris attacks, and matched group buccal nitroglycerine tablets 0.5mg writes down analgesic time respectively, uses to make to judge curative effect.And after medication half an hour check before electrocardiogram and the medication electrocardiogram and make curative effect relatively.

3. criterion: quickly alleviating pain curative effect judging standard, produce effects: pain relieving in 3 minutes behind the pastille; Effectively: pain relieving in 3～8 minutes behind the buccal; Invalid: pain relieving more than 8 minutes behind the pastille.

4. result:

(1) quickly alleviating pain curative effect, treatment group obvious effective rate is 40.20%, total effective rate is 88.28%; Matched group is respectively 53.33%, 93.33%, two group of relatively there was no significant difference (P＞0.05), illustrates that two groups have similar curative effect to angina pectoris, see Table 1-2.

Table 1-2 angina pectoris quickly alleviating pain curative effect group example digital display effect (%) effectively (%) invalid (%) total effective rate (%) treatment is organized 102 41 (40.20) 49 (48.04) 12 (11.76) 90 (88.24) matched groups, 30 16 (53.33) 12 (40.00) 2 (6.67) 28 (93.33) (2) ECG curative effect relatively, treatment group obvious effective rate is 15.69%, total effective rate is 37.26%, and matched group is respectively 20%, 40%.Two groups are compared there was no significant difference (P＞0.05) and see Table 1-3.

ECG curative effect after the table 1-3 medication

Group example digital display is imitated (%) effectively (%) invalid (%) total effective rate (%)

Treatment organizes 102 16 (15.69) 22 (21.57) 64 (62.74) 38 (37.26)

The relation of matched group 30 6 (20.00) 6 (20.00) 18 (60.00) 12 (40.00) (3) treatment group angina pectoris traditional Chinese medical science typings and curative effect, see Table 1-4, show that FUFANG DANSHEN DIWAN is identical to the curative effect to treat angina pectoris of the different typings of the traditional Chinese medical science, is not subjected to the influence of traditional Chinese medical science typing.

table 1-4 treatment group angina pectoris Syndrome Types of TCM and curative effect concern somatotype number of cases produce effects, (%) effective, (%) invalid, (%) total effective rate, (%) qi depression to blood stasis 42 18, (42.86) 19, (45.24) 5, (11.90) 37, (88.10) the wet impatency 24 7 of phlegm, (29.17) 14, (58.33) 3, (12.50) 21, (87.50) deficiency of Yin cold solidifying 74, (57.14) 2, (28.57) 1, (14.29) 6, (85.71) the deficiency of both qi and yin blood stasis 29 12 of holding concurrently, (41.38) 14, (48.28) 3, (10.34) 26, (89.66)

Conclusion: show by above-mentioned experiment, FUFANG DANSHEN DIWAN to the quick treatment of angina pectoris and nitroglycerin than no significant difference, both also do not have significant difference buccal treatment back ECG curative effect half an hour, and composite salvia dropping pill for curing angina pectoris is not subjected to the influence of traditional Chinese medical science typing.(3) FUFANG DANSHEN DIWAN is to the influence of coronary heart attack, angina pectoris frequency and nitroglycerin consumption

1. case is selected: the angina pectoris case is selected by the WHO diagnostic criteria, at least three months effort angina medical histories, and angina pectoris attacks is weekly 〉=5 time, and the bicycle ergometor exercise positive, but through having a rest or the Sublingual contains the nitroglycerin relief of symptoms, totally 64 examples.

2. research method: adopt the randomized, double-blind grouping, divide two stages.Phase I is 2 weeks (being the eluting phase) by a definite date, and except that with the nitroglycerin, the various other drugs of stopping using are used placebo treatment; 8 weeks of second stage, use FUFANG DANSHEN DIWAN 10-15 grain for one group, 3 times on the one, another group is used sorbitrate 10-15mg, 3 times on the one.

3. result: the patient who takes FUFANG DANSHEN DIWAN organizes the angina pectoris attacks number of times and reduces to 0.48 ± 1.33 time by 1.93 ± 3.10 times, and difference has statistical significance (P＜0.01).The nitroglycerin consumption has notable statistics difference (P＜0.01) by reducing to 0.51 ± 1.44 1.88 ± 2.96 of every days.See Table 1-5.

The variation of table 1-5 angina pectoris attacks number of times and nitroglycerin consumption

Composite Salvia Dropping Pill group (n=34) sorbitrate group (n=30)

Treatment back angina pectoris attacks number of times before treat the treatment back before the treatment (inferior/day) 1.93 ± 3.10 0.48 ± 1.33 ^*## 1.91 ± 2.44 1.64 ± 1.62 ^*Nitroglycerin consumption (sheet/day) 1.88 ± 2.96 0.51 ± 1.44 ^*## 1.86 ± 4.51 1.64 ± 1.46 ^*

Annotate: compare before and after the treatment ^*P＜0.05 ^*Relatively the visible FUFANG DANSHEN DIWAN in ##P＜0.01 can the allevating angina pectoris attack times between P＜0.01, two group, reduces the consumption of nitroglycerin.Take FUFANG DANSHEN DIWAN after a period of time, the anginal degree of each outbreak, persistent period is all thought the good direction development, seizure frequency also obviously reduces, illustrate outside the rapid alleviating pain of FUFANG DANSHEN DIWAN decapacitation, more blood supply has good improvement effect to anginal heart arteries and veins, reaches the purpose of effecting a permanent cure.(4) FUFANG DANSHEN DIWAN is to the improvement effect of coronary heart disease patient blood pressure and cardiac function

Case selection and research method are with (three).

The results are shown in Table 1-6, table 1-7.The proof FUFANG DANSHEN DIWAN is to the coronary heart disease patient's heart functions, and the hematodinamics index all has improvement in various degree.

The variation of table 1-6 FUFANG DANSHEN DIWAN and sorbitrate treatment back heart rate, blood pressure and two products

Index Composite Salvia Dropping Pill group (n=34) sorbitrate group (n=30)

Treatment back SBP (Kpa) 24.52.1 23.2 ± 1.4 before the treatment of treatment back before the treatment ^*## 23.9 ± 4.1 24.8 ± 1.1DBP (Kpa) 11.8 ± 4.1 11.1 ± 2.1 ^*## 11.8 ± 3.2 12.1 ± 2.1 pair product 24,399 18932 ^*## 24,399 26203 annotates: through paired t-test, and ratio before and after the treatment: ^*Compare the mechanical index variation of surging of ##P＜0.01 table 1-7 FUFANG DANSHEN DIWAN and sorbitrate treatment bleeding from anus between P＜0.01, two group

Index Composite Salvia Dropping Pill group (n=34) sorbitrate group (n=30)

Treatment back PAP (mmHg) 34.4 ± 6.1 27.4 ± 8.8 34.8 ± 5.1 33.9 ± 6.6PCWP (mmKg) 34.8 ± 9.1 24.3 ± 6.7 32.6 ± 8.1 31.1 ± 5.1CO (L/min) 2.81 ± 0.4 4.64 ± 1.1 3.81 ± 0.1 3.89 ± 1.1CI (Imin before the treatment of treatment back before the treatment ^-1/ m ²3.47 ± 1.1 3.89 ± 0.3 3.51 ± 1.0 3.58 ± 1.6EF (%) 76 ± 11 74 ± 16 77 ± 14 78 ± 11 annotates: through paired t-test, ratio before and after the treatment: ^*P＜0.05 ^*Compare of the influence of #p＜0.05 ##P＜0.01 (five) FUFANG DANSHEN DIWAN between P＜0.01, two group to aspects such as patients with coronary heart disease electrocardiogram and hemorheologys

FUFANG DANSHEN DIWAN and the old medicine sorbitrate of antianginal of generally acknowledging are compared, study its clinical efficacy and toxic and side effects.

1. object and method

1.1 case: the coronary heart disease patients with stable angina pectoris is totally 109 examples, all meets WHO standard in 1979, cardiac function I～II level.Be divided into two groups of (treatment group) 57 examples at random, sorbitrate group (matched group) 52 examples.

1.2 method: stop using at least 5 half-life of all medicaments for resisting myocardial ischemia before all beginnings of being tried.The person that has the angina pectoris attacks, interim giving and the nitroglycerin sublingual administration.Treatment organize to FUFANG DANSHEN DIWAN, matched group is given and sorbitrate (red flag pharmaceutical factory of Shanghai Medical Univ), 10-15mg/ time, 3 times/day.Be for 4 weeks the course of treatment.

1.3 record index: angina pectoris frequency of disease development, position, degree, the rhythm of the heart, blood pressure, persistent period, risk factor, nitroglycerin consumption, drug effect time, treadmill exercise test and hemorheology index

1.4 curative effect judging standard:

1.4.1 symptom standard: 1. produce effects: the fatigue of equal extent does not cause that angina pectoris or seizure frequency reduce＞90%.Substantially do not use nitroglycerin.2. effective: angina pectoris attacks frequency and nitroglycerin consumption all reduce 50-90%.3. invalid: as not reach above standard person.4. increase the weight of: angina pectoris attacks frequency and nitroglycerin consumption all increase more than 50.

1.4.2 electrocardiographic criteria: 1. produce effects: treadmill exercise test transfers feminine gender to by the positive or exercise tolerance rises 〉=2 grades.2. effective: treadmill exercise test electrocardiogram ischemic ST rise 〉=1.5mm, or 1 grade of exercise tolerance rising is 3. invalid: do not reach above standard person.

2 results

2.1 symptom observation of curative effect: see Table 1-8.Total effective rate: treatment group 93.0%; Matched group 86.5%.Compare no significant difference (P＞0.05) between two groups

2.2 ECG curative effect is observed: see Table 1-9, table 1-10.Two groups are brought out angina pectoris time and exercise induced ST section decline 〉=0.1mv required time and quantity of motion after treatment, maximum ST section drop-out value and maximal workload all have improvement, do not have significant difference (P＞0.05) between two groups.All obviously improve (P＜0.01) before and after the above-mentioned every index treatment of treatment group itself.

2.3 observing, hemorheology index sees Table 1-11.The every index in treatment group treatment back all has improves (P＜0.01), every index there was no significant difference (P＞0.05) after the treatment of control group.Every hemorheology index relatively has significant difference (P＜0.01) after treatment group and the treatment of control group.Show that Composite Salvia Dropping Pill group has the effect that improves hemorheology index.

Symptom relatively before and after two groups of treatments of table 1-8

Curative effect group example number

The produce effects enabledisable increases the weight of total effective rate (%) Composite Salvia Dropping Pill group 57 32 21 31 93.0 ^*Sorbitrate group 52 28 17 52 86.5 is annotated: compares with matched group, ^*Electrocardiogram relatively before and after P＞two groups of treatments of 0.05 table 1-9

Example curative effect group

Digital display is imitated enabledisable and is increased the weight of total effective rate (%) Composite Salvia Dropping Pill group 49 19 11 18 1 61.4 ^*Sorbitrate group 47 16 12 17 2 59.6 is annotated: compares with matched group, ^*P＞0.05

The treadmill exercise index changes before and after two groups of treatments of table 1-10

Exercise induced exercise induced ST section motion lures under the ST section the required fortune of peak load group 0.1mV that 0.1mV falls that angina pectoris descends under the routine maximum ST section

Number take time (s) take time after preceding 228 ± 60 204 ± 79 4.2 ± 2.0 2.5 ± 1.8 7.3 ± 1.2 medications of (s) momentum (MET) depreciation (mm) amount (METS) Composite Salvia Dropping Pill group 49 medications 301 ± 94 ^*268 ± 92 ^*5.6 ± 2.3 ^*1.8 ± 1.1 ^*9.8 ± 2.1 ^*303 ± 89 257 ± 85 5.8 ± 2.6 1.6 ± 0.8 10.1 ± 2.2 annotate after preceding 230 ± 39 210 ± 76 4.5 ± 1.8 2.2 ± 0.9 7.8 ± 1.6 medications of sorbitrate group 47 medications: compare P＜0.01 before * and the treatment of this group; With comparison after the treatment of control group, P＞0.05

Hemorheology index changes before and after two groups of medications of table 1-11

Example whole blood viscosity plasma viscosity ESR equation K value platelet adhesion external thrombus group

Preceding 5.31 ± 0.89 1.83 ± 0.86 103.78 ± 12.68 30.25 ± 7.84 18.5 ± 3.0 treatment backs 4.67 ± 0.71 of digit rate (%) length (mm) Composite Salvia Dropping Pill group 52 treatments ^*1.35 ± 0.92 ^*96.45 ± 10.21 ^*25.30 ± 5.90 ^*16.0 ± 3.1 ^*50 treatments preceding 5.33 ± 0.93 1.81 ± 0.81 105.15 ± 12.68 30.75 ± 6.93 18.2 ± 2.7 of sorbitrate group are treated back 5.20 ± 0.96 1.80 ± 0.68 102.26 ± 12.11 29.10 ± 8.50 18.0 ± 2.4 and are annotated: compare before * and the treatment of this group, compare P＜0.01 after P＜0.01 and the treatment of control group

Treatment front and back self paired t-test: ^*P＞0.05.T check between 2 groups: ^*P＞0.05.

3. conclusion

FUFANG DANSHEN DIWAN is compared with sorbitrate, does not have significant difference (P＞0.05) aspect patients with coronary heart disease electrocardiogram and the average every index of exercise test improving, and mean motion is tested every index and all obviously improved (P＜0.01) before and after the Composite Salvia Dropping Pill group treatment.This test shows that FUFANG DANSHEN DIWAN treatment angina pectoris effect equates with sorbitrate, but do not see nitrate esters side effect and drug resistance that sorbitrate causes, and in that to improve hemorheology unusual, blood viscosity lowering alleviates arteriosclerosis and prevents that the thrombosis aspect obviously is better than sorbitrate.Can be used as the drug of first choice of treatment coronary heart disease.(6) the FUFANG DANSHEN DIWAN life-time service is to the curative effects of treatment coronary heart disease

By contrasting, inquire into the curative effect of both life-time service treatment coronary heart disease with sorbitrate.

1. object: patients with stable angina pectoris 40 examples are divided into two groups, treatment group (Composite Salvia Dropping Pill group) 20 examples, matched group (sorbitrate group) 20 examples at random.

2. method: observe FUFANG DANSHEN DIWAN, 10/time, 3 times/day with the double-blind method administration; Sorbitrate 10mg, 3 times/day.

3. result:

3.1 angina pectoris effective percentage: two groups of zero differences during 2 weeks of the course of treatment, be respectively 90% pair 75% (P＞0.05) during 4,6,8 weeks, 90% pair 70% (P＜0.05), 95% pair 65% (P＜0.01) treatment group is better than matched group.

3.2 electrocardiogram (ECG) effective percentage: during 2 weeks; Do not have significant difference between two groups, be respectively 80% pair 65% (P＜0.05) course of treatment when 4,6,8 weeks, and 75% pair 55% (P＜0.05), 80% pair 50% (P＜0.01), the treatment group is better than matched group, sees Table 1-12.

Table 1-12 curative effect to treat angina pectoris and ECG curative effect are relatively

2 all 4 all 6 all 8 all curative effects

Compound Salviae Miltiorrhizae compound Salviae Miltiorrhizae compound Salviae Miltiorrhizae compound Salviae Miltiorrhizae

Sorbitrate sorbitrate sorbitrate sorbitrate

dripping pill dripping pill dripping pill dripping pill heart strand produce effects 5, (25.0) 6, (30.0) 6, (30.0) 5, (25.0) 6, (30.0) 4, (20.0) 7, (35.0) 3, (15.0) pain treats effective 12, (60.0) 12, (60.0) 12, (60.0) 10, (50.0) 12, (60.0) 10, (50.0) 12, (60.0) 10, (50.0) effect invalid 3, (15.0) 2, (10.0) 2, (10.0) 5, (25.0) 2, (10.0) 5, (25.0) 0, (0) 5, (25.0), (%) increase the weight of 0, (0) 0, (0) 0, (0) 0, (0) 0, (0) 1, (5.0) 1, (5.0) 2, (10.0)

Effective percentage 17 (85.0) 18 (90.0) 18 (90.0) 15 (75.0) 18 (90.0) ^*14 (70.0) ^*19 (95.0) 13 (65.0)

P value＞0.05＜0.05＜0.05＜0.01 electrocardio produce effects 4, (20.0) 4, (20.0) 5, (25.0) 3, (15.0) 5, (25.0) 3, (15.0) 6, (30.0) 2, (10.0) figure treats effective 10, (50.0) 11, (55.0) 11, (55.0) 10, (50.0) 10, (50.0) 8, (40.0) 10, (50.0) 8, (40.0) effect invalid 6, (30.0) 5, (25.0) 4, (20.0) 5, (25.0) 4, (20.0) 7, (35.0) 3, (15.0) 7, (35.0), (%) increase the weight of 0, (0) 0, (0) 0, (0) 2, (10.0) 1, (5.0) 2, (10.0) 1, (5.0) 3, (15.0)

Effective percentage 14 (70.0) 15 (75.0) 16 (80.0) 13 (65.0) 15 (75.0) ^*11 (55.0) ^*16 (80.0) 10 (50.0)

P value＞0.05＜0.05＜0.05＜0.01

Annotate: 6 weeks of the course of treatment compared with 2 weeks: the treatment group ^*P＞0.05; Matched group ^*P＜0.05.

4.1 conclusion: take for a long time FUFANG DANSHEN DIWAN to angina pectoris effective percentage, EGC effective percentage apparently higher than sorbitrate, stable curative effect be difficult for to produce drug resistance.Sorbitrate obviously reduces intravascular pressure rapidly, causes endogenous neuro humor system to activate and the blood volume increase, and sorbitrate mainly plays a role by sulfenyl in the blood vessel wall in addition, take the sorbitrate sulfenyl through for a long time to be exhausted, thereby curative effect weakens.And FUFANG DANSHEN DIWAN to be many target spots, multi-level, multipath improve myocardial cell, especially produce expansion blood volume effect by good slow calcium channel retardation; Stable to myocardial cell membrane; And remove the body free radical; Regulate myocardial cell energy metabolism, improve the whole body platelet aggregation, cholesterol reducing and blood viscosity, from several basic links improve myocardial ischemia and the antianginal effect.So FUFANG DANSHEN DIWAN life-time service more remarkable treatment effect.(7) FUFANG DANSHEN DIWAN is treated unstable angina

By clinical experiment, study the therapeutical effect of FUFANG DANSHEN DIWAN to unstable angina.1. object and method

1.2 case: unstable angina patient's 65 examples, be divided into two groups at random, wherein 34 examples are organized in treatment, male 22 examples, women 12 examples; Matched group 31 examples, male 20 examples, women 11 examples.

1.3 method: 2 groups of equal conventional dead point FUFANG DANSHEN ZHUSHEYE 30ml of patient, Qd and oral aspirin 80mg, Qd, treatment organize to FUFANG DANSHEN DIWAN, 10/time, 3 times/day; Matched group is given and sorbitrate, and 10mg/ time, 3 times/day, be 20 days two groups of courses of treatment.Withdraw all coronary dilating, lipid lowerers during the treatment,, then give and nitroglycerin my humble abode buccal if pain is heavier.

2. result:

2.1 curative effect relatively: treatment group produce effects, effective, invalid and to worsen routine number be that 26%, 6%, 2%, 0 total effective rate is 94.1%; Matched group is 15%, 8%, 6%, 2%, and total effective rate is 74.2%, two group of curative effect is checked through Ridit, P＜0.05.

2.2 the coronary heart disease size scale is: before and after the treatment two groups of angina pectoris size scales, the treatment group is slight, the routine number of moderate, weight degree, severe is respectively 27,4,2,1, matched group is 14,9,7,1, through Ridit check, P＜0.05.

2.3 electrocardiogram relatively: treatment group total effective rate is 61.7%, and 41.94%, two group of total effective rate of matched group total effective rate relatively has significant difference.

2.4 simultaneous phenomenon curative effect: simultaneous phenomenon refers to cardiopalmus, uncomfortable in chest, dispute cyanosis or ecchymosis is arranged.Comparison shows that the treatment group is compared with matched group before and after treatment, uncomfortable in chest, tongue is from dark or have ecchymosis that significant differences (P＜0.01) is arranged, and the dispute cyanosis has significant difference.The cardiopalmus symptom does not have significant difference (P＜0.05).

2.5 hemorheological variation.See Table 1-13

The hemorheological variation of table 1-13

Observation group's matched group index

Treat back whole blood height before treating after treating before treating and cut viscosity (cp) 4.91 ± 0.42 4.02 ± 0.32 ^{* △}4.86 ± 0.38 4.56 ± 0.41 packed cell volume (%) 49.20 ± 2.74 42.28 ± 2.12 ^*52.00 ± 2.52 48.53 ± 2.13 erythrocyte sedimentation rates (mm/h) 24.65 ± 9.76 22.18 ± 8.23 25.10 ± 9.34 22.30 ± 8.17 Fibrinogens (mg%) 487.50 ± 85.14 403.33 ± 91.15 ^{* △ △}494.33 ± 86.02 487.00 ± 89.61 annotate: relatively preceding with the treatment of this group ^*P＜0.05; Compare with matched group ^△P＜0.05, ^{△ △}P＜0.01

3. discuss

Show that by above experiment FUFANG DANSHEN DIWAN all has the minimizing myocardial oxygen consumption, improve to irritate the shape artery blood flow, recover the aerobic and equilibrated effect of oxygen supply of cardiac muscle, the curative effect of unstable angina pectoris is better than sorbitrate.

Other has the observation of curative effect of 60 routine composite salvia dropping pill for curing angina of effort

1. case is selected: totally 60 examples, and male 42 examples, women 18 examples, 32～75 years old age, 52.2 years old mean age, and be treadmill exercise and test positive person

2. medication: give FUFANG DANSHEN DIWAN, sublingual administration, each 10,3 times on the one, be 6 weeks the course of treatment.

3. therapeutic outcome: judge with reference to revision CHD curative effect to treat angina pectoris evaluation criteria in 1997:

(1) produce effects: angina pectoris is not reaccessed, and the physical exertion tolerance does not once add person's 21 examples (35%), and the treadmill exercise test transfers negative patient 15 examples (25%) to.

(2) improve: minimizing 2/3 of angina pectoris attacks number of times or pain time be shortening person's 29 examples (48.3%) obviously, person's 28 examples (46.5%) that the treadmill exercise test transfers the probable positive to.

(3) invalid: angina pectoris attacks number of times, persistent period no change person 10 examples (16.7%), treadmill exercise test still negative person's 17 examples (28.3%).

4. conclusion: FUFANG DANSHEN DIWAN is allevating angina pectoris effectively, correct myocardial ischemia, point out it that reduction myocardial oxygen consumption is arranged, improve coronary flow, recover the aerobic and oxygen supply balanced action of cardiac muscle, and have atherosclerosis, prevent its generation and development function.Be prevention at present and treatment coronary heart disease, angina pectoris, antiatherogenic ideal medicament.(8) the old anginal research of composite salvia dropping pill for curing

FUFANG DANSHEN DIWAN and pained establishing a capital can be used for treating angina pectoris, but latter's side effect is big, should not take for a long time.For selecting to be fit to the medicine that the aged coronary heart disease patient takes for a long time, this group is carried out check analysis with FUFANG DANSHEN DIWAN and the anginal curative effect of heart analgesic therapy treatment aged coronary heart disease.1. data and method

1.1 alternative aged coronary heart disease patient with angina pectoris 50 examples are divided into 2 groups: Composite Salvia Dropping Pill group (treatment group) 30 examples, heart analgesic therapy group (matched group) 20 examples.Two groups of no significant differences aspect sex, age, the course of disease and Chinese medical discrimination typing have comparability.

1.2 method treatment group is used FUFANG DANSHEN DIWAN, each 10～15, every day 3 times; The analgesic therapy of the The control group heart, each 10～15mg, every day 3 times; 30d was 1 course of treatment.All with protecting quick-witted sublingual spraying forever, use simultaneously during the treatment and do not have the other treatment that obviously influence is observed when 2 groups of patient's angina pectoris attackses are emergent.

1.3 number of times, the persistent period of angina pectoris attacks before and after the observation item medication, protect the number of times that soul is sprayed every day forever, 12 lead electrocardiogram, blood pressure, heart rate, hematuria routine, hepatic and renal function, blood fat and blood viscosity etc.

1.4 the statistical analysis measurement data adopts the t check, counting x ²Check.

2. the minimizing of efficacy determination angina pectoris attacks number of times and persistent period is produce effects more than 80%, reducing is effective more than 50%, low with 50% be invalid, to change the electrocardiogram improvement situation of observing before and after NST and the ∑ ST, NST represent 12 lead in the number that leads that forces down of ST section, ∑ ST represent conventional 12 lead in the ST section force down the summation of numerical value.

3. result

3.1 clinical efficacy sees Table 1-14

30 19 (63.33) 8 (26.67) 3 (10.00) 90 matched groups 20 8 (40.00) 4 (20.00) 8 (40.00) 60 are organized in comparative example (%) group example digital display effect enabledisable total effective rate (%) treatment of two groups of treatment backs of table 1-14 clinical efficacy

Annotate; With matched group relatively P＜0.053.2 electrocardiogram change and protect soul spraying number of times situation of change every day forever and see Table 1-15

Table 1-15 NST and ∑ ST and the number of times of spraying every day change relatively group example number NST ∑ ST to be protected soul spraying number of times treatment group forever control preceding 30 4.21 ± 1.31 1.76 ± 0.87 3.1 ± 1.0 every day

Control back 3.10 ± 1.21 1.05 ± 0.61 1.0 ± 0.5 matched groups and control preceding 20 4.20 ± 1.25 1.75 ± 0.85 3.21 ± 1.1

Controlling back 3.90 ± 1.13 1.60 ± 0.71 2.2 ± 0.8 annotates: control the back and control preceding relatively P＜0.05, treatment group and matched group be P＜0.05. relatively

3.3 side effect heart analgesic therapy group has 3 examples headache to occur, the two ankle edemas of 2 examples, 1 routine bradycardia.The treatment group is not found side effect such as hepatic and renal function injure, gastrointestinal reaction, arrhythmia.

Conclusion: FUFANG DANSHEN DIWAN is to establish at the pathogenesis of obstruction of qi in the chest and cardialgia, has blood circulation promoting and blood stasis dispelling, the effect of regulating QI to relieve pain, and effect rapidly, long action time, consumption is little, has no side effect etc., and heart analgesic therapy belongs to fugitive calcium antagonist, half-life is short, and action time is short, so the medication intermission is prone to angina pectoris, and side effect is many, and a lot of research reports are taken heart analgesic therapy for a long time can increase the arteria coronaria hazard event.FUFANG DANSHEN DIWAN has the effect that obviously resists myocardial ischemia, and helps to prevent progression of atherosclerosis.(9) composite salvia dropping pill for curing silent myocardial ischemia 1. clinical datas: 52 examples are organized in treatment, coronary heart disease 39 routine ischemic cardiomyopathy 4 examples wherein, positive 9 examples of exercise test, male 38 examples, women 14 examples; Matched group 52 examples are coronary heart disease 43 routine ischemic cardiomyopathy 6 examples wherein, positive 3 examples of exercise test, male 34 examples, women 18 examples (two groups of cases all meet WHO in 1979 about ischemic heart desease name and diagnostic criteria).2. Therapeutic Method: the treatment group is taken FUFANG DANSHEN DIWAN, and each 10, every day 3 times; The The control group sorbitrate, each 10mg, every day 3 times.Be for 4 weeks two groups of courses of treatment, the medicine of other all treatment myocardial ischemia of stopping using during the treatment.3. criterion of therapeutical effect: produce effects: ECG ST-T change return to roughly normal; Take a turn for the better: more than the ST section rise 0.5mm of reduction, the T popin is smooth to be become uprightly, and ripple is inverted and is shoaled more than 25%, and conduction block improves; Invalid: electrocardiogram no change before and after the treatment.4. result:

(1) after composite salvia dropping pill for curing group and the sorbitrate treatment of control group, two groups are moved after treating schedule, and effective percentage progressively improves (seeing Table 1-16), and the check group difference is (P＜0.01) significantly.

Treatment group produce effects (example) 12 17 21 22 (n=52) (example) 10 13 15 17 that take a turn for the better around the 3rd week of second week efficient first week of dynamic change group of two groups of 1-16 of table treatment back the

Effective percentage (%) 42.3 57.7 69.2 75.0 matched group produce effects (example) 8 10 11 12 (n=52) improvement (example) 5678

Effective percentage (%) 25.0 30.8 34.6 38.5

(2) the 24h dynamic electrocardiographic recording shows, behind the composite salvia dropping pill for curing, the average per minute persistent period of patient's premature beat number of times obviously descends, and drops to treatment back 1.58min by the each 5.37min before the treatment, compares significant difference (seeing Table 1-17) before and after the treatment.

Dynamic electrocardiographic recording premature beat frequency time ratio before and after the table 1-17 treatment

The preceding 95 510 5.37 treatment backs 24 38 1.58 of average duration of seizure (minute/time) treatment of premature beat number of times (inferior) premature beat accumulation total time (min) ^*

All patient's myocardial ischemia duration of seizure of this group case all shorten, and in use do not find toxic and side effects, and are safe and reliable, take no toleration for a long time, and have immediate effect, characteristics of high efficiency, shown superiority of this medicine and wide application prospect.Two. the ARR observation of composite salvia dropping pill for curing () FUFANG DANSHEN DIWAN is to ARR treatment

1. object: coronary heart disease companion arrhythmia patient's 56 examples (male 39 examples, women 7 examples); No cardiovascular diseases arrhythmia person 55 examples (male 36 examples, women 19 examples).

2. arrhythmia is as the criterion according to electrocardiogram, cardiac monitoring result, stops using 5 half-life of antiarrhythmic Agents before the monitoring.FUFANG DANSHEN DIWAN, each 10, every day 3 times, check electrocardiogram or cardiac monitoring after 2 weeks of logotype.

3. result: arrhythmia conditions (seeing Table 2-1) before and after the treatment of (1) CHD group

Arrhythmia conditions relatively before and after the treatment of table 2-1 CHD group

The slow room of hole early has a common boundary after preceding 14 21 7 32 11 5 treatments of chamber AVB bundle branch block treatment early early 3 ^*5 ^*2 ^*8 ^*4 ^*3

Annotate: compare before and after the treatment ^*P＜0.05, ^*P＜0.01, part patient can have several arrhythmia simultaneously.(2) arrhythmia situation (seeing Table 2-2) before and after the treatment of control group

Arrhythmia conditions (example) before and after the table 2-2 treatment of control group

The slow room of hole early has a common boundary after preceding 8 16 4 23 64 treatments of chamber AVB bundle branch block treatment early early 2 ^*3 ^*29 ^*32

Annotate: compare before and after the treatment ^*P＜0.05, ^*P＜0.01.

Conclusion: the treating irregular heart pulse effect that FUFANG DANSHEN DIWAN coronary heart disease causes is more obvious, and is also effective to no cardiovascular diseases's arrhythmia patient arrhythmia.The mechanism of its effect may be 1. calcium antagonism, and danshensu can reduce intracellular calcium concentration, prevent " calcium overload ", its effect is better than verapamil.2. the Stabilization of cell membrane, FUFANG DANSHEN DIWAN has the effect of protecting myocardial cell, thereby reduces arrhythmia.3. to measured by esr technique.4. promote energy to produce and utilization, bradyarrhythmia is relevant with the energy undersupply with the conduction block part.(2) FUFANG DANSHEN DIWAN is to the influence of myocarditis arrhythmia and cardiac function late result

1. clinical data: 120 routine myocarditis patients meet the standard that nineteen ninety-five whole nation myocarditis, cardiomyopathy symposium are formulated, and after 1 month, are divided into two groups through the routine treatment at random, each 60 example.Composite Salvia Dropping Pill group (treatment group), male 33 examples, women 27 examples; DIAOXINXUE KANG group (matched group), male 31 examples, women 29 examples.

2. Therapeutic Method: the treatment group gives FUFANG DANSHEN DIWAN, and 10/time, 3 times/day oral; Matched group gives DIAOXINXUE KANG JIAONANG (production of pharmaceutical factory of Chengdu Inst. of Biology, Chinese Academy of Sciences), each 200mg, and 3 times on the 1st are oral, and be 2～6 months two groups of courses of treatment.

3. result: (1) two group of symptom curative effect: two groups of treatment backs are uncomfortable in chest, cardiopalmus, out of breath having clear improvement, and clinical total effective rate treatment group and matched group are respectively 93%, 73% (seeing Table 2-3).

Two groups of symptom curative effects of table 2-3 relatively group n produce effects enabledisable total effective rate (%) treatment are organized 60 25 31 4 93.0 matched groups 60 17 27 16 73.0

Annotate: P＜0.01 is compared in two groups of treatments

(2) two groups of ECG curative effect: the two groups of rhythms of the heart in treatment back do not have significant change, and ST-T and T ripple, chamber are early, the room early all obviously improves, but the treatment group is better than matched group, sees Table 2-4.

Two groups of ECG curative effect of table 2-4 relatively group n produce effects enabledisable total effective rate (%) treatment are organized 60 24 32 4 93.0 matched groups 60 15 24 11 65.0

Annotate: P＜0.01 is compared in two groups of treatments

(3) two groups of cardiac ultrasonics change: cardiac ultrasonic shows that the heart size variation is little before and after two groups of treatments, treatment group treatment back average left ventricular ejection fraction rises to 62% from 48%, the unusual incidence rate of left ventricle ventricular wall motion drops to 18% from 46%, all is better than matched group, sees Table 2-5.

Cardiac ultrasonic changes relatively before and after two groups of treatments of table 2-5

Treatment group matched group

After treating before the preceding treatment of the treatment back treatment

Cardiac dilatation/example 18 12 12 1 left ventricular ejection fractions/% 48 62 49 52 left ventricle ventricular wall motions are unusual/and % 46 18 43 28 annotates: and two groups of treatments are P＞0.05 relatively

(4) routine blood test, hepatic and renal function are measured: two groups all change not obvious before and after treatment.

With DIAOXINXUE KANG relatively, FUFANG DANSHEN DIWAN and DIAOXINXUE KANG all have the arrhythmia improved after the myocarditis and cardiac function to reduce to change, but FUFANG DANSHEN DIWAN is better than DIAOXINXUE KANG, it is more remarkable that it improves myocardial ischemia, ECG ST section and the change of T ripple.In addition, FUFANG DANSHEN DIWAN also has the platelet aggregation of minimizing, lowers the effect of blood viscosity.Therapeutic outcome shows that myocardium patient takes FUFANG DANSHEN DIWAN for a long time can eliminate symptom, recurrence again after the prevention myocarditis.Three. FUFANG DANSHEN DIWAN is to the reverse effect of ventricular hypertrophy

FUFANG DANSHEN DIWAN is to the reverse effect of left ventricular hypertrophy

The reverse effect of FUFANG DANSHEN DIWAN to left ventricular hypertrophy (LVH) in depth studied in this experiment.1. object and method

1.1 case: all cases are selected from outpatient service and inpatient, get rid of secondary hypertension, coronary heart disease, cardiomyopathy, diabetes and other makings heart disease.LVH all diagnoses through the ultrasoundcardiogram institute.Be divided into two groups at random, 34 examples are organized in treatment, male 21 examples, women 13 examples; Matched group 20 examples, male 12 examples, women 8 examples.Two groups of there are no significant aspect age, sex, course of disease differences.

1.2 method: the treatment group is taken FUFANG DANSHEN DIWAN, 10/time, and 3 times/day; Matched group is taken metoprolol 50mg, and 3 times/day, 6～December was 1 course of treatment, and other cardiovascular drugses of stopping using in the treatment are taken two groups of comparing property detections in front and back and check, to make comparisons.

1.3 record index and criterion: adopt color Doppler to do the cardiac ultrasonic inspection.Measure relaxing period left ventricular internal diameter (LVID), interventricular septal thickness (IVST) and left ventricular posterior wall thickness (LVPWT), and calculate: left chamber flesh weight (LVM)=1.04 * [(LVID+LVPWI+IVST) ³-LVID ³]-1.36 and left ventricular mass index (LVMI)=LVM/ body surface area.Left ventricular hypertrophy is the day-mark standard really: 1. IVST 〉=12mm; 2. LVPWT 〉=12mm; 3. LVMI 〉=135g/m ²(man) or 110g/m ²

2. result

2.1 the effect of shrinking back to LVH: the IVST of treatment group, LVPWT and LVMI all have obvious reduction (P＜0.05 or 0.01), though and the matched group These parameters descends, the significant treatment of nothing meaning.See Table 3-1

The comparison of left ventricular hypertrophy heart B ultrasonic index before and after two groups of treatments of table 3-1

Treatment back LVID (mm) 5.58 ± 0.59 5.21 ± 0.33 before the treatment of treatment back before the treatment of treatment group matched group project ^*5.62 ± 0.64 5.59 ± 0.65IVST (mm) 13.6 ± 1.3 10.9 ± 1.4 ^*12.8 ± 1.6 12.4 ± 1.8LVPWT (mm) 13.0 ± 1.7 11.0 ± 1.2 ^*12.6 ± 1.5 11.9 ± 1.6LVM (g) 252.6 ± 58.2 198.7 ± 30.96 ^*238.6 ± 59.8 229.8 ± 42.5LVMI (g/m ²) 136.9 ± 22.6 108.9 ± 18.6 ^*139.8 ± 19.3 135.7 ± 20.6 notes: * and preceding relatively P＜0.05 of treatment compare P＜0.01 before * * and the treatment

2.2 the influence to cardiac functional parameter: FUFANG DANSHEN DIWAN can make SV, CI, VPE, EWK obviously increase, and VER, TPR, HOV then obviously descend, and can lighten the load thus increases new function.See Table 3-2

The comparison of parameters of left ventricular function before and after two groups of treatments of table 3-2

Whenever rich cardiac output (SVml/ is rich) 68.32 ± 1.55 79.87 ± 1.92 after the treatment before treat the treatment back before the treatment of treatment group matched group project ^*70.16 ± 1.52 69.68 ± 1.20 cardiac index (CL/ branch/m ²) 3.20 ± 0.78 3.98 ± 0.39 ^*3.54 effective pump power (the VPE public affairs of ± 0.66 3.52 ± 0.43 left ventricle

1.6210 ± 0.16 1.8825 ± 0.64 ^*1.5814 ± 0.12 1.6627 ± 0.33 jin/rich) left chamber spray blood impedance (VER) 238 ± 1.64 150 ± 1.28 ^*240 ± 1.32 238 ± 1.56 myocardium of left ventricle Energy Efficient profits

0.244 ± 0.084 0.297 ± 0.021 ^*0.254 ± 0.112 0.271 ± 0.03 usefulness rate (EWK) Peripheral resistance (the TPR dyne: second

984.78 ± 86.01 902.35 ± 54.16 ^*1103.66 ± 74.26 986.58 ± 78.27 ²/ m ²) myocardial oxygen consumption (HOV) 44.954 ± 1.5 41.210 ± 1.2 ^*43.167 ± 1.1 42.164 ± 0.9 notes: * and preceding relatively P＜0.05 of treatment compare P＜0.01 before * * and the treatment

2.3 the influence to the blood pressure and the rhythm of the heart: FUFANG DANSHEN DIWAN can reduce heart rate, mean arterial pressure and RPP, thereby eliminates the risk factor of LVH.See Table 3-3

The variation of heart rate and blood pressure before and after two groups of treatments of table 3-3

Treatment back heart rate 80.2 ± 12.18 72.8 ± 8.64 before the treatment of treatment back before the treatment of treatment group matched group project ^*81.00 ± 10.20 75.81 ± 8.13 ^*Mean arterial pressure 118.0 ± 9.11 101.11 ± 5.50 ^*116.28 ± 10.21 112.92 ± 5.8RPP 116.42 ± 13.57 98.46 ± 11.29 ^*118.55 ± 12.88 108.86 ± 10.64 notes: * and preceding relatively P＜0.05 of treatment compare P＜0.01 before * * and the treatment

2.4 to the blood viscosity parameter influence: FUFANG DANSHEN DIWAN can reduce blood viscosity, and the formation of anti-tampon reduces the resistance of blood vessel, eliminates the factor that causes LVH.See Table 3-4

The variation of blood viscosity before and after two groups of treatments of table 3-4

Treatment back blood viscosity (η b) 4.714 ± 0.34 3.680 ± 0.12 before the treatment of treatment back before the treatment of treatment group matched group project ^*4.773 ± 0.36 4.631 ± 0.24 blood reduction degree (η r) 7.889 ± 0.030 6.326 ± 0.14 ^*7.416 ± 0.12 7.385 ± 0.18 plasma viscosity (η p) 2.532 ± 0.13 1.400 ± 0.08 ^*2.486 ± 0.16 2.495 ± 0.12

Notes: * and preceding relatively P＜0.05 of treatment compare P＜0.01 before * * and the treatment

2.5 the influence to arteriosclerotic index: FUFANG DANSHEN DIWAN can make APOA ^-1(ApoA) and SOD increase, APOB ^-100Reduce with WsFs, thereby arteriosclerosis and antidotal effect are arranged.See Table 3-5

The comparison of arteriosclerosis index before and after two groups of treatments of table 3-5

Treatment back APOA before the treatment of treatment back before the treatment of treatment group matched group project ^-1(mg/ml) 108.9 ± 46.8 134.3 ± 50.6 ^*122.4 ± 48.4 130.6 ± 46.9APOB ^-100(mg/ml) 161.2 ± 62.6 120.8 ± 52.4 ^*153.4 ± 66.2 148.9 ± 53.8WsFs (u) 17.8 ± 7.9 13.5 ± 2.4 ^*16.9 ± 8.6 15.8 ± 2.2SOD (u/ml) 272.86 ± 110.30 361.87 ± 92.44 ^*286.31 ± 99.71 302.13 ± 96.25

Notes: * and preceding relatively P＜0.05 of treatment compare P＜0.01 before * * and the treatment

2.6 the influence to nail fold microcirculation: the FUFANG DANSHEN DIWAN obviously stasis of blood of microcirculation improvement stagnates and blood fluidity, increases erythrocytic oxygen carrying capacity.See Table 3-6.

The comparison of nail fold microcirculation index before and after two groups of treatments of table 3-6

Treatment back flow velocity (mm/s) 0.126 ± 0.413 0.332 ± 0.111 before the treatment of treatment back before the treatment of treatment group matched group project ^*0.125 ± 0.430 0.185 ± 0.419 different in nature blood vessel (%) 64.21 ± 37.32 63.92 ± 37.66 63.86 ± 31.85 62.88 ± 34.22 fluidised form clouds cotton-shaped 28 82.4% 5 14.8% ^*18 52.9% 15 44.1% dotted line shapes 6 17.6% 29 85.2% ^*16 47.1% 19 55.9%

Notes: * and preceding relatively P＜0.05 of treatment compare P＜0.013. before * * and the treatment and discuss

Show that by above experiment FUFANG DANSHEN DIWAN not only has free radical resisting damage, prevent the effect that arteriosclerosis forms, can also pass through microcirculation improvement, blood viscosity lowering and peripheral vascular resistance are adjusted the compliance of cardiac muscle and are played the effect of reverse LVH.Four. FUFANG DANSHEN DIWAN is to the influence of hypertensive therapeutical effect () FUFANG DANSHEN DIWAN to hypertensive patients patients with coronary heart disease cardiac structure and function

1. object of study: hypertensive patients patients with coronary heart disease 140 examples, the course of disease 4～15 years, wherein men and women's ratio is 5: 1.

2. research method: test stop using in preceding 1 week other antianginal and depressor, continue clothes placebo every day 3 times, continued for 1 week, obey 10 of FUFANG DANSHEN DIWAN then, every day 3 times, 8 weeks were 1 course of treatment.

3. observation index: resting electrocardiogram, blood pressure, heart rate, clinical symptoms and untoward reaction; Norepinephrine in the blood plasma (NE), epinephrine (E), atrial natriuretic peptide (ANP), Endothelin (ET), nitric oxide (NO); Left side cell structure and function (LVED (Left Ventricular End Systolic Dimension) LVDd, interventricular septum IVS, LVPW PWT, left ventricular mass LVMI).

4. write down index and criterion: left ventricle structure and function adopt the color Doppler echocardiography survey meter, measure LVED (Left Ventricular End Systolic Dimension) (LDVd), interventricular septum (IVS) and Left ventricular posterior wall thickness (PWI), calculate Left ventricular mass index (LVMI), i.e. LVMI={1.04[LDVd+IVS+PWT according to formula] ³-13.6} ²/ body surface area, man＞125g/m ², woman＞110g/m ²Be defined as left ventricular hypertrophy (LVH), automatically count cardiac output (CO) and ejection fraction (EF) according to Teichholz formula and aortic root blood flow frequency spectrum, according to the maximum relaxing period measuring of blood flow A peak speed (DAV) of Bicuspid valve, E peak speed (DEV) and A/E ratio, The above results all adopt average value measured three times.

5. statistical procedures: continuous data is represented with X ± s.Adopt the paired t-test method before and after the treatment.

6. result: (1) angina pectoris symptom and ECG curative effect (seeing Table 4-1):

Table 4-1 project example digital display is imitated (%) effectively (%) invalid (%) total effective rate (%) angina pectoris symptom 140 48 80 12 91.4 ECG ST sections 100 40 32 28 80

(2) variation of blood pressure and heart rate: decreased heart rate to 76.24 ± 9.37 time/min (P＜0.01); Systolic pressure (SBP) is reduced to 19.40 ± 1.74Kpa by 20.9 ± 1.71Kpa, and diastolic pressure (DBP) is reduced to 10.69 ± 0.70Kpa by 12.07 ± 1.99Kpa.

(3) variation (seeing Table 4-2) of ANP, ET, NO, NE, E before and after the treatment: FUFANG DANSHEN DIWAN can reduce ET, ANP, NE, E, elevation of NO.

Table 4-2

Preceding 132.7 ± 3.84 48.9 ± 11.8 10.97 ± 4.3 0.437 ± 0.02 0.098 ± 0.02 treatment backs 93.8 ± 27.5 of ANP (pg/L) ET (pg/L) NO (umol/L) NE (pg/L) E (pg/L) treatment ^*29.4 ± 0.6 ^*16.7 ± 8.6 ^*0.232 ± 0.03 ^*0.072 ± 0.01 ^*

Annotate: compare before and after the treatment, ^*P＜0.05, ^*P＜0.01

(4) to the influence (seeing Table 4-3) of left cell structure: FUFANG DANSHEN DIWAN has the interventricular septum of reduction, left locular wall is thick and the effect of Left ventricular mass index.

Table 4-3

LVDd (mm) IVS (mm) PWT (mm) LVMI (g/m ²) preceding 46.9 ± 2.67 12.83 ± 2.48 11.93 ± 1.51 132.89 ± 28.66 treatment backs 40.2 ± 3.09 of treatment ^*9.82 ± 1.44 ^*8.28 ± 1.36 ^*121.58 ± 26.84 ^*

Annotate: compare before and after the treatment, ^*P＜0.05, ^*P＜0.01 (5) influence to left chamber function (seeing Table 4-4): FUFANG DANSHEN DIWAN is obviously improved left chamber diastolic function.

Table 4-4

Preceding 50.14 ± 11.02 0.75 ± 0.13 0.73 ± 0.19 1.21 ± 0.32 treatment backs 51.47 ± 9.81 0.57 ± 0.41 of EF (%) DAV (m/s) DEV (m/s) A/E treatment ^*0.89 ± 0.12 ^*0.98 ± 0.34 ^*

Annotate: compare before and after the treatment, ^*P＜0.05, ^*P＜0.01

(6) untoward reaction: do not occur serious adverse effects before and after this group case is taken medicine.

Discuss: experiment shows that FUFANG DANSHEN DIWAN has the reverse ventricular hypertrophy, interrupts ventricular hypertrophy, improves the effect of left auxocardia function, thereby brings high blood pressure down effectively, antianginal.(2) FUFANG DANSHEN DIWAN is to hypertension insulin resistant and influence of plasma endothelins

1. purpose: investigate FUFANG DANSHEN DIWAN to insulin resistant and influence of plasma endothelins in the patients with hypertension body

2. object: treated for 1 week to 80 satisfied routine patients of controlling of blood pressure with amlodipine

3. method: 80 routine patients are divided into two groups, and matched group continues former treatment, adds Composite Salvia Dropping Pill group and adds 10 of FUFANG DANSHEN DIWAN, every day 3 times, detects after continuous 4 weeks.

4. result: the comparison (seeing Table 4-5) that blood pressure and endothelin level change before and after (1) treatment: after the treatment, two groups of endothelin level are all than descending (P＜0.05) to some extent before the treatment, wherein add Composite Salvia Dropping Pill group and matched group relatively descend particularly evident (P＜0.05).

Relevant parameter comparison relevant parameter adds the simple amlodipine group (n=40) of Composite Salvia Dropping Pill group (n=40) before and after showing the simple amlodipine of 4-5 hypertension and adding the composite salvia dropping pill for curing

Treatment back Body Mass Index (kg/m before the treatment of treatment back before the treatment ²) 23.39 ± 1.82 23.37 ± 1.67 23.95 ± 2.01 23.96 ± 1.92 systolic pressures, (kPa) 21.43 ± 1.69 17.39 ± 1.44 21.40 ± 1.67 18.09 ± 1.55 diastolic pressures, (kPa) 12.72 ± 0.58 11.01 ± 0.59 12.85 ± 0.54 11.25 ± 0.68 endothelin level, (ng/) 56.4 ± 6.78 38.7 ± 4.62 57.2 ± 7.31 42.6 ± 4.78

(2) comparison (seeing Table 4-6) that insulin level and insulin sensitivity change before and after the treatment: the equal no significant difference of body weight index before and after treatment and between two groups.Add Composite Salvia Dropping Pill group after 4 weeks of treatment, blood insulin levels significantly descends (P＜0.05) than before, and before blood insulin/blood glucose also is lower than treatment, and treatment of control group front and back blood insulin and blood insulin/blood glucose value have no significant change.

Relevant parameter comparison relevant parameter adds the simple amlodipine group (n=40) of Composite Salvia Dropping Pill group (n=40) before and after showing the simple amlodipine of 4-6 hypertension and adding the composite salvia dropping pill for curing

Treatment back blood glucose (mmol) before the treatment of treatment back before the treatment

Empty stomach 5.26 ± 0.84 5.01 ± 0.78 5.19 ± 0.56 5.27 ± 0.59

60min????????9.63±1.94????????7.26±0.31????????????9.86±0.65???????9.76±0.52

120min 7.64 ± 0.80 6.21 ± 0.15 7.69 ± 0.81 8.01 ± 0.76 blood insulin (mU/L)

Empty stomach 26.24 ± 1.83 20.32 ± 1.57 25.34 ± 1.74 25.31 ± 1.73

60min????????126.79±1.90??????99.66±2.00???????????122.01±1.91?????121.65±1.89

120min 90.53 ± 1.75 71.42 ± 1.96 91.62 ± 1.96 92.56 ± 1.66 blood insulins/blood glucose ratios 5.06 ± 1.29 4.19 ± 0.93 5.24 ± 1.01 5.18 ± 1.07

Conclusion: in effective controlling blood pressure, improve insulin sensitivity, reduce blood insulin levels and improve vascular endothelial function, should be as the steps necessary of treatment hypertension.In the blood pressure lowering treatment, use FUFANG DANSHEN DIWAN and can effectively reach this purpose.Five. FUFANG DANSHEN DIWAN is to therapeutical effect () the composite salvia dropping pill for curing hyperlipemia of hyperlipemia

By comparing with low-dose aspirin, the research FUFANG DANSHEN DIWAN is to hyperlipemia and arteriosclerotic treatment.

1. object and method

1.1 case: come out-patient's 53 examples, be divided into two groups at random: treatment group (Composite Salvia Dropping Pill group) 25 examples, matched group (aspirin group) 28 examples.

1.2 method: the treatment group is used FUFANG DANSHEN DIWAN, 10/time, 3 times/day.Took continuously 6 months.Matched group uses enteric coated aspirin 50mg, and is 1 time/day, oral.

1.3 index: 1. IMT (tremulous pulse arteries intima-media thickness) measures, and 1,2,3,6 month scanning common carotid artery whole process, the inside and outside tremulous pulse of neck and subclavian artery major axis and each minor axis tangent plane after medication are respectively measured the IMT and the record in thickness; 2. hemorheology comprises that the whole blood height cuts viscosity (hHb), and whole blood is low cuts viscosity (hLb), plasma viscosity (hP), erythrocyte aggregation index indexs such as (AIR); 3. blood fat is measured, and comprises T-CHOL in the blood (TC) and triglyceride (TG); 4. statistical procedures adopts the paired t-test method.

2. result: (1) medication 6 months, the measurement result of IMT sees Table 5-1, treatment group common carotid artery attenuation (P＜0.05), and matched group does not have significant change.

Two groups of patient's medications of table 5-1 artery IMT measures

Group is surveyed routine number IMT (mm) FUFANG DANSHEN DIWAN

Treat preceding 41 2.2 ± 0.7

Treatment back 41 2.1 ± 0.6 ^*Aspirin

Treat preceding 43 2.0 ± 0.8

Treatment back 43 2.1 ± 0.7

Annotate: relatively preceding with the treatment of this group, ^*P＜0.05

(2) hemorheology the results are shown in Table 5-2, medication after 6 months two groups of blood viscositys decline is all arranged, do not have significant difference (P＞0.05) between two groups of decline degree

Two groups of patient's medications front and back of 5-2 hemorheology group is as a result surveyed preceding 25 6.23 ± 1.67 10.92 ± 2.21 1.95 ± 0.08 1.79 ± 0.13 treatment backs 25 4.35 ± 1.02 of routine number η Hb (mpa.s) η Lb (mpa.s) η P (mpa.s) AIR composite salvia dropping pill for curing ^*8.30 ± 1.14 ^*1.77 ± 0.08 ^*1.39 ± 0.11 ^*Preceding 28 6.12 ± 1.56 10.38 ± 1.96 1.89 ± 0.12 1.82 ± 0.17 treatment backs 28 4.28 ± 1.07 of aspirin treatment ^*8.21 ± 1.03 ^*1.67 ± 0.07 ^*1.40 ± 0.10 ^*

Annotate: relatively preceding with the treatment of this group, ^*P＜0.01

(3) lipid determination the results are shown in Table 5-3, and medication is after 6 months, and treatment group TC, TG level have obvious decline (P＜0.01), and matched group does not have significant change.

Lipid determination result before and after two groups of patient treatments of table 5-3

Group is surveyed routine number η Hb (mpa.s) η P (mpa.s) FUFANG DANSHEN DIWAN

Treat preceding 41 6.08 ± 1.5 1.91 ± 0.68

Treatment back 41 4.91 ± 1.44 ^*1.54 ± 0.56 ^*Aspirin

Treat preceding 43 6.10 ± 1.67 1.83 ± 0.82

Treatment back 43 5.92 ± 1.81 1.76 ± 0.94

Annotate: relatively preceding with the treatment of this group, ^*P＜0.01

Discuss: originally studies show that, FUFANG DANSHEN DIWAN has the effect of clear and definite blood fat reducing and improves the effect of hemorheological property, the particularly attenuation of IMT significance after the medication illustrates this medicine except that having above-mentioned effect, also has the effect of certain atheromatous plaque that disappears simultaneously.(2) FUFANG DANSHEN DIWAN merges the observation of curative effect of high blood viscosity to the aged coronary heart disease angina pectoris

1. case: 48 routine angina pectoriss merge the high blood viscosity patients, male's 39 examples wherein, women's 9 examples; Stable angina pectoris 41 examples, unstable angina pectoris 7 examples.

2. medication: the other drug of stopping using gives FUFANG DANSHEN DIWAN after 2 weeks, sublingual administration, and each 10,3 times on the one, be 4 weeks the course of treatment.Drawing up arm venous blood morning on an empty stomach measures the hemorheology index, observes angina pectoris situation and drug side effect.

3. result

(1) curative effect to treat angina pectoris: produce effects 25 examples (52.0%) in the 48 routine angina pectoriss, effective 16 examples (33.3%), invalid 7 examples (14.5%).

(2) hemorheology is learned the index variation.See Table 5-4

Table 5-4 hemorheology is learned index and is changed

P value after the medication before the project medication

Whole blood viscosity high value of cutting 6.76 ± 3.22 4.53 ± 1.06＜0.01

Whole blood viscosity high value of cutting 9.93 ± 3.42 7.81 ± 1.83＜0.01

Blood plasma viscosity 1.91 ± 0.18 1.70 ± 0.16＜0.05

Packed cell volume 0.44 ± 0.08 0.43 ± 0.07＞0.05

(3) effect is observed: serious side effects appears in none example in 48 examples, no hemorrhage and headache.The 3 examples stomach discomfort on the 3rd of taking medicine changes the then transference cure of taking medicine after meal into.Feeling of fullness in the head after 1 example is taken medicine, continuing to take medicine adapts to sx gradually.

Conclusion: it is safe and reliable that FUFANG DANSHEN DIWAN is used for the gerontal patient, is that the angina pectoris of treatment aged coronary heart disease merges one of active drug of high blood viscosity.Six. composite salvia dropping pill for curing high viscosity syndrome

High viscosity syndrome (HS) is a Pathophysiology notion, it is the syndrome due to raising by or several hyperlipidemia factors, can cause pathological changes such as vitals generation ischemia, anoxia, infraction such as the heart, brain, kidney, we obtain better effects with composite salvia dropping pill for curing HS.

This group patient is totally 41 examples, male 23 examples, women 18 examples, age 39-68 year, average 50.7 years old.Protopathy: essential hypertension II phase, hypertensive renal disease 22 examples, cerebral infarction 9 examples wherein, coronary heart disease 13 examples; The nephrotic syndrome 19 examples.Use FUFANG DANSHEN DIWAN, each 10, every day 3 times, serve on for 4 weeks.Self contrasts before and after adopting, the t method of inspection.

The result: after the treatment of 28 days routine doses, the symptom of patient HS alleviates gradually, alleviates, disappears as the symptom of coronary heart disease such as dizzy, weak, as to feel suffocated, have palpitation, cerebral infarction, nephropathy.Blood pressure reduces, and microcirculation improves, and TC, TG, Apo-B descend, and HDLC, Apo-A1 rise, and every index of blood examination all reduces, and renal blood flow increases, renal function improves, urine protein reduces, cardiac function improves.See Table 6-1,6-2,6-3.

Blood fat and apolipoprotein variation before and after the table 6-1 HS (x ± s)

TC??????????TG???????????HDLC???????Apo-Al???????Apo-B

(mmol/L) (mmol/L) (mmol/L) (g/L) back 6.26 ± 1.53 2.03 ± 1.46 1.37 ± 0.31 1.48 ± 0.19 1.06 ± 0.45P value＜0.01＜0.01＜0.01＜0.01＜0.01 of preceding 8.07 ± 1.45 2.41 ± 1.32 1.21 ± 0.29 1.27 ± 0.18 1.58 ± 0.46 treatments of (g/L) treatment

Table 6-2 HS front and back Hemorheology changes (rear P value whole blood contrast viscosity (height is cut) 7.94 ± 1.28 5.06 ± 1.19＜0.01 whole blood contrast viscosities for the treatment of (low cutting) 11.87 ± 1.69 8.07 ± 1.25＜0.01 plasma viscosities 1.96 ± 0.37 1.48 ± 0.16＜0.01 packed cell volume 46.85 ± 3.11 42.79 ± 3.15＜0.01 erythrocyte aggregation index 2.08 ± 0.14 1.39 ± 0.13＜0.01 before x ± s) project is treated

Blood pressure, heart rate and changes of cardiac function before and after the table 6-3 HS

Systolic pressure (kPa) diastolic pressure (kPa) heart rate (inferior/min) 15.9 1.4 11.2 1.3 73.9 6.4＞1P value＜0.01＜0.01, back＜0.01 seven is treated in cardiac function E/A treatment preceding 22.8 1.6 14.9 1.5 81.2 7.5＜1. and FUFANG DANSHEN DIWAN is to the treatment of Acute Myocardial Infarction effect

FUFANG DANSHEN DIWAN influences acute myocardial infarction patients serum TnT

1. the object of observation: emergency treatment AMI (myocardial infarction) patient 56 examples, male 35 examples, women 22 examples, 40～70 years old age.Be divided into treatment at random in 1: 1 ratio and organize 28 examples, matched group 28 examples.Normal group: from the Physical Examination person with machine testing 40 examples, wherein male 23 examples, women 17 examples, 42～73 years old age.

2. medication: treatment group: give FUFANG DANSHEN DIWAN, each 10,3 times on the one, serve on for 2 weeks; Matched group: adopt the doctor trained in Western medicine conventional therapy, i.e. absolute bed rest, oxygen uptake keeps free movement of the bowels; Oral sorbitrate 10mg, 3 times/d; Enteric coated aspirin 75mg, 1 time/d; Captopril 12.5mg, 2 times/d, nitroglycerin 5mg+ polarized solution, quiet, 1 time/d.

3. observational technique: all patients respectively adopt ulnar vein blood 1 time, about 2ml at go to a doctor at once, be admitted to hospital back 6h, 12h, 1d, 3d, 5d, 7d, 9d, 11d, 13d.Assay method adopts sandwich enzyme-linked immunoabsorption of a step.

4. result: (1) normal human serum TnT concentration is positive skewness and distributes, and normal value is 0.26 ± 0.14ug/L, be significantly rising greater than 0.38ug/L.

(2) treatment group and matched group different onset time serum T nT concentration determination result see Table 7-1.Two groups of serum T nT concentration all are positive skewness and distribute.Treatment group serum T nT promptly significantly raise in morbidity in 3～6 hours, reached the peak about 47d, and the about 9d of persistent period that raises recovers normal about 11d; The clear TnT of matched group promptly significantly raise in morbidity in 4～6 hours, reached the peak about 48d, and the about 10d of persistent period that raises recovers normal about 12d.

The 6h 12h 1d 3d 5d 7d 9d 11d 13d treatment at once of table 7-1 treatment group and matched group different onset time serum T nT concentration determination result (ng/L) group example number organizes 28 0.29 ± 0.58 ± 0.89 ± 3.27 ± 7.65 ± 5.39 ± 2.85 ± 0.48 ± 0.28 ± 0.22 ±

0.17 0.21 0.36 0.93 1.36 1.22 0.81 0.27 0.13 0.12 matched group 28 0.28 ± 0.67 ± 0.95 ± 4.03 ± 9.64 ± 7.13 ± 4.28 ± 1.63 ± 0.39 ± 0.25 ±

0.15????0.26????0.35????1.12????1.79????1.42????1.20????0.68????0.17????0.14

(3) treatment group and matched group serum T nT interpretation of result see Table 7-2.Treatment group peak value significantly is lower than matched group (P＜0.01).TnT raises persistent period and return to normal time all significantly early than matched group (P＜0.05); Two groups of time to peaks compare there was no significant difference.

Table 7-2 treatment group and matched group serum T nT interpretation of result group example number peak value (ug/L) time to peak (d) rising persistent period (d) recover normal time (d) treatment and organize 28 8.96 ± 1.57 47.21 ± 2.18 9.37 ± 1.24 10.96 ± 1.39 matched groups 28 11.02 ± 2.13 48.38 ± 2.75 10.16 ± 1.36 11.87 ± 1.48

Conclusion: FUFANG DANSHEN DIWAN is by coronary artery dilator, and microcirculation improvement has been saved and faced downright bad myocardial cell frequently, has dwindled myocardial infarct size, thereby has played the effect of protecting myocardial cell.Therefore AMI uses FUFANG DANSHEN DIWAN in early days, can protect cardiac muscle, improves prognosis, the while taking convenience, and side effect is little, is worth applying clinically.Eight. FUFANG DANSHEN DIWAN is to the therapeutical effect of cerebral infarction

Composite salvia dropping pill for curing cerebral infarction

All cases all are defined as cerebral infarction through the brain CT examination, take 2: 1 at random the ratio of seeing and treating patients divide into groups, treatment all admits to hospital.A organizes 102 examples, and is oral with FUFANG DANSHEN DIWAN, and each 10,6 hours 1 time (can not orally give nasal feeding), and cooperate general composite treatment (necessary dehydrant, infection, keep fluid and electrolyte balance, and in good time acupuncture, massage etc.) treatment according to the state of an illness; The B group is used merely with composite treatment (the same), and 2 groups is the course of treatment with 4 weeks all.

Efficacy assessment standard: the clinical neurologic deficit of stroke patients degree standards of grading and the clinical efficacy evaluation criteria that adopt whole nation cerebrovascular academic conference for the second time in 1986 to formulate are treated the front and back scoring.Be almost recovered: invalid degree is 0 grade.

(1) produce effects: the functional impairment scoring reduced more than 21 minutes, and invalid degree is in the 1-3 level.

(2) effective: the functional impairment scoring reduces the 8-20 branch.

(3) invalid: the functional impairment scoring reduces or increased less than 8 minutes.

(4) worsen: the functional impairment scoring increases by 9 minutes or more.

After the treatment of therapeutic outcome: A group is 98 examples effectively always, accounts for 96.08%, and total effective 37 examples of B group account for 72.55%, through X ²Check, P＜0.001, the prompting A group B group that is better than evident in efficacy sees Table 8-1.

This recovery from illness of table two groups of therapeutic outcome comparative examples of 8-1 (%) group example base produce effects enabledisable worsens total effectively A and organizes 102 14 41 43 40 98

(13.72) (40.20) (42.16) (3.92) (0) (96.08) B organizes 51 5 14 18 11 3 37

(9.80)??(27.45)?(35.30)??(21.57)??(5.88)?(72.55)

Annotate: two groups of total effective rates are checked through X2, X2=18.133, P＜0.001

FUFANG DANSHEN DIWAN is used for because the disease that cerebral ischemia, cerebral infarction or cerebral hemorrhage etc. cause all has curative effect preferably.Nine. FUFANG DANSHEN DIWAN is to the microcirculatory effect of body

Patients with coronary heart disease not only has obstacle on the hemorheology of whole body systemic circulation, also exist in various degree microcirculation disturbance.The discovered in recent years patients with coronary heart disease is reduced by indexs such as microcirculation half turnover rates mostly, and there is obvious general microcirculation disturbance in prompting coronary heart disease.Research at present mostly with nail fold microcirculation or bulbar Conjunctiva Microcirculation as window, observe systemic microcirculation.(1) to the influence of nail fold microcirculation: see Table 3-6.(2) to the influence of bulbar Conjunctiva Microcirculation

FUFANG DANSHEN DIWAN is to patients with coronary heart disease bulbar Conjunctiva Microcirculation and thrombelastogram influence

By contrasting, inquire into the influence of FUFANG DANSHEN DIWAN to patients with coronary heart disease bulbar Conjunctiva Microcirculation and thrombelastogram with SUXIAO JIUXIN WAN.

1. case: patients with coronary heart disease 120 examples, have thoracic obstruction primary symptom, above angina pectoris patient shows effect weekly twice.Be divided into 1. FUFANG DANSHEN DIWAN small dose group 30 examples at random; 2. dosage group 30 examples in the FUFANG DANSHEN DIWAN; 3. the FUFANG DANSHEN DIWAN heavy dose is organized 30 examples; 4. SUXIAO JIUXIN WAN matched group 30 examples.

2. method: the equal sublingual administration of FUFANG DANSHEN DIWAN and SUXIAO JIUXIN WAN, dosage is by being followed successively by from low to high: 5/time, 10/time, 15/time, matched group is 10/time.Dialectical clear and definite after, do not take in 2 hours and medicine that this treatment has nothing to do.Detect patient's bulbar Conjunctiva Microcirculation, every data of thrombelastogram after 2 hours respectively, the variation of every index of check bulbar Conjunctiva Microcirculation in 10,20,30,60,90,120,240 minutes the different time in back of taking medicine, the variation of the every index of check thrombelastogram after 240 minutes.

3. detection index: the detection of (1) bulbar Conjunctiva Microcirculation: adopt multi-functional microcirculation mirror, amplify 50 times and observe left eye temporo side bulbar Conjunctiva Microcirculation state, select blood flow clear, the fine artery and vein that is easy to labelling is recorded a video.Fine motion, vein blood vessel internal diameter and blood flow rate are measured with microcomputer Microcirculatory Image processing system (MCMP) in the back, calculate the arteriole blood flow, i.e. blood flow=π * (vessel diameter/2) ²* blood flow rate.Each every numerical value of organizing before the case medication is all calculated by 100%.

(2) detection of thrombelastogram: utilize the thrombelastogram instrument, adopt the change in physical properties in the multiple calcium method observation of whole blood blood clot formation and the course of dissolution thereof.Leading indicator has: reflection time (r), blood coagulation formation time (k), thrombelastogram amplitude peak (ma), thrombosis are cut speed (∈).3. result: (1) sees Table 9-1,9-2,9-3,9-4 to the influence of patients with coronary heart disease bulbar Conjunctiva Microcirculation.

Table 9-1 is to the influence of patient's arteriole vessel diameter (M ± SD)

In low dose of (n=30) after preceding 100 100 100 100 medications of heavy dose of (n=30) matched group (n=30) medication of dosage (n=30) 10 minutes 104.45 ± 9.85 131.78 ± 9.38 141.27 ± 8.45 134.31 ± 9.32

20 minutes 114.36 ± 8.76 146.89 ± 9.91 156.72 ± 9.87 142.71 ± 9.65

30 minutes 119.32 ± 9.34 154.21 ± 9.43 178.56 ± 9.11 ^*138.12 ± 9.88

60 minutes 121.66 ± 8.23 156.57 ± 8.36 ^*198.34 ± 9.36 ^*127.85 ± 9.13

90 minutes 103.26 ± 8.89 146.11 ± 9.12 ^*186.46 ± 9.89 ^*110.00 ± 9.00

120 minutes 109.37 ± 8.38 123.45 ± 9.21 ^*143.78 ± 9.11 ^*100.11 ± 7.89

240 minutes 101.67 ± 7.32 119.9 ± 6.98 127.72 ± 8.11 101.00 ± 7.93

Compare with matched group, ^*P＜0.05

Table 9-2 is to the influence of patient's venule vessel diameter (M ± SD)

In low dose of (n=30) after preceding 100 100 100 100 medications of heavy dose of (n=30) matched group (n=30) medication of dosage (n=30) 10 minutes 99.76 ± 5.36 90.31 ± 9.11 85.12 ± 8.21 88.67 ± 5.12

20 minutes 9.34 ± 8.56 87.34 ± 8.87 81.46 ± 8.81 86.71 ± 7.21

30 minutes 96.12 ± 9.56 81.35 ± 9.11 76.34 ± 9.22 ^*89.56 ± 7.33

60 minutes 97.66 ± 9.21 79.11 ± 8.81 ^*75.74 ± 9.12 ^*91.56 ± 9.31

90 minutes 99.36 ± 8.81 89.37 ± 8.85 ^*83.34 ± 7.89 ^*96.45 ± 9.91

120 minutes 101.3 ± 8.21 95.55 ± 9.31 87.36 ± 8.21 ^*97.12 ± 7.88

240 minutes 104.8 ± 7.32 98.91 ± 6.56 96.72 ± 8.14 98.00 ± 7.56 with matched group relatively, ^*P＜0.05

Table 9-3 is to the influence of patient's arteriole vascular flow speed (M ± SD)

In low dose of (n=30) after preceding 100 100 100 100 medications of heavy dose of (n=30) matched group (n=30) medication of dosage (n=30) 10 minutes 104.05 ± 5.36 124.31 ± 9.12 85.12 ± 8.21 130.33 ± 8.86

20 minutes 114.34 ± 8.81 136.34 ± 8.11 81.46 ± 8.81 148.71 ± 7.32

30 minutes 117.10 ± 7.34 148.56 ± 8.87 76.34 ± 9.22 ^*139.66 ± 8.11

60 minutes 121.56 ± 6.78 136.13 ± 8.56 ^*75.74 ± 9.12 ^*133.34 ± 8.87

90 minutes 109.34 ± 6.69 129.73 ± 8.11 ^*83.34 ± 7.89 ^*118.21 ± 8.56

120 minutes 101.34 ± 7.67 118.97 ± 8.78 87.36 ± 8.21 ^*112.34 ± 6.85

240 minutes 108.10 ± 8.95 110.37 ± 7.87 96.72 ± 8.14 108.87 ± 7.89

Compare with matched group, ^*P＜0.05

The influence of table 9-4 patient tremulous pulse blood capillary blood flow (M ± SD)

In low dose of (n=30) after preceding 100 100 100 100 medications of heavy dose of (n=30) matched group (n=30) medication of dosage (n=30) 10 minutes 119.12 ± 4.56 126.71 ± 8.81 137.67 ± 8.81 123.21 ± 8.56

20 minutes 121.56 ± 5.11 134.37 ± 8.23 145.45 ± 8.65 138.17 ± 8.38

30 minutes 127.15 ± 5.59 139.65 ± 8.19 159.76 ± 8.23 ^*131.55 ± 8.23

60 minutes 128.34 ± 6.98 136.31 ± 8.37 ^*166.89 ± 8.23 ^*120.11 ± 8.17

90 minutes 119.12 ± 6.67 128.67 ± 8.16 ^*154.21 ± 7.98 ^*120.34 ± 8.36

120 minutes 101.56 ± 7.66 122.79 ± 8.31 145.56 ± 8.11 ^*117.32 ± 7.56

240 minutes 106.12 ± 8.32 110.73 ± 7.34 125.70 ± 8.56 114.12 ± 7.13 with matched group relatively, ^*P＜0.05 (2) influence to the patients with coronary heart disease thrombelastogram sees Table 9-5.

The influence of every index before and after the table 9-5 medication

Heavy dose of (n=30) matched group (n=30) of dosage (n=30) in low dose of (n=30)

M ∈ 321.9 before r 2.35 ± 1.01 2.56 ± 0.980 2.54 ± 0.897 2.45 ± 0.985 usefulness k 4.56 ± 1.31 4.34 ± 1.23 4.17 ± 1.45 4.17 ± 1.21 medicine ma 76.3 ± 19.8 77.5 ± 17.3 46.5 ± 18.1 75.7 ± 19.3 ± 24.7 344.4 ± 20.9 325.5 ± 21.8 311.5 ± 23.9

R 3.56 ± 1.78 5.98 ± 1.71 ^*7.32 ± 1.67 ^*4.78 ± 1.43 usefulness

K 4.88 ± 1.67 6.82 ± 1.88 ^*8.89 ± 1.34 ^*5.67 ± 1.46 medicines

Ma 75.3 ± 16.7 67.3 ± 19.2 ^*60.4 ± 18.4 ^*74.5 after ± 20.3

M ∈ 304.8 ± 19.35 205.8 ± 21.4 ^*154.2 ± 22.5 ^*292.2 ± 25.5 with matched group relatively, ^*P＜0.05, normal value: r=4.35 ± 1.089; K=5.030 ± 1.528; Ma=57.46 ± 20.33;

m∈＝135.09±25.519

Conclusion: according to above experimental result as can be known, angina pectoris patient bulbar Conjunctiva Microcirculation, thrombelastogram are had clear improvement.Ten. FUFANG DANSHEN DIWAN influences FUFANG DANSHEN DIWAN to the effect of erythrocyte immune adhesion function to hematid immunity function

Complement sensitization yeast blood clotting method C is adopted in this experiment _3bThe method of agglutination test of sensitization yeast and double-antibody sandwich indirect ELISA detects the influence of FUFANG DANSHEN DIWAN to patients with coronary heart disease erythrocyte immune adhesion function, CIC, SIL-2R respectively.

1. object: patients with coronary heart disease 20 examples, diagnostic criteria meets the WHO diagnostic criteria for coronary heart disease.

2. method:

(1) hematid immunity function is measured: vein is got blood, through anticoagulant heparin, washes 3 times with normal saline, is made into 1 * 10 ⁸/ ml red blood cell suspension, erythrocyte immune adhesion function are measured the complement sensitization yeast blood clotting method that adopts.

(2) mensuration of CIC: get the patients serum, be diluted to 1: 8 successively, 1: 16,1: 32,1: 64, the mensuration of CIC adopts C _3bThe SYCA method

(3) mensuration of solubility IL-2R: get the patients serum, adopt the double-antibody sandwich indirect elisa method.

3. result:

(1) influence of immune adherence function, blood clotting degree 1: 32 o'clock, after taking medicine, the erythrocyte immune adhesion function shows that apparently higher than take medicine preceding (P＜0.01) FUFANG DANSHEN DIWAN obviously has potentiation to patients with coronary heart disease erythrocyte immune adhesion function and sees Table 10-1.

The influence of table 10-1 patients with coronary heart disease immune adherence function

1: 41: 81: 16 1: 32 ^△1: 64 ^△1: 128 group example number

Example (%) example (%) example (%) example (%) example (%) example (%) test group 20 20 (100) 20 (100) 20 (100) 19 (95) 16 (90) 8 (40) matched groups 20 20 (100) 20 (100) 19 (95) 12 (60) 5 (25) 0 (0) are annotated: ^△P＜0.01

(2) influence of change of serum C IC, blood clotting degree 1: 32 o'clock after taking medicine, before its CIC positive rate is starkly lower than and takes medicine (P＜0.01), shows that FUFANG DANSHEN DIWAN can remove intravital CIC and see Table 10-2.

The influence of table 10-2 patients with coronary heart disease circulating immune complex

1: 81: 16 1: 32 ^△1: 64 ^△Group example number

Example (%) example (%) example (%) example (%) test group 20 17 (85) 15 (75) 8 (40) 3 (15) matched groups 20 20 (100) 17 (85) 15 (75) 12 (60)

Annotate: ^△P＜0.01

(3) before the influence of patients with coronary heart disease SIL-2R, patient's SIL-2R content are starkly lower than and take medicine (P＜0.01), show that FUFANG DANSHEN DIWAN can obviously reduce the SIL-2R level and see Table 10-3.

Table 10-3 patients with coronary heart disease SIL-2R influences group example number sample size test group 20 76.38 ± 72.08 matched groups 20 150.69 ± 86.58

Annotate: P＜0.01

Conclusion: show that by this test FUFANG DANSHEN DIWAN can reduce the level of the light middle SIL-2R of patient's blood, enhancing body's immunological function strengthens erythrocytic immune adherence function.11. FUFANG DANSHEN DIWAN is to neuro vegetative regulating action

FUFANG DANSHEN DIWAN is to the neuro vegetative regulating action of qi stagnation and blood stasis type angina pectoris patient

" Wenger-is towards middle heavy hero " vegetative nerve balance factor analytic process is adopted in this test, to measure heart rate variability type (HRV), be degree or long-time continuously each R-R interval degree of variation of measuring that heart rate fluctuates about average heart rate in certain minute, the single data that calculate have thus comprised sympathetic and parasympathetic influence, can reflect the neuro adjusting function of heart.

1. case is selected: with reference to International Society of Cardiology and association (ISFC) and The World Health Organization's clinical name standard association special topic group formulation ischemic heart desease naming standard and diagnostic criteria (1979), dialectical is qi stagnation and blood stasis type.Be divided into two groups at random, the treatment group: buccal FUFANG DANSHEN DIWAN, each 10, one day 3 times; Matched group: buccal sorbitrate, a 10mg, one day 3 times.Two groups are course of treatment all being January.

2. observation index: vegetative nerve equilibrium index (y) before and after (1) treatment: by " Wenger-is towards middle heavy hero " vegetative nerve balance factor assay.Y=0 ± 0.56 is normal; Y＞+0.56 is unusual, and the prompting sympathetic nerve function strengthens; Y＜-0.56 is unusual, and the prompting parasympathetic functions strengthens.

(2) heart rate variability (HRV) before and after the treatment: 24 hours electrocardiograms of continuous detecting change, and record 24 hours total R-R interval standard deviations (SDNN), represent heart rate variability with SDNN.

3. the result shows: behind the composite salvia dropping pill for curing, and the percentage rate of y＞+0.56 obviously descend (P＜0.05); And this decline of y＞+0.56 not obvious (P＞0.05) before and after the treatment of sorbitrate group sees Table 11-1.Behind the composite salvia dropping pill for curing, R-R interval standard deviation (SDNN) obviously improves (P＜0.01); And R-R interval standard deviation (SDNN) there was no significant difference (P＞0.05) before and after the treatment of sorbitrate group sees Table 11-2.The reduction of HRV is patient's sympathetic activation, becomes positive correlation with the angina pectoris state of an illness, and the probability of generations such as increasing sudden death, arrhythmia is arranged.FUFANG DANSHEN DIWAN can suppress high sympathetic activation preferably, regulates patient's vegetative nerve poised state, is an advantage of composite salvia dropping pill for curing coronary heart disease.

The variation of vegetative nerve equilibrium index (y) before and after the table 11-1 treatment

Treat the back treatment before y＞+0.56 y＜preceding treatment of-0.56 group example number treatment back treatment and organize 30 13 (43.33) 7 (23.33) 3 (10.00) 2 (6.67) matched groups 23 10 (43.48) 9 (39.13) 3 (13.04) 1 (4.35)

The variation of heart rate variability (HRV) before and after the table 11-2 treatment

30 4.20 ± 0.19 4.41 ± 0.29＜0.01 matched groups 23 4.18 ± 0.20 4.23 ± 0.21＞0.05 12 are organized in the P value treatment of treatment back before the treatment of SDNN (ms) group example number. and FUFANG DANSHEN DIWAN is to the research of the anti-chronic hepatopathy fibrosis of therapeutical effect () the FUFANG DANSHEN DIWAN effect of hepatopathy

1. clinical data:

1.1 physical data: the diagnosis typing standard by nineteen ninety whole nation viral hepatitis academic conference revision is diagnosed as chronic active hepatitis 45 examples, early stage liver cirrhosis 20 examples, wherein male 55 examples, women 10 examples.

1.2 Therapeutic Method: chronic active hepatitis group: potenlin associating FUFANG DANSHEN DIWAN (A group), single with potenlin (B group), potenlin injection (the fine pharmacy head factory in sky, Jiangsu is produced) 6 weeks of 80～100ml/ day logotype; 30 of FUFANG DANSHEN DIWAN every days, logotype 3 months; 45 of early stage liver cirrhosis group FUFANG DANSHEN DIWAN every day, logotype 3 months.

2. result:

(1) potenlin associating composite salvia dropping pill for curing chronic active type hepatitis B clinical symptoms is improved situation (seeing Table 12-1).

Table 12-1 therapeutic alliance and list are with potenlin treatment back doing well,improving situation relatively

Weak poor appetite abdominal distention uncomfortable liver area

A group B group A group B group A organizes B group A group B group treatment preceding unusual 45 45 43 44 38 36 32 30

The multiple normal average Chang Tian again in 41 (91.1) 34 (75.6) 39 (90.7) 37 (84.1) 36 (94.7) 27 (75.0) 29 (90.6) 25 (83.3) number (%) P value＜0.05＞0.05＜0.05＞0.05 in number treatment back

P value＜0.05＞0.05＜0.05＞0.05 of meansigma methods ± SD) by table 12-1 as seen 13.6 (: potenlin is united FUFANG DANSHEN DIWAN can obviously improve the weak of patient to ± 2.4 19.1 ± 2.9 15.8 ± 2.6 17.8 ± 2.5 10.8 ± 1.9 17.4 ± 2.8 15.2 ± 2.3 16.8 ± 2.5 numbers, symptoms such as abdominal distention all have notable difference (P＜0.05) than the matched group normalization rate and between answering often.

(2) potenlin associating composite salvia dropping pill for curing chronic active type hepatitis B sign recovery situation (seeing Table 12-2).

Two groups of treatment backs of table 12-2 patient's sign recovery situation

Liver size spleen size yellow sclera

Unusual several 23 20 15 16 19 18 treatment back significant figures (%) 25 (88.5) 9 (45.0) 7 (46.7) 1 (6.3) 18 (94.5) 15 (83.3) before the treatment of A group B group A group B group A group B group

The on average multiple normal natural law in P value＞0.05＜0.05＞0.05

33.6 ± 3.8 36.5 ± 4.9 58.9 ± 9.6 65 18.4 ± 3.3 29.6 ± 5.1 (meansigma methods ± SD)

P value＞0.05＞0.05＜0.05 is by table 12-2 as seen: after the therapeutic alliance patient liver, spleen all have more obviously dwindle, softening, and case rate that spleen dwindles and recovery time and matched group have notable difference (P＜0.05), and also obvious to the jaundice eliminating effect.

(3) potenlin associating composite salvia dropping pill for curing chronic active type hepatitis B liver function recovery situation (seeing Table 12-3)

Liver function recovery situation before and after two groups of treatments of table 12-3

ALT?????????????????AST?????????????????A/G????????????????DBIL

A group B organizes A group B group A group B group A and organizes (%) the on average multiple normal number of days in P value＜0.05＜0.05＞0.05＜0.05 of the front abnormal several 45 45 44 45 25 21 32 29 rear complex constants 43 (95.6) 37 (82.2) 41 (93.2) 36 (80.0) 18 (72.0) 14 (66.7) 30 (93.8) 24 (82.8) for the treatment of of B group treatment

P value＜0.05＜0.05＞0.05＜0.05 of meansigma methods ± SD) by table 12-3 as seen 19.1 ± 3.4 28.4 ± 3.1 22.6 ± 4.0 37.8 ± 3.9 35.9 ± 7.2 39.1 ± 7.4 26.5 ± 3.2 34.7 ± 3.7 (: potenlin associating FUFANG DANSHEN DIWAN is transaminase lowering obviously, can comparatively fast reduce the bilirubin level in the serum, and obviously shorten (P＜0.05) than matched group between on average answering often; But albumen ratio variable effect is little.

(4) potenlin associating composite salvia dropping pill for curing chronic active type hepatitis B is to the influence (seeing Table 12-4) of hepatic fibrosis index.

The variation of two groups of treatment backs of table 12-4 fibrosis index

Glycocholic acid hyaluronic acid III procollagen type peptide laminin

Mean value 46.5 48.9 246.2 251.8 188.6 169.9 385.7 391.6 (mean value 20.1 42.6 138.9 218.4 89.7 152.4 142.3 298.2 (mean value ± SD) ± 3.1 ± 5.4 ± 11.4 ± 10.8 ± 7.1 ± 9.2 ± 10.6 ± 16.9 after mean value ± SD) ± 6.2 ± 6.7 ± 20.5 ± 11.4 ± 9.7 ± 9.5 ± 21.1 ± 24.5 treatments before the treatment of A group B group A group B group A group B group A group B group

12-4 is shown in P value＜0.01＜0.05＜0.05＜0.01 as seen: the fibrosis index all obviously reduces (P＜0.05) after the therapeutic alliance.

(5) composite salvia dropping pill for curing early stage liver cirrhosis is to the change (seeing Table 12-5) of fibrosis index.

Table 12-5 early stage liver cirrhosis is to the change of fibrosis index

Meansigma methods before the treatment of glycocholic acid hyaluronic acid III procollagen type peptide laminin

62.8 ± 7.4 389.6 ± 21.4 294.8 ± 18.9 517.7 ± 24.8 (treatment of meansigma methods ± SD) back meansigma methodss

37.1 ± 62 287.5 ± 16.1 135.6 ± 9.8 282.5 ± 10.2 (meansigma methods ± SD)

12-5 is shown in P value＜0.05＞0.05＜0.05＜0.05 as seen: FUFANG DANSHEN DIWAN can reduce serum liver fibrosis index level, the wherein preceding obviously reduction (P＜0.05) of treatment of glycocholic acid, III procollagen type, laminin. (two) composite salvia dropping pill for curing active cirrhosis 47 examples

1. clinical data: due to illness in March, 1996～1998 accept active cirrhosis patient 93 examples due to the virus hepatitis year March altogether for medical treatment, are divided into Radix Salviae Miltiorrhizae group 47 examples at random, matched group 46 examples.

2. Therapeutic Method: two groups of Therapeutic Method, medicinal glucose, inosine, Energy mixture, vitamin Ks such as adopt that all tradition protects the liver, supports, suits the medicine to the illness ₁, vitamin C, vitamin B group and blood product etc.Radix Salviae Miltiorrhizae group patient adds with 10/time of FUFANG DANSHEN DIWAN, 3 times/day.

3. observation item: hyaluronic acid (HA), III procollagen type peptide (PIIIP), IV procollagen type (IV-C), flaggy element (LN), gamma globulin and glutamate pyruvate transaminase (ALT).

3. result: see Table 12-6

The variation of each observation item of table 12-6

The unusual gamma globulin of the unusual ALT of the unusual LN of the unusual HA of the unusual IV-C of PIIIP is unusual

Control % control % control % control % control % control the back %

Preceding Radix Salviae Miltiorrhizae group 36 111 before and after before and after before and after before and after the front and back ^*75 38 13 ^*65.8 36 9 ^*75 41 12 ^*70.7 47 2 ^△95.7 47 17 ^{△ △}63.8 matched group 34 26 29 37 29 21.6 35 29 17.1 39 26 33.3 45 7 84.8 45 38 15.6

Annotate: ^*P＜0.05, ^*P＜0.01, P＞0.05, △ P＜0.025.Conclusion: FUFANG DANSHEN DIWAN has the obvious control fibrosis effect, and clinical efficacy is satisfied.(3) composite salvia dropping pill for curing cirrhosis patients in decompensation patient's observation of curative effect

1. method: cirrhosis patients in decompensation patient is totally 28 examples.Observation group's 14 examples, except that routine protects the liver, diuresis, suit the medicine to the illness, add each 15 of FUFANG DANSHEN DIWAN the Supporting Therapy, every day 3 times, 2 weeks were a course of treatment; The same observation group of matched group 14 routine conventional therapies.

2. result: see Table 12-7

Table 12-7 treats effective (%) invalid (%) total effective rate (%) observation group of curative effect situation group example digital display effect (%) 14 7 (50.00) 6 (44.29) 1 (7.14) 13 (94.29) matched groups 14 3 (21.43) 5 (35.72) 6 (44.29) 8 (57.15) of cirrhosis patients in decompensation patient

Annotate: learn by statistics and handle P＜0.05, significant difference is promptly arranged.

Conclusion: add with FUFANG DANSHEN DIWAN the cirrhosis patients in decompensation patient is had obvious treatment meaning.Its effect is stronger than Radix Salviae Miltiorrhizae Tabellae, and non-evident effect, is that the auxiliary treatment liver cirrhosis loses one of compensatory medicine.13. FUFANG DANSHEN DIWAN is improved the senile diabetes obstacle to therapeutical effect () the composite salvia dropping pill for curing of diabetes and complication thereof

40 routine diabeticss, diagnosis meets WHO diagnosis of diabetes standard in 1985, wherein male 21 examples, age (70.2 ± 8.4), women 19 examples, year at age (66.8 ± 5.6), course of disease 3-25, on average (16.8 ± 6.4), 25 examples of companion's cardiovascular disease, 18 examples of companion's cerebrovascular disease, 8 examples of companion's nephropathy, 12 examples of companion's neuropathy, 15 examples of companion's oculopathy, other complication 6 examples.

The employing FUFANG DANSHEN DIWAN is oral, and each 10, every day 3 times, 3 months courses of treatment.The nail fold microcirculation comprehensive monitor is produced by Shanghai laser institute.

The result shows: 40 routine old-aged diabetic's oral administration FUFANG DANSHEN DIWAN after 3 months the every detection index of nail fold microcirculation in various degree improvement is all arranged, the integrated integral value descends, there have 24 examples to be improved as moderate in unusual 28 examples of former severe to be unusual, there are 10 examples to be improved as mile abnormality in unusual 12 examples of former moderate, significant difference is relatively arranged before and after the treatment.See Table 13-1, table 13-2.

Table 13-1 treats the variation (x ± s) of forward and backward nail fold microcirculation

After treating before the treatment

Pipe loop number (bar/millimeter) 3.8 ± 1.2 5.2 ± 2.8 ^*

Input tap footpath (μ m) 7.2 ± 2.4 8.0 ± 1.6 ^*

Output tap footpath (μ m) 8.9 ± 3.2 10.1 ± 2.7 ^*

Loop top diameter (μ m) 10.8 ± 3.6 12.0 ± 3.3

Long (the μ m) 389 ± 127 360 ± 89 of pipe loop ^*

Pipe loop crossing number (%) 52.7 ± 19.5 42.8 ± 18.2 ^{* *}

Pipe loop deformity number (%) 22.4 ± 8.3 19.2 ± 7.5 ^*

Vasomotion (inferior/min) 3.0 ± 1.5 2.6 ± 1.0 ^*

Leukocyte count (individual/15 second) 16.4 ± 8.6 14.0 ± 7.4 ^*

Relatively preceding with treatment: ^*P＜0.05 ^*P＜0.01 ^{* *}P＜0.001

Table 13-2 treats forward and backward nail fold microcirculation integrated integral value (x ± s)

After treating before the treatment

Form integration 1.0 ± 0.4 0.9 ± 0.3

Fluidised form integration 3.6 ± 1.7 3.2 ± 0.9

Manage all State integral 2.5 ± 0.8 2.2 ± 0.6

Total mark 6.8 ± 2.7 5.9 ± 1.8 (two) composite salvia dropping pill for curing diabetes peripheral neuritis, 1. clinical datas: totally 36 examples, male 9 examples, women 27 examples; The oldest is 82 years old, minimum 45 years old; The course of disease reaches 4 years most.Select case by " practical internal medicine " the 9th edition " diabetic neuropathy " diagnostic criteria.

2. Therapeutic Method: blood sugar control is in normal range.FUFANG DANSHEN DIWAN, oral, each 10, every day 3 times, one after each meal changes each 5 into to taking effect, and every day 3 times, 40 days is a course of treatment.

3. therapeutic outcome: produce effects (clinical symptoms complete obiteration) 31 examples; Effective (symptom is obviously improved) 5 examples; Invalid (symptom does not have improvement) 0 example.

Conclusion: FUFANG DANSHEN DIWAN has excellent curative to diabetes peripheral neuritis.14. FUFANG DANSHEN DIWAN is to the effect of optical fundus blood vessel treatment of diseases

The composite salvia dropping pill for curing retinal vein occlusion

1. case situation: among the 42 routine patients, simple eye morbidity 27 examples, eyes 15 examples of falling ill, central vein blocks (CRVO) 18 examples, branch vein obstruction (BRVO) 24 examples.

2. Therapeutic Method: adopt heavy dose of FUFANG DANSHEN DIWAN oral, each 15,3 times on the one, it is main oral also can adopting FUFANG DANSHEN DIWAN, and urokinase subconjunctival injection and an amount of oral cooperation of hormone treat that the state of an illness tends towards stability, and absorb the available laser therapy that takes a turn for the better.

3. efficacy evaluation: produce effects: vision progress 5 row or return to more than 1.0; Progressive: 2-4 is capable in the vision progress; No significant change: the vision progress or 1 row that regresses; Worsen: vision regresses more than 2 row.With produce effects and progressive as effective.

3. the results are shown in Table 15-1

Vision compares (routine .%) before and after the table 15-1 treatment

＜0.1????????????0.1～0.5?????????0.6～1.0???????????1.0

Control back BRVO 3 (18) 1 (4) 11 (48) 6 (27) 8 (35) 10 (43) 1 (4) 6 (26) CRVO 10 (58) 9 (47) 8 (42) 8 (42) 1 (5) 2 (11) 0 (0) 0 (0) before controlling after controlling before controlling after controlling before controlling after controlling before controlling

The retinal vein occlusion cause of disease is unclear fully as yet, hypertension, hyperlipemia and arteriosclerosis, hemodynamic deficiency are considered to be the high-risk factor of the retinal vein occlusion, the traditional Chinese medical science think the blood vessels stasis of blood stagnate smooth due to, FUFANG DANSHEN DIWAN energy blood circulation promoting and blood stasis dispelling, microcirculation improvement, alleviate edema, promote blood to absorb, so vision is improved.Except that the retinal vein occlusion, FUFANG DANSHEN DIWAN also can be widely used in the various optical fundus blood vessel diseases that treatment belongs to " blood stasis " card.As: central retinal artery occlusion, hypertension retinal arteriosclerosis, ret diab change, middle slurry optic neuropathy, in ooze optic neuropathy, ischemic optic neuropathy, optic neuritis, optic atrophy etc.15. FUFANG DANSHEN DIWAN to the hemorheological FUFANG DANSHEN DIWAN that influences to the rheol influence of cervical spondylosis blood samples of patients

Cervical spondylosis patient's selection meets the diagnostic criteria that in May, 1984, whole nation cervical spondylosis symposium was formulated.80 routine patients are divided into two groups at random: FUFANG DANSHEN DIWAN+universe Chinese pill for curing hyperosteogeny group (observation group) 50 examples, universe Chinese pill for curing hyperosteogeny group (matched group) 30 examples.FUFANG DANSHEN DIWAN is taken by observation group, one time 10, one day 3 times, universe Chinese pill for curing hyperosteogeny, one time 1 ball, one day 2 times; Matched group simple oral universe Chinese pill for curing hyperosteogeny, one time 1 ball, one day 2 times; Be 2 months two groups of courses of treatment.

The result: compare with treatment is preceding after taking FUFANG DANSHEN DIWAN (1), and except that Fibrinogen, whole blood viscosity, whole blood reduced viscosity, plasma viscosity, packed cell volume, erythrocyte aggregation index all reduce, and difference has significance (P＜0.05 or P＜0.01).Compare with matched group, the reduction of whole blood viscosity, whole blood reduced viscosity, plasma viscosity, erythrocyte aggregation index has significant difference (P＜0.05 or P＜0.01).Erythrocyte aggregation index have significant change (P＜0.05 or P＜0.01) only before and after the treatment of control group.See Table 16-1.

(2) (main symptom and simultaneous phenomenon disappear observation group's clinical cure, positive sign is normal substantially) 17 profits (34.0%), (main symptom and simultaneous phenomenon alleviate 50% to produce effects, positive sign is near normal) 20 examples (40.0%), effectively (main symptom and simultaneous phenomenon alleviate less than 50%, positive sign is recovered to some extent) 12 examples (24.0%), invalid 1 example, total effective rate 98.0%.Matched group clinical cure 6 examples (26.7%), produce effects 10 examples (33.3%), effective 10 examples (33.3%), invalid 2 examples (6.7%), total effective rate 93.4%.

(x ± s) group is treated the sticking plasma viscosity Fibrinogen packed cell volume erythrocyte of whole blood viscosity whole blood reduction to the hemorheology variation of two groups of treatment backs of table 16-1

(mPa.s) (mPa.s) (g/L) (V) preceding 5.66 ± 1.12 8.72 ± 1.46 2.16 ± 0.82 3.94 ± 0.84 48.12 ± 3.84 1.08 ± 0.14 (50 examples) treatment back 4.98 ± 0.84 8.01 ± 1.25 of aggregate index observation group treatment of degree (mPa.s) ^{△ *}1.62 ± 0.36 ^△3.90 ± 0.81 44.70 ± 4.67 0.86 ± 0.12

^{△ △ * * △ △ △ △ * *}Preceding 5.42 ± 1.35 8.72 ± 1.52 2.24 ± 1.02 3.98 ± 0.90 48.16 ± 4.85 1.06 ± 0.10 (30 examples) treatment of treatment of control group back 5.48 ± 1.08 8.74 ± 1.43 2.20 ± 0.48 4.02 ± 0.87 45.53 ± 5.78 0.98 ± 0.14

Annotate: with compare before the treatment, ^△P＜0.05, ^{△ △}P＜0.01; With compare after the treatment of control group, ^*P＜0.05, ^*P＜0.01 16. and FUFANG DANSHEN DIWAN is to therapeutical effect () the composite salvia dropping pill for curing chronic cardiopulmonary disease of chronic cardiopulmonary disease

90 routine chronic cardiopulmonary diseases all meet the diagnostic criteria of national pulmonary heart disease meeting revision in 1977, are divided into treatment group and matched group at random.Wherein treatment group (FUFANG DANSHEN DIWAN) 60 examples, matched group (persantin) 30 examples.In antiinflammatory, eliminating phlegm and stopping cough, heart tonifying diuresis, improve on the cardiac function basis, the treatment group gives FUFANG DANSHEN DIWAN, each 10, every day 3 times, matched group gives persantin, each 50mg, every day 3 times, one month course of treatment.1. curative effect determinate standard

(2) produce effects: the cough with asthma symptom significantly alleviates, pulmonary rale disappears or significantly reduces (base of lung idol is heard and a small amount of thin bubble), cyanosis obviously alleviates, ascites disappears, and edema of lower limbs disappears, heart rate reduce to 100 times/below the min, cardiac function recovers more than the 1-2 level, urinate more preceding increase by two every days more than the 600mL, lose weight 4%, the tip circulation takes a turn for the better.

(2) effective: above-mentioned every indexing section alleviates or takes a turn for the better to some extent.

(3) invalid: above-mentioned every index does not all have improvement.3. the result shows: treatment group total effective rate (produce effects+effectively) 95%, significantly (P＜0.05=shows that FUFANG DANSHEN DIWAN is better than persantin to 76%, two group of poor opposite sex of persantin group total effective rate.See Table 17-1.Hemorheology treatment group changes obviously than matched group, sees Table 17-2.

Table 17-1 is imitated the treatment of enabledisable total effective rate to clinical aggregate efficiency comparison group example digital display before and after the pulmonary heart disease treatment and is organized 60 35 (0.583) 22 (0.367) 3 (0.05) 57 (0.95) matched groups 30 14 (0.47) 9 (0.3) 7 (0.23) 23 (0.76)

Hemorheology index before and after the table 17-2 treatment

Treatment groups and control groups before treatment after treatment before treatment after treatment P-value P-value of blood viscosity 4.55 ± 0.84 3.54 ± 0.63 <0.01 4.35 ± 0.81 3.66 ± 0.58 <0.05 hematocrit (VOL%) 0.53 ± 0.05 0.33 ± 0.22 <0.01 0.48 ± 0.05 0.37 ± 0.05 <0.05 fibrinogen (g / L) 4.33 ± 0.35 1.073 ± 0.145 <0.01 4.22 ± 0.34 3.60 ± 0.23 <0.05 platelet aggregation rate (%) 39.27 ± 2.137 21.66 ± 19.30 <0.01 4.16 ± 2.32 32.28 ± 20.30 <0.05 (two) CSDP acute exacerbation of pulmonary heart disease treatment

70 routine patients are chronic cardiopulmonary disease acute exacerbation phase patient, meet the diagnostic criteria of whole nation pulmonary heart disease meeting revision for the second time in 1977.Two groups are all adopted conventional therapies such as antiinflammatory, relieving cough and resolving phlegm, heart tonifying diuresis and low discharge oxygen uptake, and wherein 36 are the treatment group, add on the basis of conventional Comprehensive Treatment and use FUFANG DANSHEN DIWAN, each 10-15 grain, every day 3 times, continuous two weeks; 36 examples are matched group, and except that without the FUFANG DANSHEN DIWAN, all the other treatments and the course of treatment are all identical with the treatment group.

1. curative effect determinate standard

(1) produce effects: treatment back cardio-pulmonary function is improved and is reached the II level, cough under the clinical manifestation rest state, coughs up phlegm, dyspnea and cyanosis disappear or obviously alleviate, liver retraction, pulmonary rale disappearance or obviously alleviate.

(2) effective: cardio-pulmonary function is improved the I level, and clinical manifestation is an above-mentioned symptom and sign alleviates or part alleviates.

(3) invalid: the cardio-pulmonary function and the state of an illness do not have significant change or the state of an illness increases the weight of.

2. the result shows: relatively, obvious effective rate and total effective rate are significant difference (X between two groups of groups ²=4.46 and 4.95, P is all＜0.05), illustrate that treatment group curative effect is better than matched group, sees Table 17-3.Before and after the treatment of treatment group, the blood samples of patients rheology has highly significant or significant the variation, and treatment group and matched group relatively have significant difference (P all＜0.05).And the matched group patient through the treatment after, though indexs such as blood viscosity have decline, not statistically significant.See Table 17-4.

Table 17-3 to clinical aggregate efficiency before and after the pulmonary heart disease treatment relatively

Group example digital display is imitated the enabledisable total effective rate

Treatment organizes 36 17 (0.427) 15 (0.417) 4 (0.111) 32 (0.889)

Matched group 34 9 (0.265) 14 (0.412) 11 (0.323) 23 (0.677)

Hemorheology index before and after the table 17-4 treatment

Treatment group matched group

Treatment back P value before the P value treatment of treatment back before the group treatment

η b1, (mPa.s), 9.01 ± 1.70, 6.11 ± 1.13,＜0.01, 8.98 ± 1.82, 7.91 ± 1.95,＞0.05 η bh, (mPa.s), 6.32 ± 1.21, 5.15 ± 0.75,＜0.01, 6.30 ± 1.42, 5.91 ± 1.77,＞0.05 η p, (mPa.s), 1.95 ± 0.14, 1.70 ± 0.08,＜0.01, 1.92 ± 0.12, 1.80 ± 0.18,＞0.05, EAI, 1.57 ± 0.13, 1.40 ± 0.08,＜0.05, 1.60 ± 0.15, 1.56 ± 0.20,＞0.05, HCT, (%), 46.72 ± 5.41, 40.69 ± 5.16,＜0.05, 45.93 ± 5.32, 43.80 ± 5.92,＞0.05, ET, (s), 23.71 ± 1.77, 20.82 ± 1.08,＜0.05, 24.02 ± 1.94, 23.34 ± 2.06,＞0.05, ESR, (mm), 24.00 ± 11.28, 16.60 ± 9.30,＜0.05, 23.89 ± 12.02, 20.90 ± 13.20,＞0.05, Fb, (mg%), 301.50 ± 32.14, 270.16 ± 20.12＜0.05, 299.60 ± 39.28, 288.10 ± 40.36＞0.05, (3) Compound Danshen Dropping Pills in Treatment pulmonary heart disease secondary polycythemia

23 routine pulmonary heart disease diagnosis are all made a definite diagnosis by the standard of whole nation pulmonary heart disease meeting formulation for the second time in 1977, except that the performance of pulmonary heart disease feature, and hemoglobin man＞160g/L, woman＞150g/L; Erythrocyte overstocks man＞0.60, woman＞0.55, except polycythemia vera.

Take FUFANG DANSHEN DIWAN, each 10, every day 3 times.Give corresponding treatments such as infection, relieving cough and asthma, diuresis, expansion blood vessel, glucocorticoid in the therapeutic process according to the state of an illness.Through 20-56 days, average 38 days treatment, conjunctival congestion and lip, tongue, gentian violet dark purple all obviously improve or disappear, and hemoglobin, packed cell volume obviously descend before the treatment, before and after the treatment (x ± s): hemoglobin-3.10 ± 2.90, P＜0.01; Packed cell volume-11.80 ± 2.90, all there is significant difference P＜0.05.Do not see any side reaction in the drug administration process.17. FUFANG DANSHEN DIWAN is to the therapeutical effect composite salvia dropping pill for curing essential nephrotic syndrome of the nephrotic syndrome

Wuhan City No.2 Hospital accepted essential nephrotic syndrome patient 80 examples in 1998～1999 for medical treatment, selected case is aspect medical history, sign, auxiliary examination, the course of disease, all meet the nephrotic syndrome diagnostic criteria of the academic session discussing revision of the 3rd national nephropathy in 1992, and get rid of a variety of causes the Secondary cases nephrotic syndrome extremely.Case is divided into two groups at random.Matched group: with prednisone treatment and the Western medicine symptomatic treatment of the conventional course of treatment; The treatment group: on the prednisone treatment basis with the conventional course of treatment, without other blood fat reducings, anticoagulant, thromboembolism preventing and medicament for expanding vascellum, only use FUFANG DANSHEN DIWAN, each 10-15 grain one day 3 times, took for 8 weeks continuously.

1. criterion of therapeutical effect: classify by the criterion of therapeutical effect that for the second time national traditional Chinese medical science nephropathy meeting is formulated.

(1) alleviate fully: symptom, sign disappear, urine protein quantitation＜0.2g/24h, and renal function, blood fat recover normal, and urine erythrocyte is no more than 0～3/HP.

(2) the basic alleviation: symptom, sign disappear, urine protein quantitation＜1g/24h, urine erythrocyte a little～(+).

(3) part is alleviated: symptom, sign take a turn for the better, and lab testing take a favorable turn, but does not reach the standard of basic alleviation.

(4) invalid: more than two months, symptom, sign and lab testing all do not have improvement or worsen with this law treatment.2. the result shows:

(1) treatment group complete remission rate and total effective rate are respectively 55% and 90% among the table 18-1, are significantly higher than in the matched group

27.5% and 65% (P＜0.05) illustrates to cooperate the composite salvia dropping pill for curing can improve curative effect, reduces relapse rate.

Two groups of clinical efficacies of table 18-1 relatively

Case load is alleviated basic alleviation fully, and partly alleviating the treatment of invalid recurrence total effective rate organizes 40 22 10 443 90% matched groups 40 11 96 14 8 65%

(2) rarely seen osmotic pressure of urine, urine lysozyme, urine C3 measure among the table 18-2, on the same group before and after the treatment than P＞0.05, than P＞0.05, the infringement of prompting glomerule, renal tubules is difficult in a short time to recover after treatment group and the treatment of control group; Before all the other every indexs are treated on the same group in the table 2 with treatment back than equal P＜0.01, than P＜0.05, there were significant differences after treatment group and the treatment of control group.

(3) among the table 18-3, except that erythrocyte extrusion nonsignificance, before all the other every indexs treatments with the treatment back than equal P＜0.01, than P＜0.05, there were significant differences after treatment group and the treatment of control group.

The comparison of two groups of part biochemical indicators of table 18-2 (x ± s)

		Urine protein (g/24 h)	Plasma albumin (g/l)	Triglyceride (mmo 1/L)	Cholesterol (mmo 1/L)	Serum creatinine (μ m mol/L)	Blood urea nitrogen (mmol/ L)	Blood immunoglobulin (g/l)	Osmotic pressure of urine (mOsm/ kg.H 2O)	Urine lysozyme (mg/ml)	Urine C3 (mg/l)
												The treatment group	Before controlling	7.10± 3.67	?23.30± ?5.70	?3.79± ?1.58	?10.83± ?1.23	123.7± 87.35	?9.95± ?3.71	?5.39± ?1.70	??690± ??205	??5.42± ??4.23	??1.98± ??2.13
After controlling	0.78± 0.33	?35.42± ?0.76	?1.77± ?0.74	?4.99± ?0.92	80.35± 24.67	?5.41± ?2.13	?9.00± ?2.37	??721± ??315	??5.98± ??4.77	??1.87± ??2.27
											Matched group		Before controlling	6.24± 2.35	?24.10± ?5.30	?3.32± ?1.94	?11.23± ?1.35	127.8± 67.37	?10.73± ?4.35	?5.91± ?2.48	??603± ??298	??6.12± ??4.15	??2.16± ??2.62
After controlling	1.76± 0.54	?31.47± ?2.64	?1.99± ?0.92	?6.82± ?2.05	89.74± 51.73	?6.90± ?2.21	?7.87± ?2.19	??674± ??213	??5.98± ??4.63	??2.24± ??2.87

Two groups of hemorheologys comparisons of table 18-3 (x ± s)

Whole blood contrast viscosity whole blood contrast viscosity plasma viscosity packed cell volume erythrocyte aggregation

After after (height is cut) (low cut) index treatment group is controlled front 7.83 ± 1.31 11.78 ± 1.96 1.96 ± 0.37 46.81 ± 3.05 2.09 ± 0.11 (40 examples) and controlled, 4.96 ± 1.24 7.91 ± 1.52 1.48 ± 0.17 42.74 ± 3.23 1.41 ± 0.21 control groups are controlled front 7.46 ± 1.19 11.31 ± 2.04 1.89 ± 0.41 47.01 ± 2.99 2.11 ± 0.19 (40 examples) and are controlled 5.47 ± 1.35 8.27 ± 1.18 1.61 ± 0.26 44.35 ± 2.72 1.62 ± 0.24 ten eight. compound danshen dripping pills is observed treatment () the compound danshen dripping pills children's Zuo Zhi Bronchopneumonia curative effect of other diseases

1. clinical data:, be divided into treatment and organize 42 examples (male 25 examples, women 17 examples), matched group 36 examples (male 20 examples, women 16 examples) by principle immediately; Be the inpatient.Minimum 2 months of age, maximum 12 years old.

2. Therapeutic Method: two groups are all selected conventional anti-infective therapy, and it is oral that the treatment group adds FUFANG DANSHEN DIWAN.Dosage :～1 years old, each 2; 1～3 year old, each 3; 3～8 years old, each 5; 8～14 years old, each 8; 3 times on the equal 1st oral.3. observation item: see Table 19-1

Moist rale WBC 〉=10.0 * 10 are done by table two groups of infant clinical manifestations of 19-1 and lab testing group n fever and cough asthma pulmonary ⁹/ L rabat shows that the pneumonia treatment organizes 42 32 42 10 42 25 42 matched groups 36 22 36 8 36 20 36

4. criterion of therapeutical effect: (1) produce effects: after treating 5 days, infant heat is moved back, and two pulmonary rales disappear, and the check rabat is seen former focus basic absorption after 10 days; (2) effective: after treating 5 days, symptom and the most of disappearances of two pulmonary rales such as the above-mentioned heating of infant, the check rabat sees that former focus absorption takes a turn for the better after 10 days; (3) invalid: above-mentioned symptom and sign do not have obvious improvement, and the check rabat sees that former focus do not have obvious absorption and take a turn for the better after 10 days.5. result: see Table 19-2

Table 19-2 controls infantile pneumonia curative effect situation

Group produce effects enabledisable total effective rate (%) average course of treatment

Treatment organizes 18 20 4 90.5 10.6

Matched group 12 14 10 72.2 ^*13.4 ^*

Annotate: two groups are relatively: ^*P＜0.05, promptly there were significant differences; ^*P＜0.05, also there were significant differences.

FUFANG DANSHEN DIWAN and antibiotic share and can strengthen antiphlogistic effects, bringing down a fever, be better than matched group aspect the rale absorption, and to improving the children's bronchopneumonia cure rate, shorten the course of disease and all obviously be better than matched group, and non-evident effect.(2) composite salvia dropping pill for curing migraine

Select outpatient service migraineur 58 examples, all meet international headache classification diagnosis standard.Treatment group 10 of FUFANG DANSHEN DIWAN (25mg/ grain), every day 3 times, buccal or oral; Matched group flunarizine 5mg, every day 1 time, oral.Be for 8 weeks the course of treatment.Carrying out 1 curative effect and side effect per 2 weeks observes.Followed up a case by regular visits to 6 months.During the treatment without other analgesic drug products.

Criterion of therapeutical effect: control: headache disappears during the medication, and drug withdrawal does not show effect in June; Produce effects: headache obviously alleviates, and the persistent period obviously shortens, and attack times reduces more than 75%; Effectively: headache alleviates, and attack times reduces 50%-70%; Invalid: headache does not have obviously improvement.

The result shows: treatment group total effective rate is higher than matched group (P＜0.05), and the prompting FUFANG DANSHEN DIWAN has certain effect to treatment and prevention of migraine and recurrence thereof.See Table 19-3

Table 19-3 FUFANG DANSHEN DIWAN and flunarizine treatment migraine curative effect are relatively

Control produce effects enabledisable total effective rate Composite Salvia Dropping Pill group (30 example) 13 953 90.00% flunarizine groups (28 example) 5779 67.86%

Annotate: through X ²Check, P＜0.05 (three) composite salvia dropping pill for curing chronic gastritis

In the 35 routine chronic gastritiss, chronic superficial gastritis 15 examples, chronic erosive gastritis 6 examples, chronic atrophic gastritis 14 examples all have the congestion indication, positive 3 examples of pylorus sieve bacillus wherein, duodenal bulbar inflammation 5 examples occur together.Take FUFANG DANSHEN DIWAN, 3 times on the one, each 10.

Criterion of therapeutical effect: (1) recovery from illness, symptomatology disappears, and appetite increases, and gastroscopy focus inflammatory becomes disappearance; (2) produce effects, symptom is most of to disappear, and the apparition of gastroscopy focus inflammatory takes a turn for the better; (3) progressive, sx, gastroscopy focus inflammatory become slightly improvement; (4) invalid, symptom does not have improvement.

Therapeutic outcome: in 35 examples, 12 examples of fully recovering account for 34.3%, and produce effects 11 examples account for 31.4%; Progressive 8 examples account for 22.9%; Invalid 4 examples account for 11%; Total effective rate 88.7%.

FUFANG DANSHEN DIWAN scalable vascular function, platelet aggregation always, the anticoagulant choosing promotes fibrinolytic and suppresses thrombosis that the congestion of mediation gastric mucosa makes unobstructed vessel, can treat the stomachache of chronic gastritis; The downright bad part in the rotten to the corn position of gastric mucosa inflammatory had eliminate function faster, macrophage function is had active effect, can promote cell regeneration, thereby inflammation is had the healing of promotion effect.(4) the composite salvia dropping pill for curing is dizzy

61 routine patients are divided into 2 groups at random, and 29 examples are organized in treatment, cerebral arterial insufficiency 22 examples wherein, Meniere 7 examples, sick 5 examples of complicated hypertension, coronary heart disease 2 examples; Matched group 32 examples, cerebral arterial insufficiency 22 examples wherein, Meniere 10 examples, sick 7 examples of complicated hypertension, coronary disease pain 4 examples.Treatment is organized to 10 of FUFANG DANSHEN DIWAN, every day 3-5 sublingual administration, logotype 3-7 days.Matched group is given the quiet notes of lignocaine 50mg, once a day, and logotype 3-7 days.

Criterion of therapeutical effect: (1) produce effects: dizzy and simultaneous phenomenon complete obiteration, observe not recurrence in 12 hours.(2) effective: dizzy and cardinal symptom sign obviously alleviates.(3) invalid: symptom does not have improvement.

The result shows: treatment group total effective rate 86%, matched group are 87.5%, and difference does not have significance (seeing Table 19-4), illustrate that two groups of medicines are to treating the dizzy better curative effect that all has.Therefore, FUFANG DANSHEN DIWAN can be used as a kind of convenience and effectively medicinal application in cerebral arteries altogether insufficiency of blood cause dizzy.

Table 19-4 treats dizzy curative effect relatively

Treatment group matched group

The example digital display is imitated enabledisable total effective rate example digital display and is imitated enabledisable total effective rate cerebral arterial insufficiency 23 14 81 22, (96%) 22 12 82 20, (91%) Meniere 60333, (50%) 10 6228, (80%) adds up to 29 14 11 4 25, (86%) 32 18 10 4 28, (87.5%) annotates: through X ²Check, P＞0.05

(5) composite salvia dropping pill for curing external malleolus articular sprain

Male's 53 examples in this group case, women's 34 examples, age 14-60 year, all cases are all according to trauma history and typical clinical symptom, take the photograph sheet through the X line and get rid of fracture and make a definite diagnosis.

Therapeutic Method: 30 grindings of FUFANG DANSHEN DIWAN add 75% ethanol 30ml furnishing lotion, and every day 3 times is in order to evenly smearing the affected part, and nurse routinely.5 days is a course of treatment

Therapeutic effect: this group patient is through all recoveries from illness of treatment, and patient's subjective symptoms disappears, and it is normal that the function of joint activity recovers, and do not have obvious pressure pain point, wherein through a course of therapy 42 examples of fully recovering, 37 examples of fully recovering 2 courses of treatment, 8 examples of fully recovering 3 courses of treatment.

FUFANG DANSHEN DIWAN has the effect of blood circulation promoting and blood stasis dispelling, subduing swelling and relieving pain, and Borneolum Syntheticum wherein has the function that promotes that drug transdermal absorbs, and can make diseased region keep higher drug concentration, so treat outer sprained ankle instant effect, short treating period with it.It it Bone injury disease such as femur head necrosis, articular sprain, fracture, hyperosteogeny etc. are all had better curative effect.(6) FUFANG DANSHEN DIWAN prevention and treatment high altitude anoxia

High altitude anoxia can cause microcirculation disturbance, and microcirculation disturbance finally shows as inadequate blood perfusion.When body causes that owing to high altitude anoxia blood viscosity increases, erythrocyte number increases, and erythrocyte aggregation is strengthened, and erythrocyte hardness increases deformability and reduces, platelet aggregation power adds forces platelet aggregation and pH value to change, and all can influence blood viscosity and critical blood capillary radius.Wherein the formation of hematoblastic aggregation can obviously increase little resistance of blood flow, even can cause blood capillary to block.Blood viscosity increases, and critical blood capillary radius increases, and little resistance of blood flow is increased, and little blood flow stasis of blood stagnates.The different crowd of the change of hemorheological property on the plateau has its general character, i.e. " dense " (packed cell volume increases), " gluing " (whole blood contrast viscosity increases), " gathering " (reinforcement of erythrocyte aggregation power), and with height above sea level with migrate the different and different of plateau time.FUFANG DANSHEN DIWAN confirms that in aforesaid pharmacology and clinical research FUFANG DANSHEN DIWAN has the reduction packed cell volume, reduces the effect of erythrocyte sedimentation rate and reduction whole blood viscosity, and therefore, this medical instrument has the effect of prevention and treatment high altitude anoxia.(7) FUFANG DANSHEN DIWAN prevention and treatment senile dementia

Senile dementia can be divided into Alzheimer (Alzheimer ' s disease, AD), vascular dementia and the two and the mixed type dementia of depositing.With composite salvia dropping pill for curing Alzheimer disease and vascular dementia, the result is in the variation of scale analysis and tcm clinical practice observation index, all make moderate progress before and after the treatment, its difference has height statistical significance (p＜0.05 or p＜0.01), this medicine is to tongue disease effects of having clear improvement such as dull, of few words, forgetful, asthenia, the tongue stasis of bloods, and individual character, personality disorders such as grieved, restless, raving, susceptible to get angry are all had in various degree improvement, and the former total effective rate is 40.0%, and the latter is 85.7%.

In a word, composite salvia dropping pill for curing angina pectoris have that curative effect height, consumption are little, taking convenience, easily absorb, safe and reliable, advantage such as side effect is little.It is allevating angina pectoris rapidly, reduces the angina pectoris attacks frequency, alleviates anginal degree, reduces the consumption of nitroglycerin, takes for a long time angina pectoris effective percentage, EGC effective percentage apparently higher than sorbitrate, and stable curative effect is difficult for producing drug resistance.To the coronary heart disease patient's heart functions, hematodinamics, all there is improvement in various degree aspects such as electrocardiogram and hemorheology.To unstable angina, the silent myocardial ischemia, it is unusual to improve hemorheology, blood viscosity lowering, alleviating arteriosclerosis and prevent that the thrombosis aspect obviously is better than sorbitrate, is prevention at present and treatment coronary heart disease, angina pectoris, antiatherogenic ideal medicament.To coronary heart disease companion arrhythmia, myocardium patient takes FUFANG DANSHEN DIWAN for a long time can eliminate symptom, recurrence again after the prevention myocarditis.

FUFANG DANSHEN DIWAN not only has the free radical resisting damage, prevents the effect that arteriosclerosis forms, the treatment hyperlipemia, the high viscosity syndrome, can also pass through microcirculation improvement, blood viscosity lowering and peripheral vascular resistance are adjusted the compliance of cardiac muscle and are played the effect of reversing left ventricular hypertrophy.

Composite salvia dropping pill for curing hypertension in effective controlling blood pressure, can improve insulin sensitivity, reduces blood insulin levels and improves vascular endothelial function, becomes the steps necessary of treatment hypertension.In the blood pressure lowering treatment, use FUFANG DANSHEN DIWAN and can effectively reach this purpose.

FUFANG DANSHEN DIWAN energy enhancing body's immunological function strengthens erythrocytic immune adherence function; Improve the body microcirculation, acute myocardial infarction, cerebrovascular disease such as cerebral infarction etc. are had good effect.

FUFANG DANSHEN DIWAN can be regulated patient's vegetative nerve poised state.In preventing and treating the coronary heart disease process, suppressed high sympathetic activation, regulate the neuro vegetative balance of patient, be an advantage of composite salvia dropping pill for curing coronary heart disease.

FUFANG DANSHEN DIWAN also has the good curing effect to hepatitis B, active cirrhosis, chronic hepatopathy fibrosis, cirrhosis patients in decompensation.

FUFANG DANSHEN DIWAN has therapeutical effect to diabetes and complication thereof.

FUFANG DANSHEN DIWAN can be widely used in the various optical fundus blood vessel diseases that treatment belongs to " blood stasis " card to the therapeutical effect preferably that has of optical fundus blood vessel nervous system disease.As: the retinal vein occlusion, central retinal artery occlusion, hypertension retinal arteriosclerosis, ret diab change, middle slurry optic neuropathy, in ooze optic neuropathy, ischemic optic neuropathy, optic neuritis, optic atrophy etc.

FUFANG DANSHEN DIWAN can be used for treating dizzy that a variety of causes causes, as cerebral arterial insufficiency, Meniere, hypertension, coronary heart disease etc. cause dizzy.

FUFANG DANSHEN DIWAN can be treated chronic cardiopulmonary disease, pulmonary heart disease acute exacerbation phase, pulmonary heart disease secondary erythrocytosis etc., has assistant to control effect to children's bronchopneumonia.

FUFANG DANSHEN DIWAN can be used for the treatment of the nephrotic syndrome and complication.

FUFANG DANSHEN DIWAN can be treated multiple diseases such as migraine, chronic gastritis, fracture femur head necrosis, articular sprain, fracture, hyperosteogeny, high altitude anoxia and senile dementia.

The embodiment that enumerates the preparation aspect below further describes the present invention, and this embodiment only is used to the present invention is described and the present invention is not limited.

Embodiment one 1. prescription consumptions

Radix Salviae Miltiorrhizae 41.06g Radix Notoginseng 8.03g Borneolum Syntheticum 0.46g

Adjuvant Polyethylene Glycol-6000 18g

Make the extraction of 1000 drop pill 2. Radix Salviae Miltiorrhizaes, Radix Notoginseng

Learn from else's experience the Radix Salviae Miltiorrhizae, pseudo-ginseng of coarse pulverization to extraction pot, add 5 times of water gagings, decocted 2 hours, filter, filtering residue carries out second time and extracts, and adds 4 times of water gagings, decocted 1 hour, and filtration, filtering residue discards, merging filtrate.Filtrate decompression is concentrated into medicine liquid volume (L) and medical material weight (Kg) than being 1: 0.9～1.1, slowly adds 95% ethanol, makes medicinal liquid contain determining alcohol 69～71%, leaves standstill 12 hours.Get the supernatant of medicinal liquid behind the precipitate with ethanol, filter, filtrate recycling ethanol, the simmer down to relative density is 1.32～1.40 extractum.3. the preparation of product

Get above-mentioned extractum and Borneolum Syntheticum, evenly be heated to 85～90 ℃ of temperature, change material after 20～120 minutes, move in the dropping-pill machine jar that jar temperature remains on 85～90 ℃ with Polyethylene Glycol-6000 18g is mixed.In ℃ liquid paraffin of medicine liquid droplet to 7～8, take out drop pill, oil removing, screen cloth selects ball, promptly.4. the feature of product

The product character is reddish brown-brownish black round bead shape, and size is even, color and luster is consistent, gas perfume (or spice), bitter in the mouth.

The product ball heavily is 25mg ± 15%/grain, diameter diameter 3.34 ± 15%mm.

Embodiment 2 1. prescription consumptions

Radix Salviae Miltiorrhizae 31.12g Radix Notoginseng 9.21g Borneolum Syntheticum 0.50g

Adjuvant Polyethylene Glycol-6000 20g

Make the preparation of extraction, product of 1000 drop pill 2. Salvia miltiorrhiza and Panax notoginseng and feature with embodiment one.

Embodiment 3 1. prescription consumptions

Radix Salviae Miltiorrhizae 59.36g Radix Notoginseng 6.38g Borneolum Syntheticum 0.34g

Adjuvant Polyethylene Glycol-6000 21g

Make the preparation of extraction, product of 1000 drop pill 2. Salvia miltiorrhiza and Panax notoginseng and feature with embodiment one.

Claims (46)

1. a treatment treating coronary heart disease and angina pectoris is characterized in that it is the medicament of being made by the following weight proportion raw material

Radix Salviae Miltiorrhizae 48%～97%

Radix Notoginseng 2%～50%

Borneolum Syntheticum 0.2%～3%.

2. according to the described treatment treating coronary heart disease and angina pectoris of claim 1, it is characterized in that the weight proportion of each raw material is

Radix Salviae Miltiorrhizae 63.0%～94%

Radix Notoginseng 4.0%～35.0%

Borneolum Syntheticum 0.5%～2.0%.

3. according to the described treatment treating coronary heart disease and angina pectoris of claim 1, it is characterized in that the weight proportion of each raw material is

Radix Salviae Miltiorrhizae 75.2%～90%

Radix Notoginseng 9%～23.5%

Borneolum Syntheticum 0.5%～1.3%.

4. according to the described treatment treating coronary heart disease and angina pectoris of claim 1, it is characterized in that the weight proportion of each raw material is

Radix Salviae Miltiorrhizae 82.87%

Radix Notoginseng 16.21%

Borneolum Syntheticum 0.92%.

5. the preparation method of each described treatment angina pectoris medicine of claim 1 to 4 is characterized in that it is to take following steps:

Step 1: Radix Salviae Miltiorrhizae, the pseudo-ginseng of learning from else's experience and pulverizing, add water, heating extraction 2～4 times filters, merging filtrate, and filtrate is suitably concentrated;

Step 2: add ethanol and carry out precipitate with ethanol in concentrated solution, leave standstill, supernatant reclaims ethanol, is condensed into extractum;

Step 3: with gained extractum and Borneolum Syntheticum and adjuvant mixed evenly after, make preparation.

6. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described heating extraction temperature of step 1 is 60～100 ℃.

7. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described filtrate of step 1 concentrates to be meant and to be concentrated into medicine liquid volume and the medical material weight ratio is 1 liter: 0.7～1.3 kilogram.

8. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described alcoholic acid addition of step 2 is to make the determining alcohol of precipitate with ethanol solution reach 50～85%.

9. the preparation method of the distressed angor medicine of treatment coronary disease according to claim 5 is characterized in that the described alcoholic acid addition of step 2 is to make the determining alcohol of precipitate with ethanol solution reach 69～71%.

10. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described time of repose of step 2 is 4～24 hours.

11. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described time of repose of step 2 is 8～12 hours.

12. the preparation method of treatment angina pectoris medicine according to claim 5, the relative density that it is characterized in that the described extractum of step 2 is 1.15～1.45.

13. the preparation method of treatment angina pectoris medicine according to claim 5, the relative density that it is characterized in that the described extractum of step 2 is 1.32～1.40.

14. the preparation method of treatment angina pectoris medicine according to claim 5 is characterized in that the described preparation of step 3 can be a said dosage form on any pharmaceutics.

15. the preparation method of treatment angina pectoris medicine according to claim 14 is characterized in that the described preparation of step 3 is a drop pill.

16. the preparation method of the described treatment angina pectoris of claim 15 medicine, the preparation method that it is characterized in that described drop pill is for after mixing gained extractum and Borneolum Syntheticum and adjuvant in claim 5 step 3 evenly, add the transconversion into heat material, move into the dropping-pill machine jar, medicine liquid droplet is to cryogenic liquid paraffin, remove liquid paraffin, select ball.

17. the preparation method of treatment angina pectoris medicine according to claim 16 is characterized in that described adjuvant is the above any adjuvant of preparation drop pill of pharmaceutics.

18. the preparation method of treatment angina pectoris medicine according to claim 16 is characterized in that described adjuvant is a Polyethylene Glycol-6000, its condensation point is 53～58 ℃, and addition is extractum and Borneolum Syntheticum weight 2～6 times.

19. the preparation method of treatment angina pectoris medicine according to claim 16 is characterized in that described adjuvant is a Polyethylene Glycol-6000, addition is extractum and Borneolum Syntheticum weight 3 times.

20. the preparation method of treatment angina pectoris medicine according to claim 16 is characterized in that describedization material temperature is 60～100 ℃.

21. the preparation method of treatment angina pectoris medicine according to claim 16 is characterized in that describedization material temperature is 85～90 ℃.

22. the preparation method of treatment angina pectoris medicine according to claim 16, the temperature that it is characterized in that described cryogenic liquid paraffin is 0～10 ℃.

23. the preparation method of treatment angina pectoris medicine according to claim 16, the temperature that it is characterized in that described cryogenic liquid paraffin is 5～10 ℃.

24. the preparation method of treatment angina pectoris medicine according to claim 16, the temperature that it is characterized in that described cryogenic liquid paraffin is 7～8 ℃.

25. treatment angina pectoris preparation method according to claim 16 is characterized in that described drop pill ball heavily is 5～50mg/ grain, diameter 1.95～4.29mm.

26. treatment angina pectoris preparation method according to claim 16 is characterized in that described drop pill ball heavily is 25mg ± 15%/grain, diameter 3.34 ± 15%mm.

27. according to the application of treatment angina pectoris medicine in having the medicine of following effects of the described method preparation of claim 5, these effects comprise:

(1) coronary blood flow increasing, the vasodilator smooth muscle promotes the opening of collateral circulation, improves the venous sinus oxygen content, obviously improves acute myocardial ischemia and infraction;

(2) the protection cell is avoided the damage of anoxia and anoxia _ reoxygenation, suppresses cardiac muscle and vascular smooth muscle cell apoptosis;

(3) ischemic myocardial cells is poured into the myocardium cell necrosis variation again good protective action is arranged;

(4) microcirculation improvement;

(5) arrhythmia;

(6) antiplatelet aggregation promotes fibrinolytic, and antithrombotic forms;

(7) reduce blood viscosity, blood lipid regulation prevents atherosclerosis;

(8) improve anoxia endurance, anti peroxidation of lipid is removed harmful free radicals;

(9) content of reduction endothelin level significantly improves the organ functions such as liver, kidney and pancreas of animal;

(10) stop developing of blood vessel and neuropathy;

(11) enhance immunity;

(12) regulate the vegetative nerve balance.

28. be used for preventing or treat the application of the medicine of cardiovascular and cerebrovascular disease, nephropathy, hepatopathy, pneumonia, pulmonary heart disease, pancreatitis, diabetes, cervical spondylosis, optical fundus blood vessel disease, optical fundus nervous system disease, migraine, chronic gastritis, dizzy, Bone injury disease, high altitude disease, Senile disease etc. in preparation according to the treatment angina pectoris medicine of the described method of claim 5 preparation.

29. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of various angina pectoris diseases such as stable angina pectoris, unstable angina pectoris, old angina pectoris, silent myocardial ischemia.

30. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of arrhythmia, left ventricular hypertrophy, myocarditis, myocardial infarction, cerebral infarction disease.

31. according to claim 27 or 28 application of described treatment angina pectoris medicine in pharmacy, it is characterized in that: it has quick-acting effects to angina pectoris, sublingual administration is rapid allevating angina pectoris in 3～10 minutes.

32. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of hyperlipidemia, high viscosity syndrome, hypertension.

33. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of coronary heart disease with hypertension, coronary heart disease merging hyperlipidemia, coronary heart disease merging left ventricular hypertrophy, coronary heart disease merging cardiac arrhythmia.

34. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of the various diseases that is caused by the body microcirculation disturbance.

35. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of cerebrovascular such as diseases such as ischemia apoplexy, cerebral infarction.

36. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of diseases such as hepatitis B, chronic hepatopathy fibrosis, active cirrhosis, cirrhosis patients in decompensation.

37. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of the nephrotic syndrome and complication thereof.

38. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of diabetes and complication thereof.

39. application according to claim 27, it is characterized in that it specifically is applied in treatment and belongs in the medicine of various optical fundus blood vessel nervous system diseasies of " blood stasis " card, these diseases comprise: the retinal vein occlusion, central retinal artery occlusion, hypertension retinal arteriosclerosis, ret diab change, middle slurry optic neuropathy, in ooze optic neuropathy, ischemic optic neuropathy, optic neuritis, optic atrophy.

40. application according to claim 27 is characterized in that it specifically is applied in as in the dizzy medicine that causes of treatment a variety of causes, said dizzy comprise by cerebral arterial insufficiency, Meniere, hypertension, coronary heart disease etc. cause dizzy.

41. application according to claim 27 is characterized in that it specifically is applied in the medicine as enhancing human body immunity.

42. application according to claim 27 is characterized in that it specifically is applied in as regulating in the equilibrated medicine of patient's vegetative nerve.

43. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of femur head necrosis, articular sprain, fracture, hyperosteogeny etc.

44. application according to claim 27 is characterized in that it specifically is applied in as assistant to control in the medicine of children's bronchopneumonia.

45. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of high altitude anoxia.

46. application according to claim 27 is characterized in that it specifically is applied in as in the medicine for the treatment of senile dementia.